
<html lang="en"     class="pb-page"  data-request-id="1c4bd03a-2633-4b59-99e9-1807e860bb54"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-11;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b00178;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping" /></meta><meta name="dc.Creator" content="Michael  Juchum" /></meta><meta name="dc.Creator" content="Marcel  Günther" /></meta><meta name="dc.Creator" content="Eva  Döring" /></meta><meta name="dc.Creator" content="Adrian  Sievers-Engler" /></meta><meta name="dc.Creator" content="Michael  Lämmerhofer" /></meta><meta name="dc.Creator" content="Stefan  Laufer" /></meta><meta name="dc.Description" content="The high genomic instability of non-small cell lung cancer tumors leads to the rapid development of resistance against promising EGFR tyrosine kinase inhibitors (TKIs). A recently detected triple m..." /></meta><meta name="Description" content="The high genomic instability of non-small cell lung cancer tumors leads to the rapid development of resistance against promising EGFR tyrosine kinase inhibitors (TKIs). A recently detected triple m..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 23, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00178" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00178" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00178" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00178" /></link>
        
    
    

<title>Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00178" /></meta><meta property="og:title" content="Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0019.jpeg" /></meta><meta property="og:description" content="The high genomic instability of non-small cell lung cancer tumors leads to the rapid development of resistance against promising EGFR tyrosine kinase inhibitors (TKIs). A recently detected triple mutation compromises the activity of the gold standard third-generation EGFR inhibitors. We have prepared a set of trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif as a new structural class of EGFR inhibitors by a target hopping approach from p38α MAPK inhibitor templates. On the basis of an iterative approach of docking, compound preparation, biological testing, and SAR interpretation, robust and flexible synthetic routes were established. As a result, we report two reversible inhibitors 11d and 11e of the clinically challenging triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range. Furthermore, we developed a kinome selective irreversible inhibitor 45a with an IC50 value of 1 nM against the EGFR L858R/T790M double mutant. Target binding kinetics and metabolic stability data are included. These potent mutant EGFR inhibitors may serve as a basis for the development of structurally novel EGFR probes, tools, or candidates." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00178"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00178">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00178&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00178&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00178&amp;href=/doi/10.1021/acs.jmedchem.7b00178" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4636-4656</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00020" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00173" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Juchum">Michael Juchum</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marcel++G%C3%BCnther">Marcel Günther</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eva++D%C3%B6ring">Eva Döring</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Adrian++Sievers-Engler">Adrian Sievers-Engler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++L%C3%A4mmerhofer">Michael Lämmerhofer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Laufer">Stefan Laufer</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div><div class="corresp-info"><strong>*</strong>Phone: (+49)7071-2972459. Fax: (+49)7071-295037. E-mail: <a href="/cdn-cgi/l/email-protection#4437302122252a6a28253122213604312a2d69303121262d2a23212a6a2021"><span class="__cf_email__" data-cfemail="98ebecfdfef9f6b6f4f9edfefdead8edf6f1b5ecedfdfaf1f6fffdf6b6fcfd">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00178&amp;href=/doi/10.1021%2Facs.jmedchem.7b00178" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4636–4656</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 8, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 February 2017</li><li><span class="item_label"><b>Published</b> online</span>23 May 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 June 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00178" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00178</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4636%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMichael%2BJuchum%252C%2BMarcel%2BG%25C3%25BCnther%252C%2BEva%2BD%25C3%25B6ring%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D11%26contentID%3Dacs.jmedchem.7b00178%26title%3DTrisubstituted%2BImidazoles%2Bwith%2Ba%2BRigidized%2BHinge%2BBinding%2BMotif%2BAct%2BAs%2BSingle%2BDigit%2BnM%2BInhibitors%2Bof%2BClinically%2BRelevant%2BEGFR%2BL858R%252FT790M%2Band%2BL858R%252FT790M%252FC797S%2BMutants%253A%2BAn%2BExample%2Bof%2BTarget%2BHopping%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4656%26publicationDate%3DJune%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00178"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3255</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">31</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00178" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Juchum&quot;},{&quot;first_name&quot;:&quot;Marcel&quot;,&quot;last_name&quot;:&quot;Günther&quot;},{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;Döring&quot;},{&quot;first_name&quot;:&quot;Adrian&quot;,&quot;last_name&quot;:&quot;Sievers-Engler&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Lämmerhofer&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Laufer&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;4636-4656&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00178&quot;},&quot;abstract&quot;:&quot;The high genomic instability of non-small cell lung cancer tumors leads to the rapid development of resistance against promising EGFR tyrosine kinase inhibitors (TKIs). A recently detected triple mutation compromises the activity of the gold standard third-generation EGFR inhibitors. We have prepared a set of trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif as a new structural class of EGFR inhibitors by a target hopping approach from p38α MAPK inhibitor templates. On the basis of an iterative approach of docking, compound preparation, biological testing, and SAR interpretation, robust and flexible synthetic routes were established. As a result, we report two reversible inhibitors 11d and 11e of the clinically challenging triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range. Furthermore, we developed a kinome selective irreversible inhibitor 45a with an IC50 value of 1 nM against the EGFR L858R/T790M double mutant. Target binding kinetics and metabolic stabilit&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00178&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00178" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00178&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00178" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00178&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00178" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00178&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00178&amp;href=/doi/10.1021/acs.jmedchem.7b00178" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00178" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00178" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26pmid%3D28482151%26genre%3Darticle%26aulast%3DJuchum%26date%3D2017%26atitle%3DTrisubstituted%2BImidazoles%2Bwith%2Ba%2BRigidized%2BHinge%2BBinding%2BMotif%2BAct%2BAs%2BSingle%2BDigit%2BnM%2BInhibitors%2Bof%2BClinically%2BRelevant%2BEGFR%2BL858R%252FT790M%2Band%2BL858R%252FT790M%252FC797S%2BMutants%253A%2BAn%2BExample%2Bof%2BTarget%2BHopping%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D11%26spage%3D4636%26epage%3D4656%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (7)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292253" title="Imidazoles">Imidazoles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/jmcmar.2017.60.issue-11/20170608/jmcmar.2017.60.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The high genomic instability of non-small cell lung cancer tumors leads to the rapid development of resistance against promising EGFR tyrosine kinase inhibitors (TKIs). A recently detected triple mutation compromises the activity of the gold standard third-generation EGFR inhibitors. We have prepared a set of trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif as a new structural class of EGFR inhibitors by a target hopping approach from p38α MAPK inhibitor templates. On the basis of an iterative approach of docking, compound preparation, biological testing, and SAR interpretation, robust and flexible synthetic routes were established. As a result, we report two reversible inhibitors <b>11d</b> and <b>11e</b> of the clinically challenging triple mutant L858R/T790M/C797S with IC<sub>50</sub> values in the low nanomolar range. Furthermore, we developed a kinome selective irreversible inhibitor <b>45a</b> with an IC<sub>50</sub> value of 1 nM against the EGFR L858R/T790M double mutant. Target binding kinetics and metabolic stability data are included. These potent mutant EGFR inhibitors may serve as a basis for the development of structurally novel EGFR probes, tools, or candidates.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In recent decades, significant progress in the research fields of cell biology and cancer genetics has revealed the high instability of the tumor genome, leading to the knowledge that cancer is not a disease of an organ but rather of the genome. Around 30–35% of East Asian and 15% of Caucasian non-small cell lung cancer (NSCLC) patients bear mutations in the EGFR gene.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Most of these mutations occur in the exons 18–21 that harbor the encoding genes for the tyrosine kinase domain of the receptor.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The two most predominant types, covering 90% of these mutations, the so-called activating mutations, are exon 19 deletions or exon 21 L858R point mutations.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In the case of L858R, the receptor shows a 50-fold increased catalytic activity, representing a crucial hub for the tumor cell in terms of increased downstream signaling, cell growth, and metastasis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The two approved amino quinazoline TKIs gefitinib and erlotinib revealed very potent and selective inhibition profiles with respect to these activating mutations. These mutants lose binding affinity toward ATP,<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> whereas the TKIs bind stronger compared to the WT ones.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Promising results were confirmed in clinical studies, and TKI sensitive patients showed high response rates and significant tumor shrinkage. Unfortunately, no benefit in overall survival was recognized because long-term TKI treatment led to acquired resistance and development of new tumor tissue.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Genome analysis exposed different mechanisms of TKI resistance for these cancer cell lines. Besides different “escape pathways”<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> and histological transformations,<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> 60% of the patients revealed a specific additional T790M point mutation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Second-generation inhibitors like afatinib were developed, carrying a Michael acceptor group to target a cysteine residue in the active cleft, acting as an irreversible inhibitor. Although this transformation led to a recovery of inhibition potency, a total loss of selectivity was recognized. Inhibition of the WT EGFR led to tremendous limitations in clinical application with respect to dose-limiting toxicities.<a onclick="showRef(event, 'ref9 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref9 ref15 ref16">(9, 15, 16)</a> These problems were circumvented by the development of third-generation EGFR inhibitors. <i>N</i>-(3-((5-Chloro-2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)oxy)phenyl)-2-propenamide, <b>46</b> (WZ4002),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> was the first reported mutant-selective EGFR inhibitor showing a 40-fold selectivity for EGFR L858R/T790M over the WT. A few years later, the WT sparing inhibitors oimertinib<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and rociletinib<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> were designed and studied in clinical trials, showing promising results.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> In 2015, osimertinib was FDA approved for NSCLC patients with proven T790M mutation who were treated with TKIs before but who had developed further tumor progression. Several recent studies have revealed the development of resistance to these new third-generation TKIs.<a onclick="showRef(event, 'ref19 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref19 ref22 ref23">(19, 22, 23)</a> One study exposed the occurrence of a third point mutation, C797S, leading to a total loss of inhibitor quality in terms of the potential Michael acceptor cysteine reaction.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The unstable genome of these tumors, accompanied by the fast development of resistance, calls for the design of structurally new potent EGFR inhibitors. Efforts to gain a greater understanding of inhibitor-active site-binding properties are crucial and may lead to the discovery of new binding sites which could counteract the development of drug resistance.</div><div class="NLM_p">Herein, we report the development of a recently published target hopping strategy based on p38α MAPK inhibitor templates which resulted in the creation of potent EGFR L858R/T790M and EGFR L858R/T790M/C797S inhibitors.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> An off-target hit of a published p38α MAPK inhibitor (<b>11g</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A) revealed the efficacy of this class of ligands bound to the EGFR WT kinase domain.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0001.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Molecular docking of lead structure <b>11g</b> in the EGFR T790M kinase domain X-ray structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Hydrogen bonds are shown in orange dots. The angle between the imidazole and the fluorophenyl residue is visualized as blue dots. The Met790 gatekeeper is shown as spheres to visualize steric demands. Hydrophobic region I: area that is occupied by fluorophenyl residue, shown with purple coloration. (B) Addressed regions in our SAR study. <b>HR I</b>: hydrophobic region I, gatekeeper. <b>PBS</b>: phosphate binding site, much space, polar amino acids, Cys797 accessible. <b>RP</b>: ribose pocket, Cys797 accessible. <b>HR II</b>: hydrophobic region II, Cys797 accessible.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">While inhibition of the WT (IC<sub>50</sub> = 49.2 nM) and the activating mutant L858R (IC<sub>50</sub> = 24.1 nM) was high, inhibition of the double mutant L858R/T790M (IC<sub>50</sub> = 916 nM) was only moderate. The goal of our studies was to shift the kinase target of a known p38α MAPK inhibitor and transform it into an innovative class of potent EGFR inhibitors that have high binding affinities to the clinically challenging NSCLC mutants. In silico docking studies had shown a reasonable orientation of the mentioned lead structure <b>11g</b> in the active site kinase domain of the T790M mutant (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A) in terms of hinge binding, nonpolar interactions, and possible attachment points for acrylamides to covalently target Cys797.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Hinge binding was mediated via the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine structure. The attached phenyl ring in the 2-position of this 7-azaindole towered into the hydrophobic region II (HR II). The <i>p-</i>fluorophenyl residue in 4-position of the 7-azaindole occupied the hydrophobic region I (HR I). Earlier investigations of trisubstituted imidazoles as kinase inhibitors revealed the ideal angle and orientation of these compounds to interact with the HR I without any steric interference of the aromatic substituent in 4-position with the gate keeper side chain (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In more detail, the 4-fluorophenyl group in this position is an important structural element for inhibitors of the c-Jun N-terminal kinase 3.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> These compounds occupy the HR I by passing the Met gatekeeper. A methionine gatekeeper is also present in the clinically challenging EGFR mutant T790M. Besides the proven regain of ATP binding affinity (unlike the L858R mutant),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> the more sterically demanding methionine gatekeeper appears to clash with structural elements of first-generation EGFR inhibitors like gefitinib.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> We see the chance to occupy the HRI with our compounds without any gatekeeper interference in order to gain noncovalent binding affinity. On the basis of this promising lead structure, different synthetic strategies were developed to study the structure–activity relationships (SARs) of this new class of trisubstituted imidazoles as EGFR inhibitors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B). On the basis of in silico docking studies, we created different substitution patterns. Together with the biological data, we identified the crucial structural elements of these trisubstituted imidazoles for a potent inhibition of the clinical challenging EGFR mutants. Kinetic binding studies, metabolic stability measurements, and a kinome selectivity screen of compound <b>45a</b> were done to reveal both the effective formation of a covalent bond to the target-cysteine and stable, safe, and selective properties.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25573" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25573" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">The first set of reversible EGFR inhibitors (<b>11a</b>–<b>f</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) was synthesized using the optimized Stille cross-coupling route for trisubstituted imidazoles, published by Selig et al.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>; for details, see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Scheme S1</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Reversible EGFR Inhibitors of <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> (<b>11a</b>–<b>f</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) <i>n</i>-BuLi, Sn(Bu)<sub>3</sub>Cl, THF, −78 °C to rt (compound <b>9d</b>: (1) NIS, MeCN, rt, (2) (CH<sub>3</sub>)<sub>2</sub>CHMgCl·LiCl, Sn(Bu)<sub>3</sub>Cl, THF, 0 °C to rt); (b) Pd(OAc)<sub>2</sub>:X-Phos (3:1), dioxane, reflux; (c) HCl (conc), MeOH, reflux (<b>11e</b>: (1) DCM, TFA, rt; (2) MeOH, K<sub>2</sub>CO<sub>3(aq)</sub>, rt).</p></p></figure><div class="NLM_p">We reported the synthesis of <b>18a</b> previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><b>18b</b> was designed in the analogous way (for detailed synthesis, see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Scheme S2</a>). Amide coupling of the benzylamines <b>18a</b>,<b>b</b> with acrylic acid/(<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride (synthesized according to literature<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a>) in the presence of TBTU and DIPEA led to the desired acrylamides (<b>19a</b>,<b>c</b>)/4-dimethylamino crotonic acid amide (<b>19b</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Amide Coupling of the Benzylamines <b>18a</b>,<b>b</b> to the Inhibitors <b>19a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Acrylic acid (<b>19a</b>,<b>c</b>)/(<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride (<b>19b</b>), TBTU, DIPEA, THF, rt.</p></p></figure><div class="NLM_p">The series of inhibitors with the acrylamide attached to the phenyl at the 7-azaindole 2-position was synthesized starting from the imidazole building block <b>21a</b> that was synthesized via Radziszewski synthesis (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of the Building Blocks for the EGFR Inhibitors <b>27a</b>,<b>b</b> and <b>33</b> of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NH<sub>4</sub>OAc, MeOH, rt; (b) NaH, MOM-Cl, THF, 0 °C to rt; (c) <i>n</i>-BuLi, Sn(Bu)<sub>3</sub>Cl, THF −78 °C to rt; (d) DIPA, <i>n</i>-BuLi, I<sub>2</sub>, THF, −78 °C to rt; (e) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, MeCN, 1 M K<sub>2</sub>CO<sub>3(aq)</sub>, 60 °C; (f) (1) <i>m</i>CPBA, EA, 0 °C to rt, (2) mesyl chloride, DMF, 70 °C; (g) <i>n</i>-BuLi, B(OMe)<sub>3</sub>, Et<sub>2</sub>O, −40 °C to rt.</p></p></figure><div class="NLM_p">4-Chloro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>23*</b>) was synthesized as described in literature.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Selective deprotonation of the 2-position with <i>n</i>-BuLi (<i>ortho</i>-directing effect of the phenylsulfonyl group), followed by the addition of elemental iodine, led to the halogenated 7-azaindole <b>23</b>. It was fused with Boc-protected (3-aminophenyl)boronic acid (<b>22</b>) in a Suzuki cross-coupling reaction to obtain <b>24</b>. The second 7-azaindole building block (<b>30</b>) was synthesized starting with the commercially available 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine. Chlorination<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and MOM-protection yielded in compound <b>5b</b>. Deprotonation and borylation at the 2-position formed the boronic acid <b>28</b>. Suzuki cross-coupling reaction with Boc-protected (3-bromophenyl)methanamine (<b>29</b>) led to the building block <b>30</b>.</div><div class="NLM_p">Stille cross-coupling with <b>21a*</b> and deprotection yielded in <b>26</b> is described (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of the EGFR Inhibitors with a Michael Acceptor at the Phenyl Ring Attached to the 7-Azaindole (<b>27a</b>,<b>b</b> and <b>33</b>) of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Pd(OAc)<sub>2</sub>:X-Phos (3:1), dioxane, reflux; (b) HCl (conc), MeOH, reflux; (c) (1) 3-chloropropanoyl chloride, THF, −15 °C, (2) NaOH, H<sub>2</sub>O, 60 °C; (d) propionyl chloride, THF, rt; (e) acrylic acid, TBTU, DIPEA, THF, 0 °C to rt.</p></p></figure><div class="NLM_p">To obtain the acrylamide <b>27a</b>, the aniline was coupled with 3-chloropropanoyl chloride. Elimination of HCl in the presence of NaOH<sub>(aq)</sub> created the necessary double bond. The reversible counterpart <b>27b</b> was synthesized via the reaction of the free aniline with propionyl chloride in THF. Compound <b>31</b> was obtained by Stille cross-coupling reaction of <b>21a</b>* with <b>30</b>. Deprotection and amide coupling with acrylic acid in the presence of DIPEA and TBTU led to the final product <b>33</b>.</div><div class="NLM_p">To obtain the simplified hinge binder motifs (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>), commercially available 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine was SEM-protected (<b>34</b>) and borylated at the 2-position selectively (<b>35</b>).</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route of 7-Azaindole Hinge Binder Motifs to Study the Best Attachment Point for a Michael Acceptor (<b>37</b>, <b>41</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NaH, SEM-Cl, DMF, 0 °C to rt; (b) <i>n</i>-BuLi, B(OMe)<sub>3</sub>, Et<sub>2</sub>O, −40 °C to rt; (c) (1) 3-bromo benzylamine, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, H<sub>2</sub>O, 80 °C, (2) acryloyl chloride, DIPEA, THF, 0 °C; (d) (1) TFA, DCM, rt, (2) MeOH, NaHCO<sub>3(aq)</sub>, rt; (e) NIS, MeCN, 0–50 °C; (f) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, 1 M Na<sub>2</sub>CO<sub>3(aq)</sub>, MeCN, 60 °C; (g) (1) TFA, DCM, rt, (2) EtOH, NaHCO<sub>3(aq)</sub>, rt.</p></p></figure><div class="NLM_p">Suzuki cross-coupling with 3-bromo benzylamine followed by amide coupling with acryloyl chloride yielded <b>36</b>. Final deprotection with TFA (complete deprotection with MeOH and NaHCO<sub>3(aq)</sub>) led to the 7-azaindole with an <i>N</i>-benzylacrylamido residue in position 2 (<b>37</b>). To obtain the 3-substituted 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine, <b>4</b> was SEM-protected and iodinated at the 3-position (<b>38</b>). Suzuki cross-coupling with the prior synthesized acrylamide <b>39</b> yielded <b>40</b>, whose deprotection with TFA (complete deprotection with EtOH and NaHCO<sub>3(aq)</sub>) resulted in compound <b>41</b>.</div><div class="NLM_p">Stille cross-coupling of the SEM-protected, stannylated imidazoles with the chlorinated and SEM-protected 7-azaindole <b>5a</b> led to compounds <b>10f</b>–<b>i</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route of EGFR Inhibitors with Michael Acceptor at the Phenyl Ring Attached to the 3-Position of 7-Azaindole (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>R<sup>1</sup>–R<sup>3</sup> analogous to <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. (a) NH<sub>4</sub>OAc, MeOH, rt (<b>C</b><sub><b>3</b></sub><b>HBr</b><sub><b>2</b></sub><b>F</b><sub><b>3</b></sub><b>O</b>: (1) NH<sub>4</sub>OAc, H<sub>2</sub>O, 100 °C; (2) NH<sub>4</sub>OAc, MeOH, rt); (b) NaH, SEM-Cl, DMF, 0 °C to rt; (c) <i>n</i>-BuLi, Sn(Bu)<sub>3</sub>Cl, THF, −78 °C to rt (<b>9g</b>: (1) NIS, MeCN, rt; (2) (CH<sub>3</sub>)<sub>2</sub>CHMgCl·LiCl, Sn(Bu)<sub>3</sub>Cl, THF 0 °C to rt); (d) Pd(OAc)<sub>2</sub>:X-Phos 3:1, dioxane, reflux; (e) NBS, THF, rt (<b>10f</b>: NIS, MeCN 0–50 °C); (f) (1) 3-nitrophenyl boronic acid, K<sub>2</sub>CO<sub>3</sub> or K<sub>3</sub>PO<sub>4</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF or dioxane, H<sub>2</sub>O, 80 or 100 °C, (2) H<sub>2</sub>, Pd/C, EA, 1, 3, or 6 bar, rt or 75 °C; (f) acryloyl chloride or propionyl chloride, DIPEA, THF, 0 °C; (g) (1) TFA, DCM, rt, (2) K<sub>2</sub>CO<sub>3(aq)</sub> or NaHCO<sub>3(aq)</sub>, MeOH or EtOH, rt.</p></p></figure><div class="NLM_p last">Halogenation and Suzuki cross-coupling with 3-nitrophenyl boronic acid resulted in the coupled nitro derivatives. Slightly different reaction conditions, according to the respective starting material, were used to perform the Suzuki cross-coupling reactions (see experimental section of materials and intermediates, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Supporting Information</a>). The nitro compounds were usually obtained as inseparable mixtures with the respective dehalogenated reactant. The mixture was treated with hydrogen on Pd/C to yield the amines <b>43a</b>–<b>d</b>, which could be purified via column chromatography. Amide coupling with DIPEA in THF led to the acrylamides/propionylamides (<b>44a</b>–<b>g</b>). Final deprotection with TFA in DCM resulted in the particular irreversible inhibitors or their reversible counterparts (<b>45a</b>–<b>g</b>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Biological Evaluation and Rational Design</h3><div class="NLM_p">IC<sub>50</sub> values of the inhibitors were determined via a radioisotope filter binding assay (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). The inhibitors were incubated with kinase, substrate, cofactors, and radioisotope-labeled ATP, followed by spotting the mixture onto filter papers that bind the radioisotope-labeled phosphorylated substrate. The Glide induced fit docking tool as well as the covalent docking tool of the Schrödinger software were used for the rational draft and design of our inhibitors. Visualization was performed via PyMOL.</div><div class="NLM_p">The <i>p</i>-fluorophenyl residue appeared to be the structural element of choice for the 4-position of the imidazole. A phenyl ring (<b>11b</b>) in this position showed a slight increase in activity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In terms of metabolic stability and higher yields in the Radziszewski imidazole synthesis of the compounds (higher electron withdrawing effect), we insisted on the 4-fluorophenyl residue. Changes in the electron density of the aromatic ring (<b>11a</b>) led to a significant decrease in potency, particularly with respect to the L858R/T790M double mutant (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The first-generation amino quinazoline EGFR inhibitors (gefitinib, erlotinib) seem to clash with the methionine gatekeeper.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Crystal structures and molecular modeling of the third-generation aminopyrimidine inhibitors <b>46</b> (WZ4002),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> rociletinib,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and osimertinib<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> reveal that these compounds spare the gatekeeper area to avoid a sterical interference. Therefore, the 4-fluorophenyl group, in combination with an imidazole that has a hinge binder motif substituted in the 5-position, should be a suitable structure for the clinically challenging EGFR T790M mutant, as it seems to pass the gatekeeper methionine and reaches the HR I. This is an important additional increase in nonpolar binding affinity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Data of the First Set of Reversible Inhibitors and Reference Compounds<a class="ref internalNav" href="#t1fn1" aria-label="f">f</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0012.gif" alt="" id="GRAPHIC-d7e1051-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn2"><div class="footnote" id="t1fn2"><sup>Table a</sup><p class="last">No data.</p></div><div class="footnote" id="t1fn3"><sup>Table b</sup><p class="last">IC<sub>50</sub> value below the lowest chosen inhibitor concentration in the assay.</p></div><div class="footnote" id="t1fn4"><sup>Table c</sup><p class="last">Compounds published by Selig et al.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> as p38α MAPK inhibitors.</p></div><div class="footnote" id="t1fn5"><sup>Table d</sup><p class="last">IC<sub>50</sub> values and structure published by Günther et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div><div class="footnote" id="t1fn6"><sup>Table e</sup><p class="last">No inhibition.</p></div><div class="footnote" id="t1fn1"><sup>Table f</sup><p class="last">WT = wild-type EGFR kinase; L858R, L858R/T790M, L858R/T790M/C797S = clinical relevant EGFR mutants.</p></div></div><div></div></div><div class="NLM_p">The <i>p</i>-hydroxyphenyl ring in position 2 of the imidazole core is oriented toward a region with a high presence of polar amino acids (PBR). The physiological substrate ATP forms crucial interactions with these polar side chains via its phosphate groups. A crystal structure of ADP bound to EGFR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW">4RIW</a>)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> revealed the importance of different polar interactions of the phosphate group with the amino acid side chains Lys721, Asp831, and Asn818 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Molecular docking of <b>11h</b> (light-gray sticks) in a crystal structure of ADP bound to EGFR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW">4RIW</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> ADP (black lines), covalent interactions (gray dots), and magnesium ion (cyan sphere) are adapted from the crystal structure. Polar interactions of <b>11h</b> with hinge region and Asp831 (red dots) are postulated via Glide docking software.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Docking studies of <b>11h</b> in the same crystal structure revealed the hydroxypropyl group to be in the same orientation as the phosphate group. Furthermore, docking predicted a polar interaction of the hydroxyl group with Asp831. The importance of these interactions is well-known, and they were targeted, among others, in the optimization of p38α MAPK inhibitors<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and might be transferred to EGFR, too. The exclusion of the hydroxyl group (<b>11i</b>) led to a significant loss of potency (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), thus emphasizing its importance. Different derivatives were synthesized to study the perfect orientation of this OH group. Its migration to the 3-position (<b>11c</b>) led to a slight increase in potency. However, the replacement of the rigid aromatic phenol by an aliphatic alcohol chain increased the potency significantly (<b>11d</b>, <b>11e</b>, <b>11h</b>). Furthermore, the phenyl ring in the 2-position of 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine of 3-substituted imidazoles is an important potency increasing pattern for the inhibition of the p38α MAP kinase, especially in combination with a rigidized hinge binding motif found in the 7-azaindole.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> This increase in potency may be based on the occupation of a hydrophobic pocket that is also present in EGFR. Unfortunately, the exclusion of this phenyl ring (<b>11f</b>) led to a striking decrease in potency on EGFR (>130-fold for the double mutant). Further exchange of the hydroxypropyl group by an apolar phenyl ring in the 2-position of the imidazole (<b>11j</b>) resulted in a complete loss of potency toward the double/triple mutant. The trisubstituted imidazole <b>11h</b> was recently published<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> as a very potent reversible EGFR inhibitor with high potency against both clinically relevant mutations (IC<sub>50</sub> (L858R) = <0.5 nM; IC<sub>50</sub> (L858R/T790M) = 6.6 nM; <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Because of its high noncovalent binding affinity to the active site, this compound was not reliant on a Michael acceptor for binding covalently to C797 and therefore less vulnerable toward the recently discovered acquired triple mutation C797S (IC<sub>50</sub> = 21 nM). A slight variation in the aliphatic chain length showed no significant effect on the potency and led to two new very potent reversible EGFR inhibitors that were able to inhibit the clinically challenging triple mutant with IC<sub>50</sub> values of 7.6 nM (<b>11d</b>) and 8.4 nM (<b>11e</b>). The FDA-approved osimertinib revealed a 35-fold weaker potency with an IC<sub>50</sub> value of 278 nM. The first known third-generation inhibitor <b>46</b> demonstrated no significant inhibition of the aforementioned triple mutant (IC<sub>50</sub> = 2050 nM), indicating the Achilles’ heel of actual third-generation EGFR inhibitors.</div><div class="NLM_p">The lead structure <b>11g</b> was further applied as a template to create an irreversible inhibitor. Acrylamide (exception <b>19b</b>) was used as the warhead template as this functional group has been widely used and studied by means of irreversible kinase inhibitors. Docking studies revealed position 2 of the imidazole as a suitable point to add an acrylamide via a benzyl linker (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A).</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Covalent docking of <b>19a</b> (A) and <b>27a</b> (B) in EGFR T790M kinase active site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Predicted hydrogen bonds are indicated as red dots.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The in silico model showed a suitable length and orientation to interact with the cysteine. An increase in potency of compound <b>19a</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) could be seen compared to the lead structure <b>11g</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Data of the First Set of EGFR Inhibitors with Attached Michael Acceptor and Related Compounds<a class="ref internalNav" href="#t2fn1" aria-label="e">e</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0013.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0014.gif" alt="" id="GRAPHIC-d7e1252-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn2"><div class="footnote" id="t2fn2"><sup>Table a</sup><p class="last">IC<sub>50</sub> values and structure published by Günther et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div><div class="footnote" id="t2fn3"><sup>Table b</sup><p class="last">IC<sub>50</sub> value below the lowest chosen inhibitor concentration in the assay.</p></div><div class="footnote" id="t2fn4"><sup>Table c</sup><p class="last">No data.</p></div><div class="footnote" id="t2fn5"><sup>Table d</sup><p class="last">No inhibition.</p></div><div class="footnote" id="t2fn1"><sup>Table e</sup><p class="last">WT = wild-type EGFR kinase; L858R, L858R/T790M, L858R/T790M/C797S = clinical relevant EGFR mutants.</p></div></div><div></div></div><div class="NLM_p">The introduction of a 4-dimethylamino crotonic acid amide (<b>19b</b>) led to slightly improved IC<sub>50</sub> values against WT and the L858R mutant but not to an increase in potency toward the T790M mutant. Furthermore, the substitution of the 4-fluorophenyl residue with a cyclopropyl residue (<b>19c</b>) led to an almost complete loss of inhibitor potency, underlining the importance of the 4-fluorophenyl residue in this position. Although <b>19a</b> and <b>19b</b> provided higher potency compared to the lead structure <b>11g</b>, no substantial increase in potency was recognized. This should be expected in terms of the potential covalent bond formation. The recently published precursor <b>18a</b><a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> revealed even lower IC<sub>50</sub> values. Using a flexible alcohol chain in the 2-position of the imidazoles increased the potency substantially. Polar amino acid side chains of the PBS may “pull away” the acrylamide warhead via noncovalent interactions, thus preventing an optimal orientation toward the cysteine.</div><div class="NLM_p">Hence, we placed the acrylamide warhead to the phenyl ring attached to the 7-azaindole in the 2-position (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). Unfortunately, compounds <b>27a</b> and <b>33</b> displayed almost the same IC<sub>50</sub> values compared to the lead structure and were clearly not able to form a covalent bond with the target cysteine. The noncovalent analogue <b>27b</b> showed similar potency to its covalent counterpart <b>27a</b>. Moreover, the blank amine inhibitor <b>26</b> was more potent than all other inhibitors of this series. We synthesized the hinge binding motif with the phenyl warhead linker in the 2-position of the 7-azaindole (<b>36</b>) to examine if the desired orientation of the acrylamide was possibly hindered by the imidazole building block. No inhibition was seen at all. Obviously, the rigidized 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine hinge binding motif is very frozen, forcing the 2-phenyl ring in a special direction. Simultaneously, a nonpolar interaction of this ring with the surrounding hydrophobic pocket is estimated, which may further block the rotation. Consequently, the Michael acceptor must have an optimal orientation for targeting the cysteine, which is obviously not the case with the hinge binder described above. Thus, we attached a phenylacrylamide to the 3-position of the 7-azaindole. The simplified compound <b>41</b> revealed very promising IC<sub>50</sub> values of 67.9 nM for the double mutant and simultaneously a slight selectivity. Hence, we assumed that a covalent bond was successfully formed.</div><div class="NLM_p">When we combined the crucial structural elements of a 4-fluorophenyl in the 4-position, a 3-hydroxypropyl in the 2-position, and a 3-acrylamidophenyl in the 3-position of the 7-azaindole, we obtained a very potent EGFR double mutant (L858R/T790M) inhibitor (<b>45a</b>) with an IC<sub>50</sub> value of 1.52 nM (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biological Data of a Set of Irreversible EGFR Inhibitors and Their Irreversible Counterparts<a class="ref internalNav" href="#t3fn1" aria-label="d">d</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0016.gif" alt="" id="GRAPHIC-d7e1376-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn2"><div class="footnote" id="t3fn2"><sup>Table a</sup><p class="last">IC<sub>50</sub> value below the lowest chosen inhibitor concentration in the assay.</p></div><div class="footnote" id="t3fn3"><sup>Table b</sup><p class="last">No inhibition.</p></div><div class="footnote" id="t3fn4"><sup>Table c</sup><p class="last">No data.</p></div><div class="footnote" id="t3fn1"><sup>Table d</sup><p class="last">WT = wild-type EGFR kinase; L858R, L858R/T790M, L858R/T790M/C797S = clinical relevant EGFR mutants.</p></div></div><div></div></div><div class="NLM_p">The perfect orientation of the acrylamide warhead was also predicted via in silico docking studies (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).</div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Covalent docking of <b>45a</b> in EGFR T790M kinase active site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Predicted hydrogen bonds are indicated as red dots. (B) 2D schematic view of docked 3D structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additional polar contacts were predicted for the hydroxy group with Asn842 as well as a supplementary interaction of the acrylamide carbonyl-C with the Cys797 backbone N–H. Direct comparison with the reversible analogue <b>45b</b>, which lost 3800-fold in potency (in case of the double mutant), affirmed the formation of an irreversible bond with the target cysteine. The exchange of the 4-fluorophenyl with a cyclopropyl (<b>45c</b>, <b>45d</b>) or trifluoromethyl (<b>45e</b>) residue led to almost complete loss of inhibitor quality and thus could not be compensated by the formation of an irreversible bond in a substantial way. We further examined how an exchange of the aliphatic alcohol chain by a phenyl ring influenced the inhibitor activity. Compound <b>45f</b> lost over 100-fold activity. The reversible counterpart <b>45g</b> completely lacked activity. Consequently, a potent reversible inhibitor relies on a 4-fluorophenyl in 4-position, a flexible alcohol chain in 2-position, and a phenyl ring in 2-position of the 7-azaindole (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). To create a potent irreversible inhibitor, it was necessary to place the phenyl ring to the 3-postion of the 7-azaindole in order to attack the Cys797 with an acrylamide warhead. However, this resulted in a complete loss of triple mutant activity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Crucial Structural Elements of Trisubstituted Imidazoles with a 7-Azaindole Hinge Binding Motif as Potent EGFR Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0017.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0018.gif" alt="" id="GRAPHIC-d7e1452-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">High potency against clinically challenging EGFR T790M/L858R and T790M/L858R/C797S mutant.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">High potency against clinically challenging EGFR T790M/L858R mutant.</p></div></div><div></div></div><div class="NLM_p">To clarify any nonspecific binding of <b>45a</b> to nonconserved cysteines, we undertook a glutathione (GSH)-binding study. Phenylacrylamide was used as a reference compound.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> A stability of >90% of the compound was seen after 1 h. Metabolic stability measurements in human liver microsomes revealed good stability. After 4 h of incubation, 87% of unmetabolized <b>45a</b> was detected (stability graph and detected metabolites: see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Figures S1 and S2</a>). While the reversible inhibitors <b>11d</b> (7 mg/L) and <b>11e</b> (not detectable) were almost insoluble in the kinase assay buffer (pH = 7.5), the irreversible compound <b>45a</b> revealed good solubility (299 mg/L) as determined by HPLC with UV detection (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p">The prior published inhibitor <b>11h</b> as the most potent representative of the reversible inhibitors in the EGFR enzyme assay revealed no potency on EGFR cancer cell lines.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> However, the irreversible inhibitor <b>45a</b> showed activity on the L858R/T790M cell line (739 nM) and a >40-fold selectivity for the double mutant compared to the WT cell line (30 μM) (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Table S1</a>). The observed selectivity in the cancer cell lines compared to the enzymatic IC<sub>50</sub> data might be based on an “oncogen addiction”<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> of the mutant cancer cell lines to the EGFR pathway. The EGFR WT cells may compensate the inhibition of this pathway via alternative ones.</div><div class="NLM_p">Furthermore, kinetic measurements were applied to examine the characteristics of irreversible binding of compound <b>45a</b> (<a class="ref internalNav" href="#tbl6" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>K</i><sub>d</sub> values of Compound <b>45a</b> towards Different EGFR Mutants As Measured in Two Different Study Arms (B and C)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">EGFR mutant</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>d</sub> [nM] without dilution (C)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>d</sub> [nM] with dilution (B)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">L858R</td><td class="colsep0 rowsep0" align="left">0.93</td><td class="colsep0 rowsep0" align="left">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">L858R/T790M</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">14</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">WT = wild-type EGFR kinase; L858R, L858R/T790M = clinical relevant EGFR mutants.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Compound and kinase were combined and equilibrated for 1 h.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">compound and kinase were combined and equilibrated for 1 h, then diluted 30-fold in reaction buffer and equilibrated for 5 h.</p></div></div></div><div class="NLM_p">The ability of the inhibitor to compete with an immobilized, active-site directed ligand was measured. The inhibitor showed <i>K</i><sub>d</sub> values in the low nM range, which confirmed the high binding affinity toward the ATP binding site. <b>45a</b> effectively bound to the WT as well as to L858R and L858R/T790M. Obviously, the compound showed no significant differences in the <i>K</i><sub>d</sub> values without and after a 30-fold dilution, affirming an irreversible binding character. A recently published reversible structurally related inhibitor revealed a massive shift to >10-fold higher <i>K</i><sub>d</sub> values after 30-fold dilution,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> manifesting the typical behavior of an inhibitor with noncovalent binding properties. Another nondiluted study arm (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Table S2</a>) with an equilibration time of overall 6 h show even 3–5-fold lower <i>K</i><sub>d</sub> values of <b>45a</b> for all three kinases. This result may reflect the slow association kinetics of this compound, indicating that equilibrium had not been attained, after 1 h of incubation.</div><div class="NLM_p">Compound <b>45a</b> was tested in a kinome selectivity screen against a set of 410 kinases (397 protein kinases and 13 lipid kinases). Beside the expected extensive potency in the ErbB family (<a class="ref internalNav" href="#tbl7" aria-label="Table 6">Table 6</a>), only 13 other kinases were addressed (<a class="ref internalNav" href="#tbl8" aria-label="Table 7">Table 7</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. EGFR Profile of <b>45a</b> in a Panel of 13 EGFR Mutants at an Inhibitor Concentration of 1 μM</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">EGFR family</th><th class="colsep0 rowsep0" align="center" char=".">residual activity (% of control)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR d746-750</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR d747-749/A750P</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR d747-752/P753S</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR d752-759</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR G719C</td><td class="colsep0 rowsep0" align="char" char=".">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR G719S</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR L858R</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR L861Q</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR T790M</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR T790M/L858R</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR WT</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERBB2</td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERBB4</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Selectivity Screen of <b>45a</b> in a Panel of 410 Kinases at an Inhibitor Concentration of 1 μM</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase name</th><th class="colsep0 rowsep0" align="center" char=".">residual activity (% of control)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMX (Cys)</td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK (Cys)</td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CK1-δ</td><td class="colsep0 rowsep0" align="char" char=".">47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JNK2 (Cys)</td><td class="colsep0 rowsep0" align="char" char=".">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JNK3 (Cys)</td><td class="colsep0 rowsep0" align="char" char=".">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAP4K4</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAP4K5</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAPKAPK2 (Cys)</td><td class="colsep0 rowsep0" align="char" char=".">48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MINK1</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MST4</td><td class="colsep0 rowsep0" align="char" char=".">47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STK25 (Cys)</td><td class="colsep0 rowsep0" align="char" char=".">49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEC (Cys)</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TXK (Cys)</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Only hits with residual activity of <50% are shown. (Cys) = kinases with a targetable cysteine.</p></div></div></div><div class="NLM_p">Compound <b>45a</b> showed very high potency against the MAP4K members MAP4K4, MAP4K5, and MINK, which are involved in immunity and inflammation. MAP4K4 has recently been associated with cancer cell migration.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> No residual activity against p38α MAPK was seen (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Figure S4</a>). The selectivity screen contained 30 kinases which have been proven to be addressed by TKIs,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> but only eight kinases of the cysteinome were targeted substantially (residual activity <20% only BTK and TXK). Thus, taking into account the high inhibitor concentration of 1 μM, <b>45a</b> revealed to be a very kinome selective compound with a selectivity score of 0.063 (<a class="ref internalNav" href="#tbl9" aria-label="Table 8">Table 8</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. IC<sub>50</sub> Values of the Most Potent EGFR Compounds in a p38α MAPK Assay</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> [μM]<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.288 ± 0.0283</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.001 ± 0.0001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.007 ± 0.0006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.004 ± 0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.002 ± 0.0002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.012 ± 0.0017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b><a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.003 ± 0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11h</b></td><td class="colsep0 rowsep0" align="char" char="±">0.002 ± 0.0002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b><a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.016 ± 0.0038</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11j</b><a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.108 ± 0.0012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.214 ± 0.0097</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Mean ± SEM of three experiments.</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">Data of compounds published by Selig et al.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></p></div></div></div><div class="NLM_p">The reversible compounds <b>11d</b>, <b>11e</b>, and <b>11h</b> showed no decrease in potency regarding p38α MAPK. Compound <b>11f</b> is still a very potent p38α MAPK inhibitor despite of the lack of the HR II targeting phenyl ring. The loss of this interaction highly decreases the potency on EGFR double and triple mutant (IC<sub>50</sub> = 893, 943 nM, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). These data confirm the necessity of a hydrogen bond donating/accepting group in the 2-position of the imidazole plus a phenyl ring targeting the HR II to inhibit the EGFR double/triple mutant significantly. Nevertheless, this dual inhibition of the reversible compounds may have even positive effects because p38 MAPK is also known to be aberrantly triggered in lung cancer tissue.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> In contrast, compound <b>45a</b> revealed an IC<sub>50</sub> of 213 nM in an p38α MAPK assay, making it 140-fold less potent on this kinase compared to EGFR L858R/T790M (IC<sub>50</sub> = 1.52 nM). Direct comparison with the lead compound <b>11g</b> (IC<sub>50</sub> value on p38 MAPK = 3 nM, IC<sub>50</sub> value on EGFR T790M/L858R = 916 nM) exposed a successful switch in potency from p38 to EGFR.</div><div class="NLM_p last">With respect to the potential reactivity of the acrylamide warhead, all final compounds were checked for structural elements which are present in pan-assay interference compounds (PAINS) using the latest version of ZINC15 database.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> No PAIN hits were found and good selectivity, metabolic stability, as well as a low GSH reaction rate were detected. Thus, no unpredictable reactions with random Cys side chains were found.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">On the basis of an off-target hit of a p38α MAPK inhibitor and an iterative process of molecular docking, synthesis, and biological testing, we developed structurally novel EGFR inhibitors. Effective synthetic routes were evolved to obtain more flexible synthetic procedures that allow the modification at different parts of the molecule and tolerate less robust functional groups. Hence, a set of different trisubstituted imidazoles with a 7-azaindole hinge binding motif were synthesized to study the SARs of this class of compounds against different EGFR mutants. We revealed the possibility to address the HR I behind the Met790 gatekeeper with a combination of a 3-subsituted imidazole with a 7-azaindole hinge binding motif. By determining the crucial residues for high affinity binding to the active site, the development of the recently published reversible EGFR inhibitor <b>11h</b> could be further explained. We used this knowledge to create two equipotent low nM inhibitors <b>11d</b> and <b>11e</b> for the clinically challenging triple mutation L858R/T790M/C797S. These compounds do not need to form a covalent bond in order to achieve high potency. Furthermore, a very potent irreversible inhibitor <b>45a</b> (IC<sub>50</sub> = 1 nM) of L858R/T790M was developed. We proved the irreversible binding character via kinetic studies and revealed the compound stability based on metabolic stability measurements. A kinome scan offered excellent selectivity including the loss of potency toward p38α MAPK and exhibiting successful target hopping to EGFR. This innovative class of EGFR inhibitors may serve as a basis for the development of new EGFR L858R/T790M and L858R/T790M/C797S inhibitors.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51034" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51034" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedures</h3><div class="NLM_p last">All used reagents and solvents were purchased from Sigma-Aldrich, Acros, Fluorochem, or another commercial supplier and were used without further purification or drying procedures unless otherwise noted. The NMR spectra were measured with a Bruker Avance 200, a Bruker Avance 400, or a Bruker Avance 600 MHz (provided by the Department of Preclinical Imaging and Radiopharmacy, Tübingen). Applied solvents for NMR measurements are noted in the experimental procedures for the respective molecules. Calibration of the spectra was done by using the residual solvent peaks. Chemical shifts (δ) are indicated in parts per million (ppm). Most NMR spectra of the final compounds are very complex due to a combination of fluorine coupling, tautomerism (imidazoles, 7-azaindoles), and rotamers. Thus, some peaks in <sup>1</sup>H and <sup>13</sup>C spectra are broadened or bad resolved. Only obvious rotamer/tautomer peaks are mentioned in the NMR-reports, named as “mixture of rotamers/tautomers” and marked as r<sub>1</sub>/t<sub>1</sub> and r<sub>2</sub>/t<sub>2</sub>. Clearly evident fluorine couplings were mentioned as doublets in the <sup>13</sup>C spectra. Some final compounds were solved in a mixture of DMSO-<i>d</i><sub>6</sub>/MeOD (here only rotamers possible because of MeOD acidity). Not obvious signals are indicated as multiplets (m) or broad signals (bs). Mass experiments were performed either by TLC-MS (ESI) (Advion expression CMS) or FAB-MS (Mass Spectrometry Department, Institute of Organic Chemistry, Eberhard Karls Universität Tübingen). ESI-HRMS was done by the research group of Prof. Dr. Lämmerhofer (Pharmaceutical (Bio)-Analyses), University of Tübingen. TLC was performed with fluorescent silica gel 60 F<sub>254</sub> plates (Merck). The spots were visualized via UV illumination at 254 nm/366 nm or with a suitable stain (0.5% KMNO<sub>4</sub> in H<sub>2</sub>O; Seebach reagent: Cerium(IV) sulfate tetrahydrate, ammonium heptamolybdate tetrahydrate, H<sub>2</sub>O, conc H<sub>2</sub>SO<sub>4</sub>). Column chromatography was performed either with Davisil LC60A 20–45 μm silica from Grace Davison (flash chromatography: VWR LaFlash) or Geduran Si60 63–200 μm silica from Merck (gravity column) as stationary phase. The purity of tested compounds was determined via reverse phase high performance liquid chromatography on Hewlett-Packard HP 1090/1100 series II LC, with a UV diode array detector (DAD, detection at 230 and 254 nm). <b>The purities of all final compounds were ≥95%</b>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Methods</h3><div class="NLM_p last">The general methods A–E were taken from Selig et al.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and modified if necessary. Methods F and G were taken from Villadsen et al.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (see General Methods, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Method H: Deprotection with TFA</h3><div class="NLM_p last">The respective starting material was dissolved in dry DCM (0.08M) under argon, and the same amount of trifluoroacetic acid was added. The yellow solution was stirred at room temperature until HPLC revealed complete deprotection (more TFA was added after hours if necessary). The solvent was removed in vacuo. The residue was dissolved in MeOH or EtOH and a few drops of saturated K<sub>2</sub>CO<sub>3</sub> or NaHCO<sub>3</sub> solution were added. The cloudy solution was stirred at room temperature until HPLC revealed complete consumption of the starting material. The cloudy solution was neutralized with saturated NH<sub>4</sub>Cl solution and the solvent was removed in vacuo. The residue was treated with EA and saturated NaHCO<sub>3</sub> solution. The organic layer was separated and the water layer was extracted five times with EA. The combined organic layers were washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Method I: Amide-Coupling of Benzylamines with TBTU</h3><div class="NLM_p last">A solution of DIPEA (4 equiv, 0.088 M), TBTU (1.2 equiv, 0.026M), and acrylic acid/propionic acid (1.0 equiv, 0.022M) in dry THF was stirred under argon at room temperature for 40 min. The respective amine (1.0 equiv) was added portionwise, and the turbid solution was stirred for 10 min, quenched with saturated NH<sub>4</sub>Cl<sub>(aq)</sub>-solution, and stirred at room temperature for 15 min. The organic layer was separated, and the aqueous layer was extracted three times with EA. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Method J: Amide-Coupling with Acyl Chlorides</h3><div class="NLM_p last">The respective aniline (1 equiv, 0.025 M) and DIPEA (1.2 equiv) were dissolved in dry THF under argon and cooled down to 0 °C. Acryloyl chloride/propionyl chloride (1.1 equiv) was added dropwise, and the solution was stirred at 0 °C for 30 min. The reaction was quenched with saturated NaHCO<sub>3</sub> solution and stirred for 10 min. The suspension was extracted three times with DCM, the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Method K: Bromination of 7-Azaindoles in 3-Position</h3><div class="NLM_p last">The respective azaindole (1.0 equiv, 0.072 M) was dissolved in dry THF under argon. NBS (1.1 equiv, 0.099 M) dissolved in dry THF was added dropwise, and the solution was stirred at room temperature for 1.5 h. The solution was quenched with EA and washed three times with brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Materials</h3><div class="NLM_p last">MOM-Cl solution (2.5 M in toluene) was synthesized according to the procedure of Berliner et al.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> 4-Chloro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>23*</b>)<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> as well as (<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> were synthesized as described in literature. Detailed synthesis of the intermediates is described in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">Supporting Information</a>. The Stille cross-coupling reactions were always quenched with a KF<sub>(aq)</sub>-solution (40%) and stirred for 1 h to form insoluble tributyltin fluoride.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The precipitate was filtered off over a pad of Celite. After the workup, all coupling products were purified via flash chromatography to eliminate possible residues of organic/inorganic tin compounds. No toxic stannates were present in our final compounds.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-(4-(Furan-2-yl)-5-(2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)phenol (<b>11a</b>)</h3><div class="NLM_p last">The reaction was performed according to method D. Starting material: <b>10a</b>. Flash chromatography: DCM:MeOH 20:1. The product was obtained as a brown solid (32 mg, 66%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 12.74 (bs, 1H), 12.12 (bs, 1H), 9.76 (bs, 1H), 8.22 (bs, 1H), 7.90 (dd, <i>J</i> = 20.0, 8.1 Hz, 4H), 7.68 (bs, 1H), 7.44 (t, <i>J</i> = 7.8 Hz, 2H), 7.37–7.26 (m, 1H), 7.19 (d, <i>J</i> = 4.8 Hz, 1H), 6.88 (d, <i>J</i> = 8.3 Hz, 2H), 6.55 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 158.5, 151.5–150.1 (m), 148.2–147.1 (m), 142.9, 132.2–131.8 (m), 129.3, 128.5–128.2 (m), 127.6, 125.6, 121.6, 115.9, 112.0–111.6 (m). ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>26</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 419.1503. Found: 419.1528. HPLC (method A): <i>t</i><sub>R</sub> = 6.505 min. Purity: 97.1% (254.4 nm), 97.1% (230.4 nm).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-(4-Phenyl-5-(2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)phenol (<b>11b</b>)</h3><div class="NLM_p last">The reaction was performed according to method D. Starting material: <b>10b</b>. Flash chromatography: DCM:MeOH 20:1. The product was obtained as a yellow solid (97 mg, 99%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 8.18 (d, <i>J</i> = 5.0 Hz, 1H), 7.98 (d, <i>J</i> = 8.7 Hz, 2H), 7.75 (d, <i>J</i> = 7.2 Hz, 2H), 7.57–7.20 (m, 8H), 7.13 (d, <i>J</i> = 5.0 Hz, 1H), 6.90 (d, <i>J</i> = 8.7 Hz, 2H), 6.61 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 158.2, 150.5, 147.0, 142.8, 137.9, 131.8, 129.0, 128.5, 128.0, 127.4, 125.4, 121.5, 118.9, 115.6, 115.6, 115.4, 98.3. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>28</sub>H<sub>20</sub>N<sub>4</sub>O [M + H]<sup>+</sup>: 429.1710. Found: 429.1693. HPLC (method A): <i>t</i><sub>R</sub> = 6.596 min. Purity: 100.0% (254.4 nm), 100.0% (230.4 nm).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3-(4-(4-Fluorophenyl)-5-(2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)phenol (<b>11c</b>)</h3><div class="NLM_p last">The reaction was performed according to method D. Starting material: <b>10c</b>. The residue was washed with ice-cold Et<sub>2</sub>O, DCM, and <i>n</i>-pentane. The product was obtained as a yellow solid (87 mg, 60%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.16 (s, 1H), 9.60 (s, 1H), 8.22 (d, <i>J</i> = 4.3 Hz, 1H), 7.80 (d, <i>J</i> = 7.3 Hz, 2H), 7.62–7.57 (m, 2H), 7.56–7.52 (m, 2H), 7.43 (t, <i>J</i> = 7.8 Hz, 2H), 7.32 (dt, <i>J</i> = 10.2, 7.7 Hz, 2H), 7.19 (t, <i>J</i> = 8.4 Hz, 2H), 7.13 (d, <i>J</i> = 4.9 Hz, 1H), 6.85 (dd, <i>J</i> = 8.0, 1.8 Hz, 1H), 6.64 (s, 1H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.4 (d, <i>J</i> = 243.9 Hz), 157.6, 150.3, 146.3, 142.6, 138.0, 131.5, 131.0, 129.8 (bs), 129.7, 128.8, 127.9, 125.2, 118.7, 116.3, 115.8, 115.2 (d, <i>J</i> = 21.5 Hz), 112.4, 97.9. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>28</sub>H<sub>19</sub>FN<sub>4</sub>O [M + H]<sup>+</sup>: 447.1616. Found: 447.1654. HPLC (method A): <i>t</i><sub>R</sub> = 8.473 min. Purity: 99.3% (254.4 nm), 99.6% (230.4 nm).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 2-(4-(4-Fluorophenyl)-5-(2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)ethan-1-ol (<b>11d</b>)</h3><div class="NLM_p last">The reaction was performed according to method D. Starting material: <b>10d</b>. The residue was washed with ice-cold Et<sub>2</sub>O, DCM, and <i>n</i>-pentane. The product was obtained as an off-white solid (67 mg, 71%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.36 (s, 1H), 12.15 (s, 1H), 8.17 (bs, 1H), 7.76 (d, <i>J</i> = 7.2 Hz, 2H), 7.54–7.35 (m, 4H), 7.31 (t, <i>J</i> = 6.9 Hz, 1H), 7.22–7.00 (m, 3H), 6.53 (bs, 1H), 4.86 (s, 1H), 3.86–3.83 (m, 2H), 2.91 (t, <i>J</i> = 6.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 198.8 (d, <i>J</i> = 240.0 Hz), 188.1, 184.7, 180.3, 175.7–175.1 (m), 169.2, 167.3–166.6 (m), 166.4, 165.5, 162.7, 155.9, 153.0–152.3 (m), 136.0–135.2 (m), 97.3, 69.4. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>24</sub>H<sub>19</sub>FN<sub>4</sub>O [M + H]<sup>+</sup>: 399.1616. Found: 399.1637. HPLC: <i>t</i><sub>R</sub> = 6.652 min. Purity: 100.0% (254.4 nm), 100.0% (230.4 nm).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 4-(4-(4-Fluorophenyl)-5-(2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)butan-1-ol (<b>11e</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>10e</b>. Solvent: MeOH and saturated K<sub>2</sub>CO<sub>3(aq)</sub> solution. After the removal of the aqueous alcohol solution in vacuo, the residue was treated with EA and water and stirred for 15 min. The precipitate was filtered off and was purified via flash chromatography (DCM:MeOH 12:1 to get rid of the impurities, after that product was eluted with 100% MeOH). The product was obtained as an off-white solid (54 mg, 26% over 2 steps). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.11 (bs, 2H), 8.16 (s, 1H), 7.77 (d, <i>J</i> = 7.8 Hz, 2H), 7.49–7.40 (m, 4H), 7.31 (t, <i>J</i> = 7.3 Hz, 1H), 7.12 (bs, 2H), 7.04 (d, <i>J</i> = 4.9 Hz, 1H), 6.53 (bs, 1H), 4.40 (bs, 1H), 3.48 (t, <i>J</i> = 6.5 Hz, 2H), 2.76 (t, <i>J</i> = 7.6 Hz, 2H), 1.91–1.75 (m, 2H), 1.61–1.49 (m, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.0 (d, <i>J</i> = 243.4 Hz), 150.4, 149.3, 142.6, 137.6 (bs), 131.5, 129.3 (bs), 128.8, 127.8, 125.1, 118.3, 115 (d, <i>J</i> = 22.4 Hz), 97.9 (bs), 60.4, 32.1, 27.6, 24.6. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>26</sub>H<sub>23</sub>FN<sub>4</sub>O [M + H]<sup>+</sup>: 427.1929. Found: 427.1991. HPLC (method A): <i>t</i><sub>R</sub> = 5.799 min. Purity: 100.0% (254.4 nm), 100.0% (230.4 nm).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3-(4-(4-Fluorophenyl)-5-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)propan-1-ol (<b>11f</b>)</h3><div class="NLM_p last">The reaction was performed according to method D. Starting material: <b>10f</b>. The solvent was removed in vacuo and the residue was treated with EA and water. The organic layer was separated, and the water layer was extracted four times with EA. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (gradient: 100% DCM → DCM:MeOH 8:1). The product was obtained as a white solid (20 mg, 48%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 12.25 (d, <i>J</i> = 26.5 Hz, 1H), 11.70 (s, 0.55H, r<sub>1</sub>/t<sub>1</sub>), 11.47 (s, 0.45H, r<sub>2</sub>/t<sub>2</sub>), 8.23 (d, <i>J</i> = 4.0 Hz, 0.55H, r<sub>1</sub>/t<sub>1</sub>), 8.08 (d, <i>J</i> = 4.1 Hz, 0.45H, r<sub>2</sub>/t<sub>2</sub>), 7.47–7.26 (m, 3H), 7.18 (t, <i>J</i> = 8.3 Hz, 1H), 7.08–6.95 (m, 2H), 6.24 (s, 0.45H, r<sub>1</sub>/t<sub>1</sub>), 5.91 (s, 0.55H, r<sub>2</sub>/t<sub>2</sub>), 4.64 (s, 1H), 3.53 (bs, 2H), 2.76 (t, <i>J</i> = 7.6 Hz, 2H), 2.02–1.72 (m, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 161.3 (d, <i>J</i> = 247.4 Hz, r<sub>1</sub>/t<sub>1</sub>), 160.8 (d, <i>J</i> = 242.8 Hz, r<sub>2</sub>/t<sub>2</sub>), 149.4, 149.3, 149.1, 148.8, 142.6, 142.2, 136.2, 135.2, 133.8, 131.9, 131.0, 129.7, 129.6, 128.7, 128.7, 127.8, 127.2, 126.1, 125.1, 123.3, 117.2, 117.0, 115.6, 115.5, 114.9, 114.8, 114.8, 114.1, 101.2 (r<sub>1</sub>/t<sub>1</sub>), 100.1 (r<sub>2</sub>/t<sub>2</sub>), 60.4, 31.3 (r<sub>1</sub>/t<sub>1</sub>), 31.2 (r<sub>2</sub>/t<sub>2</sub>), 24.7. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>19</sub>H<sub>17</sub>FN<sub>4</sub>O [M + H]<sup>+</sup>: 337.1459. Found: 337.1454. HPLC (method A): <i>t</i><sub>R</sub> = 3.795 min. Purity: 97.8% (254.4 nm), 97.8% (230.4 nm).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(3-(4-(4-Fluorophenyl)-5-(2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)benzyl)acrylamide (<b>19a</b>)</h3><div class="NLM_p last">The reaction was performed according to method I. Starting material: <b>18a</b>. Flash chromatography: DCM:MeOH 20:1. The product was obtained as a yellow solid (59 mg, 35%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 13.00 (s, 1H), 12.30 (s, 0.5H, r<sub>1</sub>/t<sub>1</sub>), 12.09 (s, 0.5H, r<sub>2</sub>/t<sub>2</sub>), 8.72 (d, <i>J</i> = 5.2 Hz, 1H), 8.34–8.08 (m, 2H), 8.03 (d, <i>J</i> = 7.2 Hz, 1H), 7.81 (d, <i>J</i> = 7.4 Hz, 2H), 7.59–7.38 (m, 5H), 7.36–7.25 (m, 3H), 7.22–7.05 (m, 2H), 6.82 (s, 0.5H, r<sub>1</sub>/t<sub>1</sub>), 6.47 (s, 0.5H, r<sub>2</sub>/t<sub>2</sub>), 6.34 (dd, <i>J</i> = 17.1, 10.2 Hz, 1H), 6.16 (d, <i>J</i> = 17.0 Hz, 1H), 5.62 (t, <i>J</i> = 11.9 Hz, 1H), 4.47 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 164.66 (s), 161.8 (d, <i>J</i> = 244.6 Hz, r<sub>1</sub>/t<sub>1</sub>), 161.1 (d, <i>J</i> = 241.6 Hz, r<sub>2</sub>/t<sub>2</sub>), 150.7, 150.3, 146.5, 146.1, 142.9, 142.6, 139.8 (d, <i>J</i> = 4.8 Hz), 138.4, 137.9, 137.5, 135.6, 134.3, 131.7, 131.4, 131.3, 130.7, 130.6, 130.4–130.2 (m), 130.1, 129.7, 128.9, 128.8, 128.1, 127.8, 127.6, 127.4–127.2 (m), 125.6–125.0 (m), 124.7, 124.5, 124.1, 124.0, 118.9, 118.5, 116.2–114.4 (m), 98.5 (r<sub>1</sub>/t<sub>1</sub>), 97.3 (r<sub>2</sub>/t<sub>2</sub>), 42.3. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>32</sub>H<sub>24</sub>FN<sub>5</sub>O [M + H]<sup>+</sup>: 514.2038. Found: 514.2029. HPLC (method A): <i>t</i><sub>R</sub> = 7.938 min. Purity: 100.0% (254.4 nm), 100% (230.4 nm).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>E</i>)-4-(Dimethylamino)-<i>N</i>-(3-(4-(4-fluorophenyl)-5-(2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)benzyl)but-2-enamide (<b>19b</b>)</h3><div class="NLM_p last">The reaction was performed according to method I. Starting material: <b>18a</b>. Flash chromatography: DCM:MeOH 10:1 + 1% 7N NH<sub>3</sub> in MeOH. The product was obtained as a yellow solid (61 mg, 70%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 12.99 (s, 1H), 12.31 (s, 0.5H, r<sub>1</sub>/t<sub>1</sub>), 12.10 (s, 0.5H, r<sub>2</sub>/t<sub>2</sub>), 8.63 (d, <i>J</i> = 4.4 Hz, 1H), 8.30 (d, <i>J</i> = 4.1 Hz, 0.5H, r<sub>1</sub>/t<sub>1</sub>), 8.12 (d, <i>J</i> = 4.3 Hz, 0.5H, r<sub>2</sub>/t<sub>2</sub>), 8.08 (s, 1H), 8.02 (d, <i>J</i> = 6.9 Hz, 1H), 7.81 (d, <i>J</i> = 6.2 Hz, 2H), 7.60–7.37 (m, 5H), 7.37–7.24 (m, 3H), 7.22–7.02 (m, 2H), 6.85–6.43 (m, 2H), 6.13 (d, <i>J</i> = 15.4 Hz, 1H), 4.45 (s, 2H), 2.96 (dd, <i>J</i> = 20.8, 4.6 Hz, 2H), 2.12 (d, <i>J</i> = 14.0 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 164.7, 161.8 (d, <i>J</i> = 247.8 Hz, r<sub>1</sub>/r<sub>1</sub>), 161.1 (d, <i>J</i> = 244.8 Hz, r<sub>2</sub>/t<sub>2</sub>), 150.7, 150.3, 146.5, 146.1, 142.9, 142.5, 140.0, 139.8, 138.4, 137.9, 137.5, 135.6, 134.3, 131.8–131.3 (m), 130.7–130.5 (m), 130.4–130.0 (m), 129.6, 128.9, 128.7, 128.1, 127.8, 127.5, 127.3, 125.8, 125.6–125.0 (m), 124.8–124.4 (m), 124.2–123.7 (m), 118.9, 118.5, 116.4–114.3 (m), 98.46 (r<sub>1</sub>/t<sub>1</sub>), 97.29 (r<sub>2</sub>/t<sub>2</sub>), 59.7, 45.0, 42.2. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>35</sub>H<sub>31</sub>FN<sub>6</sub>O [M + H]<sup>+</sup>: 571.2616. Found: 571.2608. HPLC (method A): <i>t</i><sub>R</sub> = 6.120 min. Purity: 100.0% (254.4 nm), 100% (230.4 nm).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(3-(4-Cyclopropyl-5-(2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)benzyl)acrylamide (<b>19c</b>)</h3><div class="NLM_p last">The reaction was performed according to method I. Starting material: <b>18b</b>. Flash chromatography: DCM:MeOH 10:1. The product was obtained as a yellow solid (36 mg, 42%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>; rotamers/tautomers) δ 12.68–12.02 (m, 2H), 8.78–8.66 (m, 1H), 8.33–8.20 (m, 1H), 8.09–7.88 (m, 4H), 7.61–7.04 (m, 7H), 6.43–6.08 (m, 2H), 5.61 (td, <i>J</i> = 10.2, 2.5 Hz, 1H), 4.50–4.39 (m, 2H), 2.30–1.92 (m, 1H), 1.14–0.81 (m, 4H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 164.7, 150.7, 150.3, 146.0, 144.1, 143.2–142.4 (m), 141.9, 139.7, 139.6, 138.0, 137.2, 136.5, 134.6, 133.1, 132.0, 131.7, 131.6, 130.7, 130.6, 130.3, 128.9, 128.7, 128.2–127.9 (m), 127.7, 127.4–127.0 (m), 125.6–125.2 (m), 124.6, 124.3, 124.2–123.6 (m), 118.5, 115.0, 114.0–113.3 (m), 99.3 (r<sub>1</sub>/t<sub>1</sub>), 97.6 (r<sub>2</sub>/t<sub>2</sub>), 42.3, 9.2, 8.5–6.5 (m). ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>29</sub>H<sub>25</sub>N<sub>5</sub>O [M + H]<sup>+</sup>: 460.2132. Found: 460.2128. HPLC (method A): <i>t</i><sub>R</sub> = 6.433 min. Purity: 97.9.0% (254.4 nm), 98.1% (230.4 nm).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-Chloro-2-iodo-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>23</b>)</h3><div class="NLM_p last">A solution of diisopropylamine (0.12 mL, 83 mg, 0.82 mmol) in 3 mL of dry THF was cooled down to −40 °C, and a <i>n</i>-BuLi solution (0.33 mL, 2.5 M in hexane) was added dropwise. After stirring at this temperature for 20 min, the solution was warmed to 0 °C, 4-chloro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (200 mg, 0.68 mmol) solved in 1 mL of dry THF was added, and the dark-brown solution was stirred at 0 °C for 40 min. The solution was cooled down to −78 °C, and a solution of iodine (173 mg, 0.68 mmol) in 0.5 mL of dry THF was added and stirred at this temperature for 3 h. The solution was warmed to room temperature, stirred for 1 h, and was quenched with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>-solution. The organic layer was separated, and the water layer was extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (hexane:EA 4:1). The product was obtained as a mixture of starting material and product (111 mg) and was used without further purification (it was possible to purify a small amount for the analytical data). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 8.28 (d, <i>J</i> = 4.3 Hz, 1H), 8.22 (d, <i>J</i> = 7.2 Hz, 2H), 7.78–7.69 (m, 1H), 7.65 (t, <i>J</i> = 7.5 Hz, 2H), 7.33 (d, <i>J</i> = 2.3 Hz, 1H), 7.23 (s, 1H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 150.8, 145.9, 139.4, 135.7, 135.0, 130.3, 129.0, 123.7, 120.4, 118.5, 79.7. FAB-MS (<i>m</i>/<i>z</i>): Calcd 417.90 for C<sub>13</sub>H<sub>8</sub>ClIN<sub>2</sub>O<sub>2</sub>S. Found: 418.8 [M + H]<sup>+</sup>. HPLC (method A): <i>t</i><sub>R</sub> = 8.402 min. Purity: 95.7% (254.4 nm), 94.4% (230.4 nm).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>tert</i>-Butyl-(3-(4-chloro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)phenyl)-carbamate (<b>24</b>)</h3><div class="NLM_p last">A mixture of <b>22</b> (111 mg, 0.47 mmol), <b>23</b> (38 mg, 0.16 mmol), Pd(PPh<sub>3</sub>)Cl<sub>2</sub> (5 mg, 0.007 mmol), 1.5 mL of MeCN (degassed), and 1.5 mL of 1 M K<sub>2</sub>CO<sub>3(aq)</sub>-solution (degassed) was stirred vigorously under argon at 60 °C for 16 h. After cooling to room temperature, the biphasic mixture was quenched with DCM and saturated NH<sub>4</sub>Cl<sub>(aq)</sub>-solution. The organic layer was separated, and the water layer was extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (hexane:EA 4:1). The product was obtained as a white solid (52 mg, 69%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.34 (d, <i>J</i> = 5.3 Hz, 1H), 8.01–7.89 (m, 2H), 7.68 (bs, 1H), 7.55–7.47 (m, 1H), 7.46–7.34 (m, 4H), 7.24–7.16 (m, 2H), 6.72–6.58 (m, 2H), 1.54 (s, 9H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 152.8, 150.3, 145.1, 142.5, 138.5, 138.1, 136.1, 134.1, 133.0, 128.9, 128.5, 128.1, 124.9, 121.7, 119.9, 119.8, 119.2, 107.1, 80.9, 28.5. FAB-MS (<i>m</i>/<i>z</i>): Calcd 483.10 for C<sub>24</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>4</sub>S. Found: 484.1 [M + H]<sup>+</sup>. HPLC (method A): <i>t</i><sub>R</sub> = 9.034 min. Purity: 94.9% (254.4 nm), 93.3% (230.4 nm).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>tert</i>-Butyl-(3-(4-(4-(4-fluorophenyl)-1-(methoxymethyl)-2-phenyl-1<i>H</i>-imidazol-5-yl)-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)phenyl)carbamate (<b>25</b>)</h3><div class="NLM_p last">The reaction was performed according to method C. Starting materials: <b>21a</b> and <b>24</b>. Equivalents of <i>n</i>-BuLi, 1.4; equiv of Sn(Bu)<sub>3</sub>Cl, 1.7. Flash chromatography, hexane:EA 6.5:3.5; second column, DCM:MeOH 98:2. The product was obtained as a pale-yellow solid (150 mg, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.53–8.49 (m, 1H), 7.85 (d, <i>J</i> = 6.9 Hz, 2H), 7.75 (d, <i>J</i> = 5.9 Hz, 2H), 7.49 (t, <i>J</i> = 6.8 Hz, 1H), 7.43–7.32 (m, 7H), 7.28–7.26 (m, 1H), 7.23–7.16 (m, 3H), 6.91 (d, <i>J</i> = 6.8 Hz, 1H), 6.70 (t, <i>J</i> = 8.4 Hz, 2H), 6.53 (d, <i>J</i> = 5.2 Hz, 1H), 6.05 (d, <i>J</i> = 3.0 Hz, 1H), 4.83 (dd, <i>J</i> = 71.7, 8.7 Hz, 2H), 3.00 (s, 3H), 1.44 (d, <i>J</i> = 2.6 Hz, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 162.2 (d, <i>J</i> = 246.4 Hz), 152.7, 150.9, 150.5, 145.1, 142.9, 139.3, 138.6, 138.0, 133.9, 133.0, 131.2, 129.9, 129.8, 129.3, 129.0 (d, <i>J</i> = 8.0 Hz), 128.9, 128.4, 128.1, 125.4, 124.6, 122.4, 121.2, 119.9, 119.2, 115.3 (d, <i>J</i> = 21.5 Hz), 109.1, 80.8, 75.2, 55.6, 28.5. FAB-MS (<i>m</i>/<i>z</i>): Calcd 729.24 for C<sub>41</sub>H<sub>36</sub>FN<sub>5</sub>O<sub>5</sub>S. Found: 730.4 [M + H]<sup>+</sup>. HPLC (method A): <i>t</i><sub>R</sub> = 9.172 min. Purity: 100.0% (254.4 nm), 100.0% (230.4 nm).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3-(4-(4-(4-Fluorophenyl)-2-phenyl-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)aniline (<b>26</b>)</h3><div class="NLM_p last">The reaction was performed according to method D. Starting material: <b>25</b>. Flash chromatography: DCM:MeOH 30:1 + 1% 7N NH<sub>3</sub> in MeOH. The product was obtained as yellow solid (83 mg, 88%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 8.12 (bs, 1H), 8.05 (d, <i>J</i> = 7.4 Hz, 2H), 7.50–7.33 (m, 5H), 7.11–6.89 (m, 6H), 6.56 (d, <i>J</i> = 7.8 Hz, 1H), 6.44 (bs, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 162.9 (d, <i>J</i> = 245.4 Hz), 151.0, 149.5, 148.0, 143.1, 140.2, 133.2, 130.9, 130.8, 130.3, 129.6, 126.5, 120.3, 116.4, 116.1, 115.9, 115.5, 115.1, 112.1, 98.3. ESI-HRMS (m/s) exact mass calculated for C<sub>28</sub>H<sub>20</sub>FN<sub>5</sub> [M + H]<sup>+</sup>: 446.1776. Found: 446.1761. HPLC (method A): <i>t</i><sub>R</sub> = 7.098 min. Purity: 98.9% (254.4 nm), 98.7% (230.4 nm).</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-(3-(4-(4-(4-Fluorophenyl)-2-phenyl-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)phenyl)acrylamide (<b>27a</b>).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></h3><div class="NLM_p last">Compound <b>26</b> (42 mg, 0.094 mmol) was dissolved in a mixture of 7 mL of THF and 0.7 mL of water. The mixure was cooled down to −15 °C and 64 μL of a 1.6 M 3-chloropropionic acid chloride in THF were added dropwise and the solution was stirred at this temperature for 30 min. NaOH (15 mg, 0.376 mmol) was added, and the mixture was stirred vigorously at 60 °C for 20 h. After cooling down to room temperature, water was added and the mixture was extracted five times with EA. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (DCM:MeOH 10:0.6). The product was obtained as a yellow solid (35 mg, 74%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 8.28–7.92 (m, 4H), 7.67–7.27 (8, 2H), 7.19–6.99 (m, 3H), 6.66 (bs, 1H), 6.52–6.23 (m, 2H), 5.72 (dd, <i>J</i> = 9.2, 2.8 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 164.5, 162.6 (d, <i>J</i> = 245.9 Hz), 151.1, 147.5, 143.4, 140.1, 138.9 (bs), 133.0, 132.3, 130.8, 130.8–130.2 (m), 130.0, 129.4, 129.3, 127.5, 126.3, 121.5, 120.1, 119.9, 117.4, 116.1, 115.7, 99.1 (bs). ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calcd for C<sub>31</sub>H<sub>22</sub>FN<sub>5</sub>O [M + H]<sup>+</sup>: 500.1881. Found: 500.1876. HPLC (method A): <i>t</i><sub>R</sub> = 7.643 min. Purity: 100.0% (254.4 nm), 100% (230.4 nm).</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-(3-(4-(4-(4-Fluorophenyl)-2-phenyl-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)phenyl)propionamide (<b>27b</b>)</h3><div class="NLM_p last">Compound <b>26</b> (32 mg, 0.072 mmol) was dissolved in 4 mL of dry THF under argon and was cooled to 0 °C. Propionyl chloride (7 μL, 7 mg, 0.079 mmol) was added dropwise, and the cloudy solution was stirred at this temperature for 10 min. The solution was warmed to room temperature, quenched with saturated K<sub>2</sub>CO<sub>3(aq)</sub>-solution, and stirred for 10 min. The organic layer was separated, and the water layer was extracted five times with EA. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (first column, DCM:MeOH 20:1; second column, hexane:EA 1:9). The product was obtained as a yellow solid (20 mg, 56%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 12.96 (s, 1H), 12.30 (s, 0.5H, r<sub>1</sub>/t<sub>1</sub>), 12.06 (s, 0.5H,r<sub>2</sub>/t<sub>2</sub>), 9.92 (s, 0.5H, r<sub>1</sub>/t<sub>1</sub>), 9.89 (s, 0.5H, r<sub>2</sub>/t<sub>2</sub>), 8.43–7.82 (m, 4H), 7.60–7.47 (m, 6H), 7.39 (dt, <i>J</i> = 15.6, 7.5 Hz, 2H), 7.14 (dd, <i>J</i> = 110.0, 60.5 Hz, 3H), 6.92 (s, 0.5H, r<sub>1</sub>/t<sub>1</sub>), 6.39 (s, 0.5H, r<sub>2</sub>/t<sub>2</sub>), 2.34 (bs, 2H), 1.10 (bs, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 172.1, 161.8 (d, <i>J</i> = 251.8 Hz, r<sub>1</sub>/t<sub>1</sub>), 161.1 (d, <i>J</i> = 244.2 Hz, r<sub>2</sub>/t<sub>2</sub>), 150.7, 150.2, 146.5, 146.1, 143.0, 142.6, 139.8, 138.8, 137.8, 135.6, 134.2, 132.2, 131.8, 131.3, 130.6 (d, <i>J</i> = 4.9 Hz), 130.3, 129.6, 129.3, 128.9–128.4 (m), 127.3, 125.4, 125.3, 120.3–118.5 (m), 116.7–114.1 (m), 98.7 (r<sub>1</sub>/t<sub>1</sub>), 97.1 (r<sub>2</sub>/t<sub>2</sub>), 29.5, 9.6. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>31</sub>H<sub>24</sub>FN<sub>5</sub>O [M + H]<sup>+</sup>: 502.2038. Found: 502.2025. HPLC (method A): <i>t</i><sub>R</sub> = 7.663 min. Purity: 98.3% (254.4 nm), 98.7% (230.4 nm).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (4-Chloro-1-(methoxymethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)boronic acid (<b>28</b>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></h3><div class="NLM_p last">Compound <b>5b</b> (309 mg, 1.58 mmol) was dissolved in 4 mL of dry THF under argon and cooled to −40 °C. <i>n</i>-BuLi-solution (2.5 M in hexane; 0.76 mL, 1.90 mmol) was added dropwise, and the dark-brown solution was stirred at −40 °C for 1 h. Trimethyl borate (0.23 mL, 2.05 mmol) was added dropwise. The solution was warmed to room temperature overnight, quenched with 8 mL 1 N HCl solution, and stirred for 20 min. The water layer was neutralized with saturated K<sub>2</sub>HPO<sub>4(aq)</sub>-solution and poured on Et<sub>2</sub>O. The organic layer was separated, and the water layer was extracted four times with Et<sub>2</sub>O. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The product was obtained as a brown oil (352 mg, 93%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>/D<sub>2</sub>O) δ 8.26 (dd, <i>J</i> = 5.1, 0.9 Hz, 1H), 7.25 (dd, <i>J</i> = 5.1, 1.0 Hz, 1H), 7.18 (d, <i>J</i> = 0.9 Hz, 1H), 5.85 (s, 2H), 3.62 (s, 2H), 3.13 (d, <i>J</i> = 1.0 Hz, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>/D<sub>2</sub>O) δ 151.2, 145.0, 135.3, 118.8, 116.5, 109.9, 73.7, 67.3, 55.9. HPLC (method A): <i>t</i><sub>R</sub> = 5.486 min. Purity: 100.0% (254.4 nm), 92.9% (230.4 nm).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>tert</i>-Butyl-(3-(4-chloro-1-(methoxymethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)benzyl)-carbamate (<b>30</b>)</h3><div class="NLM_p last">Compounds <b>29</b> (260 mg, 0.91 mmol), <b>28</b> (200 mg, 0.83 mmol), and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (28 mg, 0.04 mmol) were combined in a reaction flask and flushed with argon. A mixture of 1 M K<sub>2</sub>CO<sub>3(aq)</sub> (1.5 mL) and MeCN (1.5 mL) was added, and the reaction was stirred at 60 °C for 1.5 h. The cooled solution was quenched with DCM and saturated NH<sub>4</sub>Cl<sub>(aq)</sub>-solution. The organic layer was separated, and the water layer was extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (hexane:EA 4:1). The product was obtained as a colorless oil (230 mg, 70%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.22 (d, <i>J</i> = 5.2 Hz, 1H), 7.70–7.56 (m, 2H), 7.53–7.32 (m, 2H), 7.15 (d, <i>J</i> = 5.2 Hz, 1H), 6.68 (s, 1H), 5.59 (s, 2H), 5.01 (s, 1H), 4.40 (d, <i>J</i> = 5.9 Hz, 2H), 3.44 (s, 3H), 1.47 (s, 9H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 156.0, 150.5, 143.5, 142.7, 139.9, 135.6, 131.9, 129.2, 128.4, 128.0, 120.0, 117.3, 99.5, 79.8, 77.4, 73.1, 56.8, 44.7, 28.5. FAB-MS (<i>m</i>/<i>z</i>): Calcd 401.15 for C<sub>21</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>3</sub>. Found: 370.2 [M – O–CH<sub>3</sub>]<sup>+</sup>. HPLC (method A): <i>t</i><sub>R</sub> = 9.162 min. Purity: 95.5% (254.4 nm), 93.8% (230.4 nm).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>tert</i>-Butyl-(3-(4-(4-(4-fluorophenyl)-1-(methoxymethyl)-2-phenyl-1<i>H</i>-imidazol-5-yl)-1-(methoxymethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)benzyl)carbamate (<b>31</b>)</h3><div class="NLM_p last">The reaction was performed according to method C. Starting materials: <b>21a</b> and <b>30</b>. Equivalents of <i>n</i>-BuLi, 1.4; equiv of Sn(Bu)<sub>3</sub>Cl, 1.8. Flash chromatography: first column, hexane:EA 6:4; second column, DCM:MeOH 98:2. The product was obtained as a pale-yellow oil (150 mg, 33%, aliphatic/X-Phos impurities). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.48 (d, <i>J</i> = 5.0 Hz, 1H), 7.97–7.88 (m, 2H), 7.59–7.29 (m, 10H), 6.89 (t, <i>J</i> = 8.8 Hz, 2H), 6.23 (s, 1H), 5.78–5.52 (m, 2H), 5.20–4.85 (m, 3H), 4.35 (d, <i>J</i> = 6.3 Hz, 2H), 3.50 (s, 3H), 3.13 (s, 3H), 1.45 (s, 9H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 162.1 (d, <i>J</i> = 246.0 Hz), 156.0, 150.4, 150.1, 147.9, 146.0, 143.5, 143.0, 139.8, 138.6, 132.1, 131.8, 130.3, 130.2, 130.1, 129.6, 129.4, 129.1, 128.9, 128.8, 128.2, 128.2, 127.9, 126.3 (d, <i>J</i> = 0.9 Hz), 120.5, 120.4, 119.0, 115.2 (d, <i>J</i> = 21.4 Hz), 100.9, 80.0, 75.3, 73.0, 56.7, 55.7, 44.6, 44.6, 28.5. FAB-MS (<i>m</i>/<i>z</i>): Calcd 647.29 for C<sub>38</sub>H<sub>38</sub>FN<sub>5</sub>O<sub>4</sub>. Found: 515.4 [M – O–CH<sub>3</sub>–COOC(CH<sub>3</sub>)]<sup>+</sup>. HPLC (method A): <i>t</i><sub>R</sub> = 9.457 min. Purity: 91.4% (254.4 nm), 88.3% (230.4 nm).</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (3-(4-(4-(4-Fluorophenyl)-2-phenyl-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)phenyl)methanamine (<b>32</b>)</h3><div class="NLM_p last">The reaction was performed according to method D. Starting material: <b>31</b>. Flash chromatography: gradient DCM:MeOH 20:1 + 1% 7N NH<sub>3</sub> in MeOH → DCM:MeOH 10:1 + 1% 7N NH<sub>3</sub> in MeOH. The product was obtained as yellow solid (52 mg, 51%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 8.22–8.07 (m, 3H), 7.73 (s, 1H), 7.66–7.22 (m, 8H), 7.17–7.04 (m, 3H), 6.59 (s, 1H), 3.75 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 162.3 (d, <i>J</i> = 245.0 Hz), 150.9, 147.2, 144.3, 143.1, 138.9, 132.1, 130.7, 130.4, 130.3, 129.3, 129.2, 129.1, 127.4, 126.1, 124.8, 124.0, 119.6, 116.0, 115.6 (d, <i>J</i> = 21.6 Hz), 98.4, 45.7. FAB-MS (<i>m</i>/<i>z</i>): Calcud 459.19 for C<sub>29</sub>H<sub>22</sub>FN<sub>5</sub>. Found: 460.3 [M + H]<sup>+</sup>. HPLC (method A): <i>t</i><sub>R</sub> = 9.457. Purity: 93.6% (254.4 nm), 87.7% (230.4 nm).</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-(3-(4-(4-(4-Fluorophenyl)-2-phenyl-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)benzyl)acrylamide (<b>33</b>)</h3><div class="NLM_p last">The reaction was performed according to method I. Starting material: <b>32</b>. Flash chromatography: DCM:MeOH 20:1. The product was obtained as an off-white solid (10 mg, 23%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD; mixture of rotamers) δ 8.27–7.99 (m, 3H), 7.68–7.29 (m, 8H), 7.23–6.93 (m, 4H), 6.67 (s, 0.5 H, r<sub>1</sub>), 6.37 (s, 0.5H, r<sub>2</sub>), 6.32–6.08 (m, 2H), 5.60 (d, <i>J</i> = 9.8 Hz, 1H), 4.39 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD; mixture of rotamers) δ 166.5, 151.1, 143.5, 140.5, 132.0, 130.9, 129.7, 129.5, 127.9, 126.4, 126.3, 125.3, 124.8, 120.0, 116.3–115.7 (m), 43.2. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>32</sub>H<sub>24</sub>FN<sub>5</sub>O [M + H]<sup>+</sup>: 514.2038. Found: 514.2043. HPLC (method A): <i>t</i><sub>R</sub> = 7.393 min. Purity: 97.9% (254.4 nm), 98.7% (230.4 nm).</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (1-((2-(Trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)boronic Acid (<b>35</b>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></h3><div class="NLM_p last">Compound <b>34</b> (208 mg, 0.84 mmol) was dissolved in 1.9 mL dry THF under argon and was cooled to −40 °C. <i>n</i>-BuLi (2.5 M in hexane; 0.4 mL, 0.10 mmol) was added dropwise, and the solution was stirred at this temperature for 35 min. Trimethylborate (0.12 mL, 113 mg, 1.09 mmol) was added dropwise and warmed to room temperature overnight. The solution was quenched with saturated NH<sub>4</sub>Cl solution and stirred for 40 min. The suspension was neutralized with saturated K<sub>2</sub>HPO<sub>4(aq)</sub>-solution and stirred for 20 min. The organic layer was separated, and the water layer was extracted three times with Et<sub>2</sub>O. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The product was obtained as a yellow foam (197 mg, 81%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.44 (s, 2H), 8.30 (dd, <i>J</i> = 4.6, 1.5 Hz, 1H), 8.00 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.10 (dd, <i>J</i> = 7.3, 5.2 Hz, 2H), 5.91 (s, 2H), 3.95–2.92 (m, 2H), 0.99–0.47 (m, 2H), −0.15 (s, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.4, 143.8, 129.0, 119.5, 116.2, 111.9, 71.0, 64.8, 17.2, −1.5. HPLC (method A): <i>t</i><sub>R</sub> = 8.947 min. Purity: 81.7% (254.4 nm), 84.8% (230.4 nm).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-(3-(1-((2-(Trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)benzyl)-acrylamide (<b>36</b>)</h3><div class="NLM_p last">Compound <b>35</b> (229 mg, 0.59 mmol), 3-bromo benzylamine (85 mg, 0.45 mmol), and K<sub>2</sub>CO<sub>3</sub> (186 mg, 1.35 mmol) were mixed with 3 mL of dioxane and 0.75 mL of H<sub>2</sub>O in a pressure tube and flushed with argon for 15 min. Pd(PPh<sub>3</sub>)<sub>4</sub> (25 mg, 0.04 mmol) was added, and the mixture was flushed with argon for 5 min. The tube was sealed, and the mixture was stirred vigorously at 80 °C for 2 h. After cooling to room temperature, EA and saturated NaHCO<sub>3(aq)</sub>-solution were added. The organic layer was separated, and the water layer was extracted 4 times with EA. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (DCM + 2% 7 N NH<sub>3</sub> in MeOH). The purified compound (134 mg, 0.38 mmol) was dissolved in 14 mL of dry THF under argon, and DIPEA (77 μL, 58 mg, 0.45 mmol) was added. The solution was cooled to 0 °C and acrylic acid chloride (37 μL, 41 mg, 0.45 mmol) was added and the solution was stirred at 0 °C for 20 min. The solution was quenched with EA and saturated NaHCO<sub>3(aq)</sub>-solution and stirred for 10 min. The organic layer was separated, and the water layer was extracted three times with EA. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (gradient: 100% hexane → hexane:EA 6:4). The product was obtained as a colorless viscous oil (117 mg, 49%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.33 (dd, <i>J</i> = 4.8, 1.4 Hz, 1H), 7.89 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.74–7.66 (m, 2H), 7.52–7.28 (m, 2H), 7.11 (dd, <i>J</i> = 7.8, 4.8 Hz, 1H), 6.56 (s, 1H), 6.42–6.04 (m, 3H), 5.71–5.58 (m, 3H), 4.58 (d, <i>J</i> = 5.8 Hz, 2H), 3.83–3.59 (m, 2H), 0.99–0.89 (m, 2H), −0.06 (s, 9H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 165.6, 149.7, 143.0, 141.9, 138.8, 132.6, 130.7, 129.2, 128.7, 128.6, 128.5, 128.0, 127.0, 120.7, 117.1, 101.2, 70.8, 66.5, 43.7, 18.2, −1.3. ESI-MS (<i>m</i>/<i>z</i>): Calcd 407.20 for C<sub>23</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>Si. Found: 430.3 [M + Na]<sup>+</sup>. HPLC (method A): <i>t</i><sub>R</sub> = 9.580 min. Purity: 100.0% (254.4 nm), 100.0% (230.4 nm).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(3-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-2-yl)benzyl)acrylamide (<b>37</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>36</b>. Solvent: MeOH and saturated NaHCO<sub>3(aq)</sub>-solution. After workup, the residue was washed with water, DCM, Et<sub>2</sub>O, and <i>n</i>-pentane, and the product was obtained as a white solid (33 mg, 54%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.17 (s, 1H), 8.66 (t, <i>J</i> = 5.3 Hz, 1H), 8.21 (d, <i>J</i> = 3.4 Hz, 1H), 7.94 (d, <i>J</i> = 7.7 Hz, 1H), 7.89–7.80 (m, 2H), 7.43 (t, <i>J</i> = 7.7 Hz, 1H), 7.25 (d, <i>J</i> = 7.5 Hz, 1H), 7.06 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 6.89 (d, <i>J</i> = 1.8 Hz, 1H), 6.33 (dd, <i>J</i> = 17.1, 10.1 Hz, 1H), 6.16 (dd, <i>J</i> = 17.1, 2.1 Hz, 1H), 5.64 (dd, <i>J</i> = 10.1, 2.1 Hz, 1H), 4.43 (d, <i>J</i> = 5.8 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.6, 149.6, 142.8, 139.9, 138.1, 131.8, 131.6, 128.9, 127.8, 127.0, 125.3, 124.5, 123.9, 120.8, 116.0, 97.1, 42.2. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>17</sub>H<sub>15</sub>N<sub>3</sub>O [M + H]<sup>+</sup>: 278.1288. Found: 278.1278. HPLC (method A): <i>t</i><sub>R</sub> = 6.167 min. Purity: 97.6% (254.4 nm), 97.6% (230.4 nm).</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 4-Chloro-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>38</b>)</h3><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.35 mmol) was dissolved in 1 mL of dry MeCN under argon and cooled to 0 °C. NIS (87 mg, 0.39 mmol) was added portionwise, and the solution was warmed to 50 °C and stirred at this temperature overnight. The solvent was removed in vacuo. The residue was purified via flash chromatography (hexane:EA 4:1). The product was obtained as a yellow oil (94 mg, 66%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.19 (d, <i>J</i> = 5.0 Hz, 1H), 7.51 (s, 1H), 7.11 (d, <i>J</i> = 5.2 Hz, 1H), 5.62 (s, 2H), 3.65–3.29 (m, 2H), 1.01–0.74 (m, 2H), −0.06 (s, 9H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 148.2, 144.1, 137.2, 134.3, 118.3, 117.8, 73.2, 66.8, 50.9, 17.9, −1.3. ESI-MS (<i>m</i>/<i>z</i>): Calcd 407.99 for C<sub>13</sub>H<sub>18</sub>ClIN<sub>2</sub>OSi. Found: 463.0 [M + Na + MeOH]<sup>+</sup>. HPLC (method A): <i>t</i><sub>R</sub> = 11.151 min. Purity: 100.0% (254.4 nm), 96.3% (230.4 nm).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(3-(4-Chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)acrylamide (<b>40</b>)</h3><div class="NLM_p last">Compounds <b>38</b> (70 mg, 0.17 mmol), <b>39</b> (39 mg, 0.21 mmol), and Pd (PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (28 mg, 0.04 mmol) were combined in a reaction flask and flushed with argon. A mixture of 1 M Na<sub>2</sub>CO<sub>3(aq)</sub> (1.5 mL) and MeCN (1.5 mL) was added, and the reaction was stirred at 60 °C for 10 min. The cooled solution was quenched with DCM and saturated NH<sub>4</sub>Cl<sub>(aq)</sub>-solution. The organic layer was separated, and the water layer was extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (hexane:EA 3:2). The product was obtained as a brown viscous oil (46 mg, 62%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.21 (d, <i>J</i> = 5.2 Hz, 1H), 7.95–7.53 (m, 3H), 7.39–7.21 (m, 3H), 7.09 (d, <i>J</i> = 5.1 Hz, 1H), 6.53–6.18 (m, 2H), 5.76–5.60 (m, 3H), 3.63–3.52 (m, 2H), 0.98–0.87 (m, 2H), 0.00–0.11 (m, 9H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 163.9, 149.2, 143.6, 137.4, 136.6, 134.9, 131.3, 128.4, 127.9, 127.7, 126.9, 122.1, 118.7, 118.1, 116.9, 112.4, 73.3, 66.7, 17.9, −1.3. ESI-MS (<i>m</i>/<i>z</i>): Calcd 427.15 for C<sub>22</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub>Si. Found: 450.1 [M + Na]<sup>+</sup>. HPLC (method A): <i>t</i><sub>R</sub> = 9.482 min. Purity: 100.0% (254.4 nm), 100.0% (230.4 nm).</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-(3-(4-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)acrylamide (<b>41</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>40</b>. Solvent: EtOH and saturated NaHCO<sub>3(aq)</sub>-solution. Flash chromatography: DCM:MeOH 95:5. The product was obtained as a white solid (11 mg, 39%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.27 (s, 1H), 10.19 (s, 1H), 8.21 (d, <i>J</i> = 5.1 Hz, 1H), 7.81 (s, 1H), 7.71–7.60 (m, 2H), 7.34 (t, <i>J</i> = 7.8 Hz, 1H), 7.20 (d, <i>J</i> = 5.4 Hz, 2H), 6.46 (dd, <i>J</i> = 16.9, 10.1 Hz, 1H), 6.25 (dd, <i>J</i> = 16.9, 1.4 Hz, 1H), 5.78–5.73 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.2, 149.5, 143.3, 138.4, 134.8, 134.5, 131.9, 127.9, 126.7, 126.2, 125.6, 121.3, 117.5, 116.8, 115.3, 115.2. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>16</sub>H<sub>12</sub>ClN<sub>3</sub>O [M + H]<sup>+</sup>: 298.0742. Found: 298.0744. HPLC (method A): <i>t</i><sub>R</sub> = 5.884 min. Purity: 97.5% (254.4 nm), 97.5% (230.4 nm).</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 4-(4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1<i>H</i>-imidazol-5-yl)-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>42a</b>)</h3><div class="NLM_p last">A solution of <b>10f</b> (167 mg, 0.22 mmol) in 2 mL of dry MeCN under argon was cooled to 0 °C and a solution of NIS (60 mg, 0.27 mmol) in 0.7 mL of dry MeCN was added dropwise. The solution was heated to 50 °C and stirred at this temperature for 5 h. A solution of NIS (10 mg, 0.04 mmol) in 0.2 mL of dry MeCN was added dropwise, and the solution was stirred at 50 °C for 12 h. The dark-brown solution was cooled down to room temperature and was quenched with a mixture of saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3(aq)</sub>-solution and brine. The mixture was extracted four times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (H:EA 4:1). The product was obtained as a brown oil (140 mg, 71%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.41 (d, <i>J</i> = 4.8 Hz, 1H), 7.51 (s, 1H), 7.33 (dd, <i>J</i> = 8.9, 5.5 Hz, 2H), 7.11 (d, <i>J</i> = 4.8 Hz, 1H), 6.80 (t, <i>J</i> = 8.8 Hz, 2H), 5.69 (s, 2H), 4.95 (dd, <i>J</i> = 112.1, 11.0 Hz, 2H), 3.87 (t, <i>J</i> = 6.0 Hz, 2H), 3.69–3.49 (m, 2H), 3.35–3.11 (m, 2H), 3.10–2.96 (m, 2H), 2.30–1.99 (m, 2H), 1.14–1.02 (m, 21H), 1.00–0.88 (m, 2H), 0.78–0.64 (m, 2H), −0.03 to −0.08 (m, 9H), −0.08 to −0.14 (m, 9H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 161.8 (d, <i>J</i> = 245.2 Hz), 149.8, 147.8, 144.2, 138.1, 134.3, 132.9, 130.8 (d, <i>J</i> = 3.1 Hz), 128.3 (d, <i>J</i> = 7.9 Hz), 121.0, 120.9 (d, <i>J</i> = 1.1 Hz), 120.6, 115.1 (d, <i>J</i> = 21.3 Hz), 73.2, 66.8, 66.3, 62.8, 52.3, 32.2, 23.8, 18.2, 17.9, 17.8, 12.2, −1.3, −1.3. ESI-MS (<i>m</i>/<i>z</i>): Calcd 878.33 for C<sub>40</sub>H<sub>64</sub>FIN<sub>4</sub>O<sub>3</sub>Si<sub>3</sub>. Found: 879.7 [M + H]<sup>+</sup>. HPLC (method B): <i>t</i><sub>R</sub> = 22.586 min. Purity: 99.1% (254.4 nm), 99.2% (230.4 nm).</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 3-(4-(4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1<i>H</i>-imidazol-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)aniline (<b>43a</b>)</h3><div class="NLM_p last">Compound <b>42a</b> (50 mg, 0.057 mmol), 3-nitro phenylboronic acid (11 mg, 0.063 mmol), K<sub>2</sub>CO<sub>3</sub> (24 mg, 0.171 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (7 mg, 0.006 mmol) were combined, flushed with argon, and 0.5 mL of a 4:1 mixture of DMF:water (degassed) were added. The mixture was stirred at 80 °C for 30 min (this reaction was repeated for three times in this small volume because upscaling led to less yield and more side products). All four reactions were cooled down to room temperature, combined, and quenched with DCM and saturated NH<sub>4</sub>Cl<sub>(aq)</sub>-solution. The mixture was stirred for 5 min, the organic layer was separated, and the aqueous layer was extracted three times with DCM. The combined organic layers were washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (gradient: hexane:EA 9:1 → hexane:EA 4:1). The product was obtained as mixture with the dehalogenated starting material (orange oil, m = 157 mg). The crude product was dissolved in 95 mL of EA, 30 mg of Pd on charcoal (10%) was added, and the mixture was stirred under 6 bar hydrogen pressure at 75 °C for 24 h. The mixture was cooled to room temperature, and the solid was filtrated over Celite. The solvent was removed in vauo. The residue was purified via flash chromatography (gradient: hexane:EA 4:1 → hexane:EA 7:3). The product was obtained as a colorless oil (90 mg, 47%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 4.8 Hz, 1H), 7.48–7.43 (m, 3H), 7.06 (d, <i>J</i> = 4.0 Hz, 1H), 6.95 (t, <i>J</i> = 7.7 Hz, 1H), 6.89 (t, <i>J</i> = 8.4 Hz, 2H), 6.54 (d, <i>J</i> = 7.3 Hz, 1H), 6.46 (d, <i>J</i> = 7.9 Hz, 1H), 6.20 (s, 1H), 5.78 (s, 2H), 4.46 (dd, <i>J</i> = 29.6, 11.4 Hz, 2H), 3.76 (t, <i>J</i> = 6.1 Hz, 2H), 3.67 (t, <i>J</i> = 8.7 Hz, 2H), 3.41 (bs, 2H), 3.19–3.03 (m, 1H), 2.81–2.75 (m, <i>J</i> = 1H), 2.62 (t, <i>J</i> = 7.9 Hz, 2H), 2.02–1.73 (m, 2H), 1.15–1.03 (m, 21H), 1.01–0.92 (m, 2H), 0.59–0.47 (m, 2H), −0.04 to −0.05 (m, 9H), −0.17 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 161.9 (d, <i>J</i> = 245.5 Hz), 149.8, 149.2, 146.3, 143.8, 136.0, 134.4, 131.8, 130.7 (d, <i>J</i> = 2.9 Hz), 128.8, 128.5 (d, <i>J</i> = 7.8 Hz), 127.3, 125.4, 120.3, 118.9, 118.2, 118.1, 115.9, 115.2 (d, <i>J</i> = 21.3 Hz), 113.6, 73.3, 72.4, 66.7, 65.9, 63.1, 31.4, 31.4, 23.7, 23.7, 18.2, 17.9, 17.7, 12.2, −1.3, −1.4. ESI-MS (<i>m</i>/<i>z</i>): Calcd 843.48 for C<sub>46</sub>H<sub>70</sub>FN<sub>5</sub>O<sub>3</sub>Si<sub>3</sub>. Found: 845.3 [M + H]<sup>+</sup>. HPLC (method B): <i>t</i><sub>R</sub> = 20.898 min. Purity: 100.0% (254.4 nm), 92.9% (230.4 nm).</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-(3-(4-(4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2(trimethylsilyl)-ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)acrylamide (<b>44a</b>)</h3><div class="NLM_p last">The reaction was performed according to method J. Starting material: <b>43a</b>. Flash chromatography: DCM:MeOH 98:2. The product was obtained as a colorless oil (115 mg, 91%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.44 (d, <i>J</i> = 4.8 Hz, 1H), 7.65 (d, <i>J</i> = 7.7 Hz, 1H), 7.51 (s, 1H), 7.43 (dd, <i>J</i> = 8.4, 5.6 Hz, 2H), 7.19–7.08 (m, 3H), 6.94–6.81 (m, 3H), 6.73 (s, 1H), 6.41–6.07 (m, 2H), 5.85–5.69 (m, 3H), 4.48 (dd, <i>J</i> = 39.7, 11.2 Hz, 2H), 3.78–3.60 (m, 4H), 3.20–2.84 (m, 2H), 2.69–2.48 (m, 2H), 2.02–1.66 (m, 2H), 1.14–0.93 (m, 23H), 0.64–0.51 (m, 2H), −0.04 (s, 9H), −0.15 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.5, 161.9 (d, <i>J</i> = 246.0 Hz), 150.0, 149.2, 144.0, 137.4, 136.1, 134.0, 131.7, 131.5, 130.5 (d, <i>J</i> = 3.2 Hz), 128.7, 128.1 (d, <i>J</i> = 7.8 Hz), 127.6, 127.4, 125.3, 124.4, 120.6, 120.3, 119.0, 118.1, 117.3, 115.3 (d, <i>J</i> = 21.4 Hz), 73.4, 72.4, 66.8, 66.0, 62.9, 31.3, 23.6, 18.2, 17.9, 17.8, 12.2, −1.3, −1.4. ESI-MS (<i>m</i>/<i>z</i>): Calcd 897.49 for C<sub>49</sub>H<sub>72</sub>FN<sub>5</sub>O<sub>4</sub>Si<sub>3</sub>. Found: 898.8 [M + H]<sup>+</sup>. HPLC (method B): <i>t</i><sub>R</sub> = 21.181 min. Purity: 100.0% (254.4 nm), 100.0% (230.4 nm).</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>-(3-(4-(4-(4-Fluorophenyl)-2-(3-hydroxypropyl)-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)acrylamide (<b>45a</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>44a</b>. Solvent: MeOH and saturated NaHCO<sub>3(aq)</sub>-solution. Flash chromatography: gradient DCM:MeOH 9:1 → DCM:MeOH 6:1. The product was obtained as a white solid (36 mg, 59%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 12.07–11.68 (m, 2H), 9.96–9.75 (m, 1H), 8.30 (s, 1H), 7.61–7.02 (m, 5H), 6.92–6.53 (m, 4H), 6.51–6.16 (m, 3H), 5.72 (d, <i>J</i> = 9.8 Hz, 1H), 4.60 (bs, 1H), 3.61–3.39 (m, 1H), 2.65 (bs, 0.8H, r<sub>1</sub>/t<sub>1</sub>), 2.50 (bs, 1.2H, r<sub>2</sub>/t<sub>2</sub>), 1.82 (bs, 0.8H, r<sub>1</sub>/t<sub>1</sub>), 1.67 (bs, 1.2H, r<sub>2</sub>/t<sub>2</sub>). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 164.4, 162.0 (d, <i>J</i> = 244.0 Hz), 150.0, 149.4, 143.4, 138.6, 136.2, 132.5, 128.6 (d, <i>J</i> = 6.9 Hz), 127.8, 126.9, 125.4, 125.0, 120.7, 118.4, 117.9, 117.7, 116.6, 116.6, 115.1 (d, <i>J</i> = 21.5 Hz), 61.4, 32.0, 25.2. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>28</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 482.1987. Found: 482.1985. HPLC (method A): <i>t</i><sub>R</sub> = 3.250 min. Purity: 98.6% (254.4 nm), 98.4% (230.4 nm).</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> <i>N</i>-(3-(4-(4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2-(trimethylsilyl)-ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)propionamide (<b>44b</b>)</h3><div class="NLM_p last">The reaction was performed according to method J. Starting material: <b>43a</b>. Flash chromatography: DCM:MeOH 98:2. The product was obtained as a yellow oil (93 mg, 89%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.43 (d, <i>J</i> = 4.8 Hz, 1H), 7.59–7.38 (m, 4H), 7.18–7.04 (m, 2H), 7.01 (s, 1H), 6.87 (t, <i>J</i> = 8.8 Hz, 3H), 6.71 (t, <i>J</i> = 1.7 Hz, 1H), 5.85–5.69 (m, 2H), 4.45 (dd, <i>J</i> = 22.8, 11.2 Hz, 2H), 3.77–3.61 (m, 4H), 3.22–2.76 (m, 2H), 2.69–2.45 (m, 2H), 2.35–2.19 (m, 2H), 2.06–1.61 (m, 2H), 1.15 (t, <i>J</i> = 7.5 Hz, 3H), 1.10–0.90 (m, 23H), 0.63–0.49 (m, 2H), −0.01 to −0.10 (m, 9H), −0.12 to −0.22 (m, 9H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 171.9, 161.8 (d, <i>J</i> = 246.0 Hz), 149.9, 149.1, 143.9, 137.6, 135.9, 133.9, 131.6, 130.4 (d, <i>J</i> = 3.2 Hz), 128.6, 128.1 (d, <i>J</i> = 7.8 Hz), 127.5, 125.2, 124.0, 120.6, 120.2, 119.0, 118.0, 117.3, 115.3 (d, <i>J</i> = 21.4 Hz), 73.3, 72.3, 66.7, 65.9, 62.8, 31.3, 30.6, 23.5, 18.2, 17.9, 17.7, 12.1, 9.6, −1.3, −1.4. ESI-MS (<i>m</i>/<i>z</i>): Calcd 899.50 for C<sub>49</sub>H<sub>74</sub>FN<sub>5</sub>O<sub>4</sub>Si<sub>3</sub>. Found: 900.8 [M + H]<sup>+</sup>. HPLC (method B): <i>t</i><sub>R</sub> = 22.312 min. Purity: 99.1% (254.4 nm), 98.8% (230.4 nm).</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-(3-(4-(4-(4-Fluorophenyl)-2-(3-hydroxypropyl)-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)propionamide (<b>45b</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>44b</b>. Solvent: MeOH and saturated NaHCO<sub>3(aq)</sub>-solution. Flash chromatography: gradient DCM:MeOH 9:1 → DCM:MeOH 5:1. The product was obtained as a white solid (34 mg, 68%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 8.24 (d, <i>J</i> = 4.9 Hz, 1H), 7.38–7.21 (m, 2H), 7.09 (d, <i>J</i> = 4.9 Hz, 1H), 6.97 (s, 1H), 6.90–6.61 (m, 5H), 6.29 (d, <i>J</i> = 6.8 Hz, 1H), 3.48 (t, <i>J</i> = 6.3 Hz, 2H), 2.61 (t, <i>J</i> = 7.6 Hz, 2H), 2.25 (q, <i>J</i> = 7.4 Hz, 2H), 1.89–1.62 (m, 2H), 1.07 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>/MeOD) δ 173.5, 163.3, 160.9, 150.0, 149.4, 143.4, 138.9, 136.2, 128.6 (d, <i>J</i> = 8.0 Hz), 127.7, 125.4, 124.6, 120.6, 118.4, 118.0, 117.6, 116.6, 115.1 (d, <i>J</i> = 21.6 Hz), 61.5, 32.1, 30.4, 25.2, 10.0. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>28</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 484.2143. Found: 484.2136. HPLC (method A): <i>t</i><sub>R</sub> = 3.250 min. Purity: 100.0 % (254.4 nm), 100.0 (230.4 nm).</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>N</i>-(3-(4-(4-Cyclopropyl-2-(3-hydroxypropyl)-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)acrylamide (<b>45c</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>44c</b>. Solvent: MeOH and saturated NaHCO<sub>3(aq)</sub>-solution. The residue was purified via flash chromatography (DCM:MeOH 5:1). The product was washed with cold DCM, Et<sub>2</sub>O, and <i>n</i>-pentane and was obtained as an off-white solid (50 mg, 67%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 11.91 (s, 1H), 11.19 (bs, 1H), 9.92 (s, 1H), 8.26 (d, <i>J</i> = 4.0 Hz, 1H), 7.63–7.35 (m, 3H), 7.06 (d, <i>J</i> = 4.7 Hz, 1H), 6.96 (t, <i>J</i> = 7.8 Hz, 1H), 6.57 (d, <i>J</i> = 7.4 Hz, 1H), 6.44 (dd, <i>J</i> = 16.9, 10.2 Hz, 1H), 6.23 (d, <i>J</i> = 16.5 Hz, 1H), 5.72 (d, <i>J</i> = 10.8 Hz, 1H), 4.66 (bs, 1H), 3.39 (bs, 2H), 2.42 (bs, 2H), 1.63 (bs, 2H), 1.32 (bs, 1H), 0.49–0.13 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 162.8, 149.5, 147.6–145.6 (m), 142.3, 138.0, 135.8, 132.1, 126.9, 126.3, 124.5, 123.8, 119.5, 117.1, 116.7, 116.4, 115.5, 60.4, 31.1, 24.7, 6.6. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>25</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 428.2081. Found: 428.2137. HPLC (method A): <i>t</i><sub>R</sub> = 2.626 min. Purity: 100.0% (254.4 nm), 99.6% (230.4 nm).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>N</i>-(3-(4-(4-Cyclopropyl-2-(3-hydroxypropyl)-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)propionamide (<b>45d</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>44d</b>. Solvent: MeOH and saturated K<sub>2</sub>CO<sub>3(aq)</sub>-solution. The residue was purified via flash chromatography (DCM:MeOH 6:1). The product was washed with cold DCM, Et<sub>2</sub>O, and <i>n</i>-pentane and was obtained as an off-white solid (42 mg, 78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1H), 9.65 (s, 1H), 8.25 (d, <i>J</i> = 4.7 Hz, 1H), 7.56–7.30 (m, 3H), 7.06 (d, <i>J</i> = 4.7 Hz, 1H), 6.91 (t, <i>J</i> = 7.8 Hz, 1H), 6.50 (d, <i>J</i> = 7.5 Hz, 1H), 3.40 (t, <i>J</i> = 6.0 Hz, 2H), 2.43 (bs, 2H), 2.30 (dd, <i>J</i> = 14.9, 7.4 Hz, 2H), 1.71–1.59 (m, 2H), 1.32 (bs, 1H), 1.08 (t, <i>J</i> = 7.5 Hz, 3H), 0.47–0.20 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.5, 149.5, 146.6, 142.3, 138.4, 135.6, 126.7, 124.4, 123.2, 119.2, 117.1, 116.8, 116.1, 115.5, 60.4, 31.1, 29.4, 24.7, 9.6, 7.2, 6.6. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>25</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 430.2238. Found: 430.2242. HPLC (method A): <i>t</i><sub>R</sub> = 2.852 min. Purity: 100.0% (254.4 nm), 100.0% (230.4 nm).</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> <i>N</i>-(3-(4-(2-(3-Hydroxypropyl)-4-(trifluoromethyl)-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)acrylamide (<b>45e</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>44e</b>. Solvent: MeOH and saturated NaHCO<sub>3(aq)</sub>-solution. The residue was purified via flash chromatography (gradient: 100% DCM → DCM:MeOH 8:1). The product was washed with cold DCM, Et<sub>2</sub>O, and <i>n</i>-pentane and was obtained as an off-white solid (28 mg, 51%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.07 (s, 2H), 9.94 (s, 1H), 8.33 (d, <i>J</i> = 4.7 Hz, 1H), 7.60 (d, <i>J</i> = 12.1 Hz, 2H), 7.37 (d, <i>J</i> = 7.8 Hz, 1H), 7.06 (d, <i>J</i> = 4.7 Hz, 1H), 6.96 (t, <i>J</i> = 7.8 Hz, 1H), 6.50 (d, <i>J</i> = 7.6 Hz, 1H), 6.44 (dd, <i>J</i> = 17.0, 10.2 Hz, 1H), 6.24 (dd, <i>J</i> = 17.0, 1.7 Hz, 1H), 5.73 (dd, <i>J</i> = 10.3, 1.6 Hz, 1H), 4.39 (s, 1H), 3.35 (t, <i>J</i> = 6.1 Hz, 2H), 2.35 (t, <i>J</i> = 7.7 Hz, 2H), 1.65–1.44 (m, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.9, 148.9, 148.5, 142.3, 138.4, 135.0, 132.0, 129.0, 127.5–127.3 (m), 126.3, 125.7, 125.5, 125.3, 125.1, 123.3, 123.2, 121.6, 119.4, 117.7, 116.7, 116.3, 116.1, 60.0, 30.5, 24.0. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 556.1642. Found: 556.1633. HPLC (method A): <i>t</i><sub>R</sub> = 5.531 min. Purity: 97.9% (254.4 nm), 97.9% (230.4 nm).</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N</i>-(3-(4-(4-(4-Fluorophenyl)-2-phenyl-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)acrylamide (<b>45f</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>44f</b>. Solvent: EtOH and NaHCO<sub>3(aq)</sub>. Flash chromatography (gradient: 100% DCM → DCM:MeOH 92:8). The product was washed with <i>n</i>-pentane and was obtained as an off-white solid (46 mg, 58%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 12.51 (s, 0.65H, r<sub>1</sub>/t<sub>1</sub>), 12.33 (s, 0.35H, r<sub>2</sub>/t<sub>2</sub>), 12.05 (d, <i>J</i> = 1.8 Hz, 0.65H, r<sub>1</sub>/t<sub>1</sub>), 11.87 (d, <i>J</i> = 1.8 Hz, 0.35H, r<sub>2</sub>/t<sub>2</sub>), 9.79 (s, 0.65H, r<sub>1</sub>/t<sub>1</sub>), 9.73 (s, 1H, 0.35H, r<sub>2</sub>/t<sub>2</sub>), 8.37 (d, <i>J</i> = 4.8 Hz, 0.65H, r<sub>1</sub>/t<sub>1</sub>), 8.33 (d, <i>J</i> = 4.8 Hz, 0.35H, r<sub>2</sub>/t<sub>2</sub>), 7.94 (d, <i>J</i> = 7.2 Hz, 0.7H, r<sub>1</sub>/t<sub>1</sub>), 7.78 (d, <i>J</i> = 7.0 Hz, 1.3H, r/t<sub>2</sub>), 7.57–7.27 (m, 5H), 7.24–7.06 (m, 3H), 6.99–6.70 (m, 4H), 6.45–6.20 (m, 2H), 6.16–6.04 (m, 1H), 5.59 (td, <i>J</i> = 9.8, 2.1 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 163.2 (r/t<sub>1</sub>), 163.1 (r/t<sub>2</sub>), 161.4 (d, <i>J</i> = 244.0 Hz, r/t<sub>1</sub>), 161.2 (d, <i>J</i> = 242.4 Hz, r/t<sub>2</sub>), 149.9, 146.1, 145.8, 143.2, 143.1, 138.6, 138.4, 138.1, 136.9, 136.0, 135.6, 135.5, 132.4, 132.3, 132.0, 131.6 (d, <i>J</i> = 2.7 Hz), 130.9 (d, <i>J</i> = 8.0 Hz), 129.7, 128.9, 128.7, 128.6, 128.5, 128.3, 128.2, 128.2, 127.4, 127.1, 126.7, 126.4, 126.0, 125.8, 125.5, 125.0, 124.9, 124.1, 123.9, 120.1, 118.1, 118.0, 117.3, 117.2, 116.8, 116.7, 116.3, 115.8, 115.1, 114.9, 114.9, 114.7. ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>31</sub>H<sub>22</sub>FN<sub>5</sub>O [M + H]<sup>+</sup>: 500.1881. Found: 500.1884. HPLC (method A): <i>t</i><sub>R</sub> = 7.355 min. Purity: 99.0% (254.4 nm), 98.9% (230.4 nm).</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>-(3-(4-(4-(4-Fluorophenyl)-2-phenyl-1<i>H</i>-imidazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)propionamide (<b>45g</b>)</h3><div class="NLM_p last">The reaction was performed according to method H. Starting material: <b>44g</b>. Solvent: EtOH and saturated NaHCO<sub>3(aq)</sub>-solution. The residue was purified via flash chromatography (gradient: 100% DCM → DCM:MeOH 92:8). The product was washed with <i>n</i>-pentane and was obtained as an off-white solid (52 mg, 65%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 12.54 (s, 0.66H, r<sub>1</sub>/t<sub>1</sub>), 12.31 (s, 0.33H, r<sub>2</sub>/t<sub>2</sub>), 12.02 (d, <i>J</i> = 1.6 Hz, 0.66H, r<sub>1</sub>/t<sub>1</sub>), 11.84 (d, <i>J</i> = 1.6 Hz, 0.33H, r<sub>2</sub>/t<sub>2</sub>), 9.44 (s, 0.66H, r<sub>1</sub>/t<sub>1</sub>), 9.38 (s, 0.34H, r<sub>2</sub>/t<sub>2</sub>), 8.37 (d, <i>J</i> = 4.8 Hz, 0.66H, r<sub>1</sub>/t<sub>1</sub>), 8.33 (d, <i>J</i> = 4.8 Hz, 0.34H, r<sub>2</sub>/t<sub>2</sub>), 7.98 (d, <i>J</i> = 7.3 Hz, 0.70H, r<sub>1</sub>/t<sub>1</sub>), 7.83 (d, <i>J</i> = 7.2 Hz, 1.4H, r<sub>2</sub>/t<sub>2</sub>), 7.54–7.09 (m, 8H), 7.01–6.69 (m, 5H), 6.37 (d, <i>J</i> = 7.6 Hz, 0.66H, r<sub>1</sub>/t<sub>1</sub>), 6.28 (d, <i>J</i> = 7.6 Hz, 0.34H, r<sub>2</sub>/t<sub>2</sub>), 2.07–1.99 (m, 2H), 0.94 (t, <i>J</i> = 7.6 Hz, 1H, t<sub>1</sub>/r<sub>1</sub>), 0.89 (t, <i>J</i> = 7.5 Hz, 2H, t<sub>2</sub>/r<sub>2</sub>). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>; mixture of rotamers/tautomers) δ 171.3 (r<sub>1</sub>/t<sub>1</sub>), 171.2 (r<sub>2</sub>/t<sub>2</sub>), 160.8 (d, <i>J</i> = 243.6 Hz, r<sub>1</sub>/t<sub>1</sub>), 160.7 (d, <i>J</i> = 242.5 Hz, r<sub>2</sub>/t<sub>2</sub>), 149.3, 149.3, 145.5, 145.2, 142.6, 142.6, 138.3, 138.2, 137.6, 136.4, 135.3, 135.1, 134.8, 131.5, 131.1 (d, <i>J</i> = 2.7 Hz), 130.4, 130.4, 129.2, 128.4, 128.3, 128.1, 128.0, 127.9, 127.7, 127.6, 126.8, 126.5, 126.1 (d, <i>J</i> = 3.2 Hz), 125.4, 125.2, 124.9, 124.5, 124.3, 123.0, 122.7, 119.5, 119.4, 117.6, 117.5, 116.9, 116.8, 116.0, 116.0, 115.7, 115.2, 114.6, 114.3, 114.1, 29.2, 9.5 (r<sub>1</sub>/t<sub>1</sub>), 9.4 (r<sub>2</sub>/t<sub>2</sub>). ESI-HRMS (<i>m</i>/<i>z</i>) exact mass calculated for C<sub>31</sub>H<sub>24</sub>FN<sub>5</sub>O [M + H]<sup>+</sup>: 502.2038. Found: 502.2137. HPLC (method A): <i>t</i><sub>R</sub> = 7.492 min. Purity: 97.4% (254.4 nm), 97.3% (230.4 nm).</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> In Silico Docking Studies</h3><div class="NLM_p last">The docking studies were performed using Glide Docking and Covalent Docking (part of the Schrödinger Suite software package). PyMOL Molecular Graphics System, version 1.3, Schrödinger, LLC, was used for visualization. The X-ray crystal structure of the EGFR kinase domain (mutation: T790M) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>) in complex with AEE788 and the EGFR kinase domain (mutations: V924R, F973A, L977A) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW">4RIW</a>) were used for docking studies with Maestro 10.4 from Schrödinger. The PDB files were directly loaded into Maestro. All water molecules, ligands, and nonprotein atoms were removed from both proteins using the “Protein Preparation” plugin for docking with the synthesized compounds. In a second approach, the crystal structure of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW">4RIW</a> was reduced to one kinase domain for an overlay with a docked inhibitor (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Ligands were drawn in ChemDraw as sdf files and prepared using the “Ligprep” plugin of Maestro. Molecules without a covalent tag were docked using Glide in Maestro with standard settings and without further modification from default settings. The grid box was centered using the residues 797, 793, and 790 for <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a> and 766 and 769 for <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW">4RIW</a>. Ligands with a covalent tag attached were docked using the “Covalent Docking“ plugin of Glide included in Maestro. Cys797 was selected as reactive residue. “Michael addition” was set as the reaction type. Docking was performed with standard settings and without further modification from default settings. For all visualizations with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>, the best predicted hit with highest docking score was used. The second best predicted pose was used for visualization with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW">4RIW</a>.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> IC<sub>50</sub> Determination</h3><div class="NLM_p last">The compounds were sent to Reaction Biology Corp., Malvern, PA, USA, for in vitro testing against EGFRWT, L858R, L858R/T790M, and L858R/T790M/C797S in a radiolabeled <sup>33</sup>P(ATP) kinase assay. The enzymes for the testing were purchased as follows: EGFR WT (Invitrogen catalogue no. PV3872), EGFR L858R (Invitrogen catalogue no. PR7447A), EGFR L858R/T790M (Invitrogen catalogue no. PR8911A), and EGFR L858R/T790M/C797S (SignalChem catalogue no. E10–12VG). IC<sub>50</sub> values of the inhibitors were determined in singlicate at five different concentrations (10-fold dilution steps, starting from 3 or 10 μM) with an ATP concentration of 1 μM. Control compound staurosporine was tested in singlicate at 10 different concentrations (4-fold dilution steps, starting at 20 μM). For a detailed description of the assay, see <a href="http://www.reactionbiology.com/webapps/site/Kinase_Assay_Protocol.aspx" class="extLink">http://www.reactionbiology.com/webapps/site/Kinase_Assay_Protocol.aspx</a>, or see the following literature.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50, 51)</a></div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Cellular Data</h3><div class="NLM_p last">The cellular data were determined according to Günther et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>K</i><sub>d</sub> Determination</h3><div class="NLM_p last">The <i>K</i><sub>d</sub> values were determined via the scanKinetic Profiling service from DiscoveRX, Fremont CA, USA. For a more detailed description of this assay technology, see Fabian et al.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Kinome Selectivity Screen</h3><div class="NLM_p last">A commercial selectivity screening of compound <b>45a</b> was performed by ProQinase GmbH in Freiburg, Germany. The compound was tested at a concentration of 1 μM against 420 kinases. The residual activity values for compound <b>45a</b> are given in 410 kinase assays. All values are calculated as % of control.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> p38α MAPK Assay</h3><div class="NLM_p last">The IC<sub>50</sub> values were determined according to Goettert et al.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00178">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42631" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42631" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00178" class="ext-link">10.1021/acs.jmedchem.7b00178</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional chemistry (schemes and description); general procedures of ESI-HRMS and HPLC; all general methods; experimental section of materials and intermediates; metabolic stability determination in vitro; in vitro reactivity study with glutathione; solubility; cellular data; <i>K</i><sub>d</sub> values of different study arms, raw data, and graphs; kinome selectivity screen (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">3D coordinates for docking plus ligand of <b>11h</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW">4RIW</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">3D coordinates for covalent docking of <b>27a</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>)  (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">3D coordinates for covalent docking of <b>19a</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">3D coordinates for covalent docking of <b>45a</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">3D coordinates for molecular docking of <b>11g</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_006.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf">jm7b00178_si_001.pdf (1.26 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_002.pdb">jm7b00178_si_002.pdb (587.61 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_003.pdb">jm7b00178_si_003.pdb (393.6 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_004.pdb">jm7b00178_si_004.pdb (393.9 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_005.pdb">jm7b00178_si_005.pdb (393.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_006.csv">jm7b00178_si_006.csv (2.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_007.pdb">jm7b00178_si_007.pdb (401.31 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b00178" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08855" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08855" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Laufer</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link">http://orcid.org/0000-0001-6952-1486</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1a696e7f7c7b7434767b6f7c7f685a6f7473376e6f7f7873747d7f74347e7f"><span class="__cf_email__" data-cfemail="b7c4c3d2d1d6d999dbd6c2d1d2c5f7c2d9de9ac3c2d2d5ded9d0d2d999d3d2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Juchum</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcel Günther</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva Döring</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adrian Sievers-Engler</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Lämmerhofer</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6374-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40714" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40714" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the research group of Prof Dr. Pichler, Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Tübingen, Germany for the 600 MHz NMR experiments. Moreover, we thank Prof. Dr. Heinz-Heiner Fiebig and Dr. Gerhard Kelter from Oncotest GmbH, Freiburg, Germany for the cellular data. Furthermore, we would like to thank Jun.-Prof. Dr. Pierre Koch for carefully proof reading the manuscript as well as Dr. Silke Bauer, Katharina Bauer, Jens Strobach, Melanie Henning and Marion Boos for biological testing.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i75" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i75"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i76" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i76"> Abbreviations Used</h2><tr><td class="NLM_term">bs</td><td class="NLM_def"><p class="first last">broad signal</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">hydrophobic region</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">PAIN</td><td class="NLM_def"><p class="first last">pan-assay interference compound</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate binding site</p></td></tr><tr><td class="NLM_term">PG</td><td class="NLM_def"><p class="first last">protecting group</p></td></tr><tr><td class="NLM_term">r1</td><td class="NLM_def"><p class="first last">rotamer 1</p></td></tr><tr><td class="NLM_term">RP</td><td class="NLM_def"><p class="first last">ribose pocket</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">2-(trimethylsilyl)ethoxymethyl</p></td></tr><tr><td class="NLM_term">t<sub>1</sub></td><td class="NLM_def"><p class="first last">tautomer 1</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">X-Phos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82773" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82773" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 53 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vivanco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Larriba, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertran-Alamillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span> </span><span class="NLM_article-title">Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">958</span><span class="NLM_x">–</span> <span class="NLM_lpage">967</span><span class="refDoi"> DOI: 10.1056/NEJMoa0904554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1056%2FNEJMoa0904554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=19692684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=958-967&author=R.+Rosellauthor=T.+Moranauthor=C.+Queraltauthor=R.+Portaauthor=F.+Cardenalauthor=C.+Campsauthor=M.+Majemauthor=G.+Lopez-Vivancoauthor=D.+Islaauthor=M.+Provencioauthor=A.+Insaauthor=B.+Massutiauthor=J.+L.+Gonzalez-Larribaauthor=L.+Paz-Aresauthor=I.+Boverauthor=R.+Garcia-Campeloauthor=M.+A.+Morenoauthor=S.+Catotauthor=C.+Rolfoauthor=N.+Reguartauthor=R.+Palmeroauthor=J.+M.+Sanchezauthor=R.+Bastusauthor=C.+Mayoauthor=J.+Bertran-Alamilloauthor=M.+A.+Molinaauthor=J.+J.+Sanchezauthor=M.+Taron&title=Screening+for+Epidermal+Growth+Factor+Receptor+Mutations+in+Lung+Cancer&doi=10.1056%2FNEJMoa0904554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Screening for epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Rosell, Rafael; Moran, Teresa; Queralt, Cristina; Porta, Rut; Cardenal, Felipe; Camps, Carlos; Majem, Margarita; Lopez-Vivanco, Guillermo; Isla, Dolores; Provencio, Mariano; Insa, Amelia; Massuti, Bartomeu; Gonzalez-Larriba, Jose Luis; Paz-Ares, Luis; Bover, Isabel; Garcia-Campelo, Rosario; Moreno, Miguel Angel; Catot, Silvia; Rolfo, Christian; Reguart, Noemi; Palmero, Ramon; Sanchez, Jose Miguel; Bastus, Roman; Mayo, Clara; Bertran-Alamillo, Jordi; Molina, Miguel Angel; Sanchez, Jose Javier; Taron, Miquel; Cuello, M.; Pallares, C.; Lianes, P.; Remon, J.; Ibeas, R.; Martinez del Prado, P.; Angeles Sala, M.; Santander-Lobera, C.; Velez de Mendizabal, E.; Vinolas, N.; Terrasa, J.; Valdivia, J.; Diz, P.; Jimenez-Berlana, U.; Velasco-Ortiz de Taranco, A.; Ales Martinez, E.; Sanchez-Escribano, R.; Carrato, A.; Guillen-Ponce, C.; Mesia, C.; Antonio Macias, J.; Lopez-Brea, M.; Oramas, J.; Barneto, I.; Garrido, P.; Mayol, M. J.; Lopez, A.; Artal, A.; Saenz, A.; Hernando, S.; Cobo, M.; Blanco, R.; Bernabe, R.; Guillem, V.; Angel Munoz, M.; Maestu, I.; Salvatierra, A.; De Las Penas, R.; Alfaro, J.; Alberola, V.; Juan, O.; Martin, C.; Puertas, J.; Felip, E.; Gonzalez-Gonzalez, J. F.; Iglesias-Docampo, L.; Dorta, F. J.; Martinez-Aguillo, M.; Salgado, E.; Mesia, R.; Lastra-Aras, E.; Garcia-Munoz, J. P.; Lastra, R.; Alvarez, I.; Roig, J.; Oruezabal, J.; Poveda, A.; Lavernia, J.; Gutierrez, D.; Filipovich, E.; Aguiar, D.; Rodriguez, D.; Buxo, J.; Cardona, A. F.; Bes, P.; Paredes, A.; Tortorella, A. M.; Moreno, J. A.; Martinez-Garcia, J.; Alonso, J. L.; Lopez-Martin, A.; Echarri-Gonzalez, M. J.; Van Kooten, M.; Guerrero, A.; Domine, M.; Diaz, I.; Heras, L.; Garcia, R.; Anton, I.; Jarchum, G.; Bartolucci, R. E.; Lomas, M.; Rubiales, A.; Duque, J. L.; Escriva de Romani, S.; Barbeta, E.; Reina, J. J.; Castro, J.; Belda, C.; Vidal, J. M.; Trigo, J. M.; Vadell, C.; Zarba, J. J.; Esunza, P.; Garau, I.; Lopez-Pousa, A.; De la Gandara, I.; Widakowich, J.; Morales, S.; Martinez, M.; Luis, R.; de la Colina, M.; Calzas, J.; Garcia-Castro, I.; Ruiz, C.; Lopez-Criado, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">958-967</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer.  We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the assocn. between the mutations and the outcome of erlotinib treatment.  From Apr. 2005 through Nov. 2008, lung cancers from 2105 patients in 129 institutions in Spain were screened for EGFR mutations.  The anal. was performed in a central lab.  Patients with tumors carrying EGFR mutations were eligible for erlotinib treatment.  EGFR mutations were found in 350 of 2105 patients (16.6%).  Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%) (P < 0.001 for all comparisons).  The mutations were deletions in exon 19 (62.2%) and L858R (37.8%).  Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 mo and 27 mo, resp.  The adjusted hazard ratios for the duration of progression-free survival were 2.94 for men (P < 0.001); 1.92 for the presence of the L858R mutation, as compared with a deletion in exon 19 (P = 0.02); and 1.68 for the presence of the L858R mutation in paired serum DNA, as compared with the absence of the mutation (P = 0.02).  The most common adverse events were mild rashes and diarrhea; grade 3 cutaneous toxic effects were recorded in 16 patients (7.4%) and grade 3 diarrhea in 8 patients (3.7%).  Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvZWnSnU_ScbVg90H21EOLACvtfcHk0lik9BQxzEmVwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M&md5=288ea35bd5201579d8c89ad6d7c4306a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904554%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCardenal%26aufirst%3DF.%26aulast%3DCamps%26aufirst%3DC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DGonzalez-Larriba%26aufirst%3DJ.%2BL.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DCatot%26aufirst%3DS.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DBastus%26aufirst%3DR.%26aulast%3DMayo%26aufirst%3DC.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DTaron%26aufirst%3DM.%26atitle%3DScreening%2520for%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Mutations%2520in%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D958%26epage%3D967%26doi%3D10.1056%2FNEJMoa0904554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor Mutations in Lung Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+Growth+Factor+Receptor+Mutations+in+Lung+Cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lgTn8c7WTtDQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520Mutations%2520in%2520Lung%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Lung Adenocarcinoma: Guiding EGFR-Targeted Therapy and Beyond</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">S16</span><span class="NLM_x">–</span> <span class="NLM_lpage">S22</span><span class="refDoi"> DOI: 10.1038/modpathol.3801018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fmodpathol.3801018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=S16-S22&author=M.+Ladanyiauthor=W.+Pao&title=Lung+Adenocarcinoma%3A+Guiding+EGFR-Targeted+Therapy+and+Beyond&doi=10.1038%2Fmodpathol.3801018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.3801018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.3801018%26sid%3Dliteratum%253Aachs%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DLung%2520Adenocarcinoma%253A%2520Guiding%2520EGFR-Targeted%2520Therapy%2520and%2520Beyond%26jtitle%3DMod.%2520Pathol.%26date%3D2008%26volume%3D21%26spage%3DS16%26epage%3DS22%26doi%3D10.1038%2Fmodpathol.3801018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Q.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+Lung+Cancer-Derived+EGFR+Mutants+and+Inhibitor+Complexes%3A+Mechanism+of+Activation+and+Insights+into+Differential+Inhibitor+Sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lgTn8c7WTtDQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520Lung%2520Cancer-Derived%2520EGFR%2520Mutants%2520and%2520Inhibitor%2520Complexes%253A%2520Mechanism%2520of%2520Activation%2520and%2520Insights%2520into%2520Differential%2520Inhibitor%2520Sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Carey, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+Analysis+of+Epidermal+Growth+Factor+Receptor+Somatic+Mutant+Proteins+Shows+Increased+Sensitivity+to+the+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor%2C+Erlotinib&doi=10.1158%2F0008-5472.CAN-06-0453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0lh3yqfNNPPsSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520Analysis%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Somatic%2520Mutant%2520Proteins%2520Shows%2520Increased%2520Sensitivity%2520to%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520Erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171%26doi%3D10.1158%2F0008-5472.CAN-06-0453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span> </span><span class="NLM_article-title">Activating and Resistance Mutations of EGFR in Non-Small-Cell Lung Cancer: Role in Clinical Response to EGFR Tyrosine Kinase Inhibitors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">S24</span><span class="NLM_x">–</span> <span class="NLM_lpage">S31</span><span class="refDoi"> DOI: 10.1038/onc.2009.198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fonc.2009.198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=19680293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=S24-S31&author=A.+F.+Gazdar&title=Activating+and+Resistance+Mutations+of+EGFR+in+Non-Small-Cell+Lung+Cancer%3A+Role+in+Clinical+Response+to+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1038%2Fonc.2009.198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors</span></div><div class="casAuthors">Gazdar, A. F.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S24-S31</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-5' triphosphate-binding site.  Somatic activating mutations of the EGFR gene, increased gene copy no. and certain clin. and pathol. features have been assocd. with dramatic tumor responses and favorable clin. outcomes with these agents in patients with non-small-cell lung cancer (NSCLC).  The specific types of activating mutations that confer sensitivity to EGFR TKIs are present in the tyrosine kinase (TK) domain of the EGFR gene.  Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed classical' mutations.  The NSCLC tumors insensitive to EGFR TKIs include those driven by the KRAS and MET oncogenes.  Most patients who initially respond to gefitinib and erlotinib eventually become resistant and experience progressive disease.  The point mutation T790M accounts for about one half of these cases of acquired resistance.  Various second-generation EGFR TKIs are currently being evaluated and may have the potential to overcome T790M-mediated resistance by virtue of their irreversible inhibition of the receptor TK domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruiv2mv5eIb7Vg90H21EOLACvtfcHk0lh3yqfNNPPsSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCrsLY%253D&md5=28d24b3739ac038b29dd0ec327808857</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.198%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26atitle%3DActivating%2520and%2520Resistance%2520Mutations%2520of%2520EGFR%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%253A%2520Role%2520in%2520Clinical%2520Response%2520to%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DOncogene%26date%3D2009%26volume%3D28%26spage%3DS24%26epage%3DS31%26doi%3D10.1038%2Fonc.2009.198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, Biologically Based Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span><span class="refDoi"> DOI: 10.1038/nrc2947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+Biologically+Based+Treatment+of+EGFR-Mutant+Non-Small-Cell+Lung+Cancer&doi=10.1038%2Fnrc2947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0lh3yqfNNPPsSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520Biologically%2520Based%2520Treatment%2520of%2520EGFR-Mutant%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774%26doi%3D10.1038%2Fnrc2947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is Associated with a Second Mutation in the EGFR Kinase Domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+Resistance+of+Lung+Adenocarcinomas+to+Gefitinib+or+Erlotinib+is+Associated+with+a+Second+Mutation+in+the+EGFR+Kinase+Domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2ea2bnpwJg2ssrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520Resistance%2520of%2520Lung%2520Adenocarcinomas%2520to%2520Gefitinib%2520or%2520Erlotinib%2520is%2520Associated%2520with%2520a%2520Second%2520Mutation%2520in%2520the%2520EGFR%2520Kinase%2520Domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Takezawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirazzoli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR(T790M) Mutation</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">933</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F2159-8290.CD-12-0108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=922-933&author=K.+Takezawaauthor=V.+Pirazzoliauthor=M.+E.+Arcilaauthor=C.+A.+Nebhanauthor=X.+L.+Songauthor=E.+de+Stanchinaauthor=K.+Ohashiauthor=Y.+Y.+Janjigianauthor=P.+J.+Spitzlerauthor=M.+A.+Melnickauthor=G.+J.+Rielyauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=K.+Politiauthor=W.+Pao&title=HER2+Amplification%3A+A+Potential+Mechanism+of+Acquired+Resistance+to+EGFR+Inhibition+in+EGFR-Mutant+Lung+Cancers+That+Lack+the+Second-Site+EGFR%28T790M%29+Mutation&doi=10.1158%2F2159-8290.CD-12-0108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0108%26sid%3Dliteratum%253Aachs%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DPirazzoli%26aufirst%3DV.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSong%26aufirst%3DX.%2BL.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DMelnick%26aufirst%3DM.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DHER2%2520Amplification%253A%2520A%2520Potential%2520Mechanism%2520of%2520Acquired%2520Resistance%2520to%2520EGFR%2520Inhibition%2520in%2520EGFR-Mutant%2520Lung%2520Cancers%2520That%2520Lack%2520the%2520Second-Site%2520EGFR%2528T790M%2529%2520Mutation%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D922%26epage%3D933%26doi%3D10.1158%2F2159-8290.CD-12-0108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1126/science.1141478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+C.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+J.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+Amplification+Leads+to+Gefitinib+Resistance+in+Lung+Cancer+by+Activating+ERBB3+Signaling&doi=10.1126%2Fscience.1141478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0liWGLndnvA1pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%2BC.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%2BJ.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520Amplification%2520Leads%2520to%2520Gefitinib%2520Resistance%2520in%2520Lung%2520Cancer%2520by%2520Activating%2520ERBB3%2520Signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1141478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shien, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Cuesta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vnencak-Jones, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Lung Cancers with Acquired Resistance to EGFR Inhibitors Occasionally Harbor BRAF Gene Mutations but Lack Mutations in KRAS, NRAS, or MEK1</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">E2127</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1073/pnas.1203530109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1073%2Fpnas.1203530109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=E2127-133&author=K.+Ohashiauthor=L.+V.+Sequistauthor=M.+E.+Arcilaauthor=T.+Moranauthor=J.+Chmieleckiauthor=Y.+L.+Linauthor=Y.+Panauthor=L.+Wangauthor=E.+de+Stanchinaauthor=K.+Shienauthor=K.+Aoeauthor=S.+Toyookaauthor=K.+Kiuraauthor=L.+Fernandez-Cuestaauthor=P.+Fidiasauthor=J.+C.+Yangauthor=V.+A.+Millerauthor=G.+J.+Rielyauthor=M.+G.+Krisauthor=J.+A.+Engelmanauthor=C.+L.+Vnencak-Jonesauthor=D.+Dias-Santagataauthor=M.+Ladanyiauthor=W.+Pao&title=Lung+Cancers+with+Acquired+Resistance+to+EGFR+Inhibitors+Occasionally+Harbor+BRAF+Gene+Mutations+but+Lack+Mutations+in+KRAS%2C+NRAS%2C+or+MEK1&doi=10.1073%2Fpnas.1203530109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1203530109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1203530109%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DShien%26aufirst%3DK.%26aulast%3DAoe%26aufirst%3DK.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DFernandez-Cuesta%26aufirst%3DL.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DVnencak-Jones%26aufirst%3DC.%2BL.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DLung%2520Cancers%2520with%2520Acquired%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520Occasionally%2520Harbor%2520BRAF%2520Gene%2520Mutations%2520but%2520Lack%2520Mutations%2520in%2520KRAS%252C%2520NRAS%252C%2520or%2520MEK1%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3DE2127%26epage%3D133%26doi%3D10.1073%2Fpnas.1203530109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Shien, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thu, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takigawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span> </span><span class="NLM_article-title">Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">3051</span><span class="NLM_x">–</span> <span class="NLM_lpage">3061</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-4136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F0008-5472.CAN-12-4136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=3051-3061&author=K.+Shienauthor=S.+Toyookaauthor=H.+Yamamotoauthor=J.+Sohauthor=M.+Jidaauthor=K.+L.+Thuauthor=S.+Hashidaauthor=Y.+Makiauthor=E.+Ichiharaauthor=H.+Asanoauthor=K.+Tsukudaauthor=N.+Takigawaauthor=K.+Kiuraauthor=A.+F.+Gazdarauthor=W.+L.+Lamauthor=S.+Miyoshi&title=Acquired+Resistance+to+EGFR+Inhibitors+Is+Associated+with+a+Manifestation+of+Stem+Cell-like+Properties+in+Cancer+Cells&doi=10.1158%2F0008-5472.CAN-12-4136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-4136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-4136%26sid%3Dliteratum%253Aachs%26aulast%3DShien%26aufirst%3DK.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DJida%26aufirst%3DM.%26aulast%3DThu%26aufirst%3DK.%2BL.%26aulast%3DHashida%26aufirst%3DS.%26aulast%3DMaki%26aufirst%3DY.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DAsano%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DK.%26aulast%3DTakigawa%26aufirst%3DN.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DLam%26aufirst%3DW.%2BL.%26aulast%3DMiyoshi%26aufirst%3DS.%26atitle%3DAcquired%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520Is%2520Associated%2520with%2520a%2520Manifestation%2520of%2520Stem%2520Cell-like%2520Properties%2520in%2520Cancer%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D3051%26epage%3D3061%26doi%3D10.1158%2F0008-5472.CAN-12-4136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Blakely, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">872</span><span class="NLM_x">–</span> <span class="NLM_lpage">875</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F2159-8290.CD-12-0387" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=872-875&author=C.+M.+Blakelyauthor=T.+G.+Bivona&title=Resiliency+of+Lung+Cancers+to+EGFR+Inhibitor+Treatment+Unveiled%2C+Offering+Opportunities+to+Divide+and+Conquer+EGFR+Inhibitor+Resistance&doi=10.1158%2F2159-8290.CD-12-0387"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0387%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DResiliency%2520of%2520Lung%2520Cancers%2520to%2520EGFR%2520Inhibitor%2520Treatment%2520Unveiled%252C%2520Offering%2520Opportunities%2520to%2520Divide%2520and%2520Conquer%2520EGFR%2520Inhibitor%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D872%26epage%3D875%26doi%3D10.1158%2F2159-8290.CD-12-0387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+Tumor+Specimens+at+the+Time+of+Acquired+Resistance+to+EGFR-TKI+Therapy+in+155+Patients+with+EGFR-Mutant+Lung+Cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0ljH_3z-rXNDTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520Tumor%2520Specimens%2520at%2520the%2520Time%2520of%2520Acquired%2520Resistance%2520to%2520EGFR-TKI%2520Therapy%2520in%2520155%2520Patients%2520with%2520EGFR-Mutant%2520Lung%2520Cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Chen, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, Y. Q.</span><span> </span><span class="NLM_article-title">Clinical Perspective of Afatinib in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">161</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2013.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.lungcan.2013.02.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=155-161&author=X.+F.+Chenauthor=Q.+Zhuauthor=L.+J.+Zhuauthor=D.+Peiauthor=Y.+Q.+Liuauthor=Y.+M.+Yinauthor=M.+Schulerauthor=Y.+Q.+Shu&title=Clinical+Perspective+of+Afatinib+in+Non-Small+Cell+Lung+Cancer&doi=10.1016%2Fj.lungcan.2013.02.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2013.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2013.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BF.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DL.%2BJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%2BQ.%26aulast%3DYin%26aufirst%3DY.%2BM.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DShu%26aufirst%3DY.%2BQ.%26atitle%3DClinical%2520Perspective%2520of%2520Afatinib%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DLung%2520Cancer%26date%3D2013%26volume%3D81%26spage%3D155%26epage%3D161%26doi%3D10.1016%2Fj.lungcan.2013.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Boyer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of PF299804 Versus Erlotinib (E): A global, Randomized Phase II Trial in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) after Failure of Chemotherapy (CT)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">18s</span><span class="NLM_x">) </span> <span class="NLM_fpage">LBA7523</span><span class="refDoi"> DOI: 10.1200/jco.2010.28.18_suppl.lba7523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1200%2Fjco.2010.28.18_suppl.lba7523" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=LBA7523&issue=18s&author=M.+J.+Boyerauthor=F.+H.+Blackhallauthor=K.+Parkauthor=C.+H.+Barriosauthor=M.+J.+Krzakowskiauthor=I.+Taylorauthor=J.+Q.+Liangauthor=L.+J.+Denisauthor=J.+P.+O%E2%80%99Connellauthor=S.+S.+Ramalingam&title=Efficacy+and+Safety+of+PF299804+Versus+Erlotinib+%28E%29%3A+A+global%2C+Randomized+Phase+II+Trial+in+Patients+%28pts%29+with+Advanced+Non-Small+Cell+Lung+Cancer+%28NSCLC%29+after+Failure+of+Chemotherapy+%28CT%29&doi=10.1200%2Fjco.2010.28.18_suppl.lba7523"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1200%2Fjco.2010.28.18_suppl.lba7523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2010.28.18_suppl.lba7523%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DM.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%2BH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DKrzakowski%26aufirst%3DM.%2BJ.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DJ.%2BQ.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%2BP.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520PF299804%2520Versus%2520Erlotinib%2520%2528E%2529%253A%2520A%2520global%252C%2520Randomized%2520Phase%2520II%2520Trial%2520in%2520Patients%2520%2528pts%2529%2520with%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%2520after%2520Failure%2520of%2520Chemotherapy%2520%2528CT%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D18s%26spage%3DLBA7523%26doi%3D10.1200%2Fjco.2010.28.18_suppl.lba7523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors Against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+J.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+N.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+Against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lj1lj2X6PatNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%2BN.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520Against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8249</span><span class="NLM_x">–</span> <span class="NLM_lpage">8267</span><span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+Potent+and+Selective+EGFR+Inhibitor+%28AZD9291%29+of+Both+Sensitizing+and+T790M+Resistance+Mutations+That+Spares+the+Wild+Type+Form+of+the+Receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lhmBhsOisSkrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520EGFR%2520Inhibitor%2520%2528AZD9291%2529%2520of%2520Both%2520Sensitizing%2520and%2520T790M%2520Resistance%2520Mutations%2520That%2520Spares%2520the%2520Wild%2520Type%2520Form%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+Mutant-Selective+Covalent+Inhibitor+of+EGFR+that+Overcomes+T790M-Mediated+Resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lgRl--47sagyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt.%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Mutant-Selective%2520Covalent%2520Inhibitor%2520of%2520EGFR%2520that%2520Overcomes%2520T790M-Mediated%2520Resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caunt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span> </span><span class="NLM_article-title">First-In-Human Evaluation of CO-1686, an Irreversible, Highly Selective Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15s</span><span class="NLM_x">) </span> <span class="NLM_fpage">8010</span><span class="refDoi"> DOI: 10.1200/jco.2014.32.15_suppl.8010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1200%2Fjco.2014.32.15_suppl.8010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8010&issue=15s&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=S.+M.+Gadgeelauthor=H.+A.+Wakeleeauthor=D.+R.+Camidgeauthor=A.+Vargaauthor=B.+J.+Solomonauthor=V.+Papadimitrakopoulouauthor=S.+S.+Jaw-Tsaiauthor=L.+Cauntauthor=P.+Kaurauthor=L.+Rolfeauthor=A.+R.+Allenauthor=J.+W.+Goldman&title=First-In-Human+Evaluation+of+CO-1686%2C+an+Irreversible%2C+Highly+Selective+Tyrosine+Kinase+Inhibitor+of+Mutations+of+EGFR+%28Activating+and+T790M%29&doi=10.1200%2Fjco.2014.32.15_suppl.8010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.8010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.8010%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DJaw-Tsai%26aufirst%3DS.%2BS.%26aulast%3DCaunt%26aufirst%3DL.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26atitle%3DFirst-In-Human%2520Evaluation%2520of%2520CO-1686%252C%2520an%2520Irreversible%252C%2520Highly%2520Selective%2520Tyrosine%2520Kinase%2520Inhibitor%2520of%2520Mutations%2520of%2520EGFR%2520%2528Activating%2520and%2520T790M%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15s%26spage%3D8010%26doi%3D10.1200%2Fjco.2014.32.15_suppl.8010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Clinical Activity of the Mutant-Selective EGFR Inhibitor AZD9291 in Patients (pts) with EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15s</span><span class="NLM_x">) </span> <span class="NLM_fpage">8009</span><span class="refDoi"> DOI: 10.1200/jco.2014.32.15_suppl.8009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1200%2Fjco.2014.32.15_suppl.8009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8009&issue=15s&author=P.+A.+J%C3%A4nneauthor=S.+S.+Ramalingamauthor=J.+C.+H.+Yangauthor=M.+J.+Ahnauthor=D.+W.+Kimauthor=S.+W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=E.+Felipauthor=C.+Watkinsauthor=M.+Cantariniauthor=S.+Ghiorghiuauthor=M.+Ranson&title=Clinical+Activity+of+the+Mutant-Selective+EGFR+Inhibitor+AZD9291+in+Patients+%28pts%29+with+EGFR+Inhibitor-Resistant+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&doi=10.1200%2Fjco.2014.32.15_suppl.8009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.8009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.8009%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DClinical%2520Activity%2520of%2520the%2520Mutant-Selective%2520EGFR%2520Inhibitor%2520AZD9291%2520in%2520Patients%2520%2528pts%2529%2520with%2520EGFR%2520Inhibitor-Resistant%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15s%26spage%3D8009%26doi%3D10.1200%2Fjco.2014.32.15_suppl.8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Piotrowska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlovich, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalsy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digumarthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzikansky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvey, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiCecca, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span> </span><span class="NLM_article-title">Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">722</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F2159-8290.CD-15-0399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=25934077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=713-722&author=Z.+Piotrowskaauthor=M.+J.+Niederstauthor=C.+A.+Karlovichauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=M.+Mino-Kenudsonauthor=L.+Fultonauthor=A.+N.+Hataauthor=E.+L.+Lockermanauthor=A.+Kalsyauthor=S.+Digumarthyauthor=A.+Muzikanskyauthor=M.+Raponiauthor=A.+R.+Garciaauthor=H.+E.+Mulveyauthor=M.+K.+Parksauthor=R.+H.+DiCeccaauthor=D.+Dias-Santagataauthor=A.+J.+Iafrateauthor=A.+T.+Shawauthor=A.+R.+Allenauthor=J.+A.+Engelmanauthor=L.+V.+Sequist&title=Heterogeneity+Underlies+the+Emergence+of+EGFRT790+Wild-Type+Clones+Following+Treatment+of+T790M-Positive+Cancers+with+a+Third-Generation+EGFR+Inhibitor&doi=10.1158%2F2159-8290.CD-15-0399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span></div><div class="casAuthors">Piotrowska, Zofia; Niederst, Matthew J.; Karlovich, Chris A.; Wakelee, Heather A.; Neal, Joel W.; Mino-Kenudson, Mari; Fulton, Linnea; Hata, Aaron N.; Lockerman, Elizabeth L.; Kalsy, Anuj; Digumarthy, Subba; Muzikansky, Alona; Raponi, Mitch; Garcia, Angel R.; Mulvey, Hillary E.; Parks, Melissa K.; DiCecca, Richard H.; Dias-Santagata, Dora; Iafrate, A. John; Shaw, Alice T.; Allen, Andrew R.; Engelman, Jeffrey A.; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance.  We biopsied patients at rociletinib progression to explore resistance mechanisms.  Among 12 patients with T790M-pos. cancers at rociletinib initiation, six had T790-wild-type rociletinib-resistant biopsies.  Two T790-wild-type cancers underwent small cell lung cancer transformation; three T790M-pos. cancers acquired EGFR amplification.  We documented T790-wild-type and T790M-pos. clones coexisting within a single pre-rociletinib biopsy.  The pretreatment fraction of T790M-pos. cells affected response to rociletinib.  Longitudinal circulating tumor DNA (ctDNA) anal. revealed an increase in plasma EGFR-activating mutation, and T790M heralded rociletinib resistance in some patients, whereas in others the activating mutation increased but T790M remained suppressed.  Together, these findings demonstrate the role of tumor heterogeneity when therapies targeting a singular resistance mechanism are used.  To further improve outcomes, combination regimens that also target T790-wild-type clones are required.  Significance: This report documents that half of T790M-pos. EGFR-mutant lung cancers treated with rociletinib are T790-wild-type upon progression, suggesting that T790-wild-type clones can emerge as the dominant source of resistance.  We show that tumor heterogeneity has important clin. implications and that plasma ctDNA analyses can sometimes predict emerging resistance mechanisms.  Cancer Discov; 5(7); 713-22. ©2015 AACR.  See related commentary by Ichihara and Lovly, p. 694.  This article is highlighted in the In This Issue feature, p.  681.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4z_KYM4-R7Vg90H21EOLACvtfcHk0lgRl--47sagyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF&md5=6512fff2abf24f5bef615a70b0f89c56</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0399%26sid%3Dliteratum%253Aachs%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKalsy%26aufirst%3DA.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DParks%26aufirst%3DM.%2BK.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DHeterogeneity%2520Underlies%2520the%2520Emergence%2520of%2520EGFRT790%2520Wild-Type%2520Clones%2520Following%2520Treatment%2520of%2520T790M-Positive%2520Cancers%2520with%2520a%2520Third-Generation%2520EGFR%2520Inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D713%26epage%3D722%26doi%3D10.1158%2F2159-8290.CD-15-0399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Eberlein, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovets, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meador, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahdesmaki, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratcliffe, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, E. L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dry, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thress, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span> </span><span class="NLM_article-title">Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">2489</span><span class="NLM_x">–</span> <span class="NLM_lpage">2500</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F0008-5472.CAN-14-3167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=25870145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFSjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2489-2500&author=C.+A.+Eberleinauthor=D.+Stetsonauthor=A.+A.+Markovetsauthor=K.+J.+Al-Kadhimiauthor=Z.+Laiauthor=P.+R.+Fisherauthor=C.+B.+Meadorauthor=P.+Spitzlerauthor=E.+Ichiharaauthor=S.+J.+Rossauthor=M.+J.+Ahdesmakiauthor=A.+Ahmedauthor=L.+E.+Ratcliffeauthor=E.+L.+C.+O%E2%80%99Brienauthor=C.+H.+Barnesauthor=H.+Brownauthor=P.+D.+Smithauthor=J.+R.+Dryauthor=G.+Beranauthor=K.+S.+Thressauthor=B.+Doughertyauthor=W.+Paoauthor=D.+A.+E.+Cross&title=Acquired+Resistance+to+the+Mutant-Selective+EGFR+Inhibitor+AZD9291+Is+Associated+with+Increased+Dependence+on+RAS+Signaling+in+Preclinical+Models&doi=10.1158%2F0008-5472.CAN-14-3167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models</span></div><div class="casAuthors">Eberlein, Catherine A.; Stetson, Daniel; Markovets, Aleksandra A.; Al-Kadhimi, Katherine J.; Lai, Zhongwu; Fisher, Paul R.; Meador, Catherine B.; Spitzler, Paula; Ichihara, Eiki; Ross, Sarah J.; Ahdesmaki, Miika J.; Ahmed, Ambar; Ratcliffe, Laura E.; O'Brien, Elizabeth L. Christey; Barnes, Claire H.; Brown, Henry; Smith, Paul D.; Dry, Jonathan R.; Beran, Garry; Thress, Kenneth S.; Dougherty, Brian; Pao, William; Cross, Darren A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2489-2500</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These results offer early insight into how acquired resistance arises to a new mutation-selective inhibitor of EGFR that is in fast-track clin. development, illustrating the inescapable cat-and-mouse chase in the evolution of cancer cell-targeting drugs in the management of cancer patients.  Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers.  Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies.  We describe the detection of heterogeneous mechanisms of resistance within populations of EGFR-mutant cells (PC9 and/or NCI-H1975) with acquired resistance to current and newly developed EGFR tyrosine kinase inhibitors, including AZD9291.  We report the detection of NRAS mutations, including a novel E63K mutation, and a gain of copy no. of WT NRAS or WT KRAS in cell populations resistant to gefitinib, afatinib, WZ4002, or AZD9291.  Compared with parental cells, a no. of resistant cell populations were more sensitive to inhibition by the MEK inhibitor selumetinib (AZD6244; ARRY-142886) when treated in combination with the originating EGFR inhibitor.  In vitro, a combination of AZD9291 with selumetinib prevented emergence of resistance in PC9 cells and delayed resistance in NCI-H1975 cells.  In vivo, concomitant dosing of AZD9291 with selumetinib caused regression of AZD9291-resistant tumors in an EGFRm/T790M transgenic model.  Our data support the use of a combination of AZD9291 with a MEK inhibitor to delay or prevent resistance to AZD9291 in EGFRm and/or EGFRm/T790M tumors.  Furthermore, these findings suggest that NRAS modifications in tumor samples from patients who have progressed on current or EGFR inhibitors in development may support subsequent treatment with a combination of EGFR and MEK inhibition.  Cancer Res; 75(12); 2489-500. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZwyXo13dZBbVg90H21EOLACvtfcHk0lhfW3i22QCTuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFSjurw%253D&md5=63691ddbbf38e2079b39b5d8f43ddef4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3167%26sid%3Dliteratum%253Aachs%26aulast%3DEberlein%26aufirst%3DC.%2BA.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%2BA.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%2BJ.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DFisher%26aufirst%3DP.%2BR.%26aulast%3DMeador%26aufirst%3DC.%2BB.%26aulast%3DSpitzler%26aufirst%3DP.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DRoss%26aufirst%3DS.%2BJ.%26aulast%3DAhdesmaki%26aufirst%3DM.%2BJ.%26aulast%3DAhmed%26aufirst%3DA.%26aulast%3DRatcliffe%26aufirst%3DL.%2BE.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DE.%2BL.%2BC.%26aulast%3DBarnes%26aufirst%3DC.%2BH.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DDry%26aufirst%3DJ.%2BR.%26aulast%3DBeran%26aufirst%3DG.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26atitle%3DAcquired%2520Resistance%2520to%2520the%2520Mutant-Selective%2520EGFR%2520Inhibitor%2520AZD9291%2520Is%2520Associated%2520with%2520Increased%2520Dependence%2520on%2520RAS%2520Signaling%2520in%2520Preclinical%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D2489%26epage%3D2500%26doi%3D10.1158%2F0008-5472.CAN-14-3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Thress, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovets, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivancos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span> </span><span class="NLM_article-title">Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+Mutation+Mediates+Resistance+to+AZD9291+in+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lhfW3i22QCTuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mutation%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Günther, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juchum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Lung Cancer: EGFR Inhibitors With Low Nanomolar Activity Against a Therapy-Resistant L858R/T790M/C797S Mutant</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10890</span><span class="NLM_x">–</span> <span class="NLM_lpage">10894</span><span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&author=M.+G%C3%BCntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+Cancer%3A+EGFR+Inhibitors+With+Low+Nanomolar+Activity+Against+a+Therapy-Resistant+L858R%2FT790M%2FC797S+Mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Guenther, Marcel; Juchum, Michael; Kelter, Gerhard; Fiebig, Heiner; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-10894</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clin. relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that addnl. mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compds. show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1QH6nrxYrVg90H21EOLACvtfcHk0li5CZFrzv04WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK&md5=c3909faa7f781c2a3679f75bd3b6c5ac</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520Cancer%253A%2520EGFR%2520Inhibitors%2520With%2520Low%2520Nanomolar%2520Activity%2520Against%2520a%2520Therapy-Resistant%2520L858R%252FT790M%252FC797S%2520Mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Selig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goettert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schattel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schollmeyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8429</span><span class="NLM_x">–</span> <span class="NLM_lpage">8439</span><span class="refDoi"> DOI: 10.1021/jm300852w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300852w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8429-8439&author=R.+Seligauthor=M.+Goettertauthor=V.+Schattelauthor=D.+Schollmeyerauthor=W.+Albrechtauthor=S.+Laufer&title=A+Frozen+Analogue+Approach+to+Aminopyridinylimidazoles+Leading+to+Novel+and+Promising+p38+MAP+Kinase+Inhibitors&doi=10.1021%2Fjm300852w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm300852w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300852w%26sid%3Dliteratum%253Aachs%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DA%2520Frozen%2520Analogue%2520Approach%2520to%2520Aminopyridinylimidazoles%2520Leading%2520to%2520Novel%2520and%2520Promising%2520p38%2520MAP%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8429%26epage%3D8439%26doi%3D10.1021%2Fjm300852w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Dimova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubbutat, M. H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schächtele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Assessing the Target Differentiation Potential of Imidazole-Based Protein Kinase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">11067</span><span class="NLM_x">–</span> <span class="NLM_lpage">11071</span><span class="refDoi"> DOI: 10.1021/jm3014508</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3014508" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOls73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=11067-11071&author=D.+Dimovaauthor=P.+Iyerauthor=M.+Vogtauthor=F.+Totzkeauthor=M.+H.+G.+Kubbutatauthor=C.+Sch%C3%A4chteleauthor=S.+Lauferauthor=J.+Bajorath&title=Assessing+the+Target+Differentiation+Potential+of+Imidazole-Based+Protein+Kinase+Inhibitors&doi=10.1021%2Fjm3014508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the Target Differentiation Potential of Imidazole-Based Protein Kinase Inhibitors</span></div><div class="casAuthors">Dimova, Dilyana; Iyer, Preeti; Vogt, Martin; Totzke, Frank; Kubbutat, Michael H. G.; Schaechtele, Christoph; Laufer, Stefan; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11067-11071</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A library of 484 imidazole-based candidate inhibitors was tested against 24 protein kinases.  The resulting activity data have been systematically analyzed to search for compds. that effectively differentiate between kinases.  Six imidazole derivs. with high kinase differentiation potential were identified.  Nearest neighbor anal. revealed the presence of close analogs with varying differentiation potential.  Small structural modifications of active compds. were found to shift their inhibitory profiles toward kinases with different functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW1f6gXOAlXrVg90H21EOLACvtfcHk0li5CZFrzv04WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOls73E&md5=2e0745b30fb1085641ee59024e89b4e5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm3014508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3014508%26sid%3Dliteratum%253Aachs%26aulast%3DDimova%26aufirst%3DD.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DVogt%26aufirst%3DM.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%2BG.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DAssessing%2520the%2520Target%2520Differentiation%2520Potential%2520of%2520Imidazole-Based%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D11067%26epage%3D11071%26doi%3D10.1021%2Fjm3014508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Muth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Günther, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Döring, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drückes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köppler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trappe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothbauer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Tetra-Substituted Pyridinylimidazoles As Dual Inhibitors of p38 alpha Mitogen-Activated Protein Kinase and c-Jun N-Terminal Kinase 3 for Potential Treatment of Neurodegenerative Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span><span class="refDoi"> DOI: 10.1021/jm501557a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501557a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=443-456&author=F.+Muthauthor=M.+G%C3%BCntherauthor=S.+M.+Bauerauthor=E.+D%C3%B6ringauthor=S.+Fischerauthor=J.+Maierauthor=P.+Dr%C3%BCckesauthor=J.+K%C3%B6pplerauthor=J.+Trappeauthor=U.+Rothbauerauthor=P.+Kochauthor=S.+A.+Laufer&title=Tetra-Substituted+Pyridinylimidazoles+As+Dual+Inhibitors+of+p38+alpha+Mitogen-Activated+Protein+Kinase+and+c-Jun+N-Terminal+Kinase+3+for+Potential+Treatment+of+Neurodegenerative+Diseases&doi=10.1021%2Fjm501557a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm501557a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501557a%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DF.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DJ.%26aulast%3DDr%25C3%25BCckes%26aufirst%3DP.%26aulast%3DK%25C3%25B6ppler%26aufirst%3DJ.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DRothbauer%26aufirst%3DU.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DTetra-Substituted%2520Pyridinylimidazoles%2520As%2520Dual%2520Inhibitors%2520of%2520p38%2520alpha%2520Mitogen-Activated%2520Protein%2520Kinase%2520and%2520c-Jun%2520N-Terminal%2520Kinase%25203%2520for%2520Potential%2520Treatment%2520of%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D443%26epage%3D456%26doi%3D10.1021%2Fjm501557a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Yoshikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukimoto-Niino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terazawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirouzu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, S.</span><span> </span><span class="NLM_article-title">Structural Basis for the Altered Drug Sensitivities of Non-small Cell Lung Cancer-Associated Mutants of Human Epidermal Growth Factor Receptor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1038/onc.2012.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fonc.2012.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=22349823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFKl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=27-38&author=S.+Yoshikawaauthor=M.+Kukimoto-Niinoauthor=L.+Parkerauthor=N.+Handaauthor=T.+Teradaauthor=T.+Fujimotoauthor=Y.+Terazawaauthor=M.+Wakiyamaauthor=M.+Satoauthor=S.+Sanoauthor=T.+Kobayashiauthor=T.+Tanakaauthor=L.+Chenauthor=Z.+J.+Liuauthor=B.+C.+Wangauthor=M.+Shirouzuauthor=S.+Kawaauthor=K.+Sembaauthor=T.+Yamamotoauthor=S.+Yokoyama&title=Structural+Basis+for+the+Altered+Drug+Sensitivities+of+Non-small+Cell+Lung+Cancer-Associated+Mutants+of+Human+Epidermal+Growth+Factor+Receptor&doi=10.1038%2Fonc.2012.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor</span></div><div class="casAuthors">Yoshikawa, S.; Kukimoto-Niino, M.; Parker, L.; Handa, N.; Terada, T.; Fujimoto, T.; Terazawa, Y.; Wakiyama, M.; Sato, M.; Sano, S.; Kobayashi, T.; Tanaka, T.; Chen, L.; Liu, Z.-J.; Wang, B.-C.; Shirouzu, M.; Kawa, S.; Semba, K.; Yamamoto, T.; Yokoyama, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-38</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain.  The non-small cell lung cancer (NSCLC)-assocd. EGFR mutants, L858R and G719S, are constitutively active and oncogenic.  They display sensitivity to TK inhibitors, including gefitinib and erlotinib.  In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants.  In this study, our biochem. analyses revealed that the introduction of the T790M mutation confers gefitinib resistance on the G719S mutant.  The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity.  The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant.  Structural analyses of the G719S/T790M double mutant, as well as the wild type and the G719S and L858R mutants, revealed that the T790M mutation stabilizes the hydrophobic spine of the active EGFR-TK conformation.  The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands.  In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop.  Notably, the introduction of the F723A mutation greatly enhanced the gefitinib sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity.  Taken together, our results provide a structural basis for the altered drug sensitivities caused by distinct NSCLC-assocd. EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr7hEqvdS5i7Vg90H21EOLACvtfcHk0lh1HeUXFD5XhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFKl&md5=f9b29aac7bcb52cc0605f157f7f14809</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.21%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DS.%26aulast%3DKukimoto-Niino%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DL.%26aulast%3DHanda%26aufirst%3DN.%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DTerazawa%26aufirst%3DY.%26aulast%3DWakiyama%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSano%26aufirst%3DS.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26aulast%3DWang%26aufirst%3DB.%2BC.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DKawa%26aufirst%3DS.%26aulast%3DSemba%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Altered%2520Drug%2520Sensitivities%2520of%2520Non-small%2520Cell%2520Lung%2520Cancer-Associated%2520Mutants%2520of%2520Human%2520Epidermal%2520Growth%2520Factor%2520Receptor%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D27%26epage%3D38%26doi%3D10.1038%2Fonc.2012.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Cha, M. Y.; Kim, M. R.; Kang, S. J.; Kim, S. Y.; Jung, Y. H.; Lee, K. O.; Song, J. Y.; Kim, Y. H.; Kim, E. Y.; Kim, M. S.</span><span> </span><span class="NLM_article-title">Preparation of Pyrimidine Derivative for Inhibiting the Growth of Cancer Cells</span>. WO2011099764A2,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Y.+Cha&author=M.+R.+Kim&author=S.+J.+Kang&author=S.+Y.+Kim&author=Y.+H.+Jung&author=K.+O.+Lee&author=J.+Y.+Song&author=Y.+H.+Kim&author=E.+Y.+Kim&author=M.+S.+Kim&title=Preparation+of+Pyrimidine+Derivative+for+Inhibiting+the+Growth+of+Cancer+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520Derivative%2520for%2520Inhibiting%2520the%2520Growth%2520of%2520Cancer%2520Cells%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Barawkar, D.; Bende, T.; Zahler, R.; Bandyopadhyay, A.; Sarangthem, R. S.; Doshi, J.; Waman, Y.; Jadhav, R.; Singh, U. P.</span><span> </span><span class="NLM_article-title">Preparation of Substituted Fused Tricyclic Compounds as JAK Kinase Inhibitors, Compositions and Medicinal Applications Thereof</span>. WO2012127506A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Barawkar&author=T.+Bende&author=R.+Zahler&author=A.+Bandyopadhyay&author=R.+S.+Sarangthem&author=J.+Doshi&author=Y.+Waman&author=R.+Jadhav&author=U.+P.+Singh&title=Preparation+of+Substituted+Fused+Tricyclic+Compounds+as+JAK+Kinase+Inhibitors%2C+Compositions+and+Medicinal+Applications+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarawkar%26aufirst%3DD.%26atitle%3DPreparation%2520of%2520Substituted%2520Fused%2520Tricyclic%2520Compounds%2520as%2520JAK%2520Kinase%2520Inhibitors%252C%2520Compositions%2520and%2520Medicinal%2520Applications%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Kwiatkowski, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelluma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soundararajan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manak, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deveraux, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kops, G. J. P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Small-Molecule Kinase Inhibitors Provide Insight into Mps1 Cell Cycle Function</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span><span class="refDoi"> DOI: 10.1038/nchembio.345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnchembio.345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=20383151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFaktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=359-368&author=N.+Kwiatkowskiauthor=N.+Jellumaauthor=P.+Filippakopoulosauthor=M.+Soundararajanauthor=M.+S.+Manakauthor=M.+Kwonauthor=H.+G.+Choiauthor=T.+Simauthor=Q.+L.+Deverauxauthor=S.+Rottmannauthor=D.+Pellmanauthor=J.+V.+Shahauthor=G.+J.+P.+L.+Kopsauthor=S.+Knappauthor=N.+S.+Gray&title=Small-Molecule+Kinase+Inhibitors+Provide+Insight+into+Mps1+Cell+Cycle+Function&doi=10.1038%2Fnchembio.345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function</span></div><div class="casAuthors">Kwiatkowski, Nicholas; Jelluma, Nannette; Filippakopoulos, Panagis; Soundararajan, Meera; Manak, Michael S.; Kwon, Mijung; Choi, Hwan Geun; Sim, Taebo; Deveraux, Quinn L.; Rottmann, Sabine; Pellman, David; Shah, Jagesh V.; Kops, Geert J. P. L.; Knapp, Stefan; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">359-368</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mps1, a dual-specificity kinase, is required for the proper functioning of the spindle assembly checkpoint and for the maintenance of chromosomal stability.  As Mps1 function has been implicated in numerous phases of the cell cycle, the development of a potent, selective small-mol. inhibitor of Mps1 should facilitate dissection of Mps1-related biol.  We describe the cellular effects and Mps1 cocrystal structures of new, selective small-mol. inhibitors of Mps1.  Consistent with RNAi studies, chem. inhibition of Mps1 leads to defects in Mad1 and Mad2 establishment at unattached kinetochores, decreased Aurora B kinase activity, premature mitotic exit and gross aneuploidy, without any evidence of centrosome duplication defects.  However, in U2OS cells having extra centrosomes (an abnormality found in some cancers), Mps1 inhibition increases the frequency of multipolar mitoses.  Lastly, Mps1 inhibitor treatment resulted in a decrease in cancer cell viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUsnJhF04gwrVg90H21EOLACvtfcHk0lh1HeUXFD5XhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFaktb0%253D&md5=965e5e5e4f85e21c5ec27b0ea9417914</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.345%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DJelluma%26aufirst%3DN.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DSoundararajan%26aufirst%3DM.%26aulast%3DManak%26aufirst%3DM.%2BS.%26aulast%3DKwon%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DDeveraux%26aufirst%3DQ.%2BL.%26aulast%3DRottmann%26aufirst%3DS.%26aulast%3DPellman%26aufirst%3DD.%26aulast%3DShah%26aufirst%3DJ.%2BV.%26aulast%3DKops%26aufirst%3DG.%2BJ.%2BP.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DSmall-Molecule%2520Kinase%2520Inhibitors%2520Provide%2520Insight%2520into%2520Mps1%2520Cell%2520Cycle%2520Function%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D359%26epage%3D368%26doi%3D10.1038%2Fnchembio.345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Yosaatmadja, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeage, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squire, C. J.</span><span> </span><span class="NLM_article-title">Binding Mode of the Breakthrough Inhibitor AZD9291 to Epidermal Growth Factor Receptor Revealed</span> <span class="citation_source-journal">J. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span><span class="refDoi"> DOI: 10.1016/j.jsb.2015.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.jsb.2015.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=26522274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2015&pages=539-544&author=Y.+Yosaatmadjaauthor=S.+Silvaauthor=J.+M.+Dicksonauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=J.+U.+Flanaganauthor=M.+J.+McKeageauthor=C.+J.+Squire&title=Binding+Mode+of+the+Breakthrough+Inhibitor+AZD9291+to+Epidermal+Growth+Factor+Receptor+Revealed&doi=10.1016%2Fj.jsb.2015.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed</span></div><div class="casAuthors">Yosaatmadja, Yuliana; Silva, Shevan; Dickson, James M.; Patterson, Adam V.; Smaill, Jeff B.; Flanagan, Jack U.; McKeage, Mark J.; Squire, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">539-544</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The discovery of genetic drivers of lung cancer in patient sub-groups has led to their use as predictive biomarkers and as targets for selective drug therapy.  Some of the most important lung cancer drivers are mutations in the EGFR gene, for example, the exon 19 deletions and the L858R variant that confer sensitivity to the front line drugs erlotinib and gefitinib; the acquired T790M variants confer drug resistance and a poor prognosis.  A challenge then in targeting EGFR is to produce drugs that inhibit both sensitizing variants and resistance variants, leaving wild type protein in healthy cells unaffected.  One such agent is AstraZeneca's "breakthrough" AZD9291 mol. that shows a 200-fold selectivity for T790M/L858R over wild type EGFR.  Our X-ray crystal structure reveals the binding mode of AZD9291 to the kinase domain of wild type EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZ-1Gcecv3LVg90H21EOLACvtfcHk0lgdQZQp5Wj7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksLbN&md5=330ba9239615813dbe0009e29d2e0983</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2015.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2015.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DSilva%26aufirst%3DS.%26aulast%3DDickson%26aufirst%3DJ.%2BM.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DMcKeage%26aufirst%3DM.%2BJ.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DBinding%2520Mode%2520of%2520the%2520Breakthrough%2520Inhibitor%2520AZD9291%2520to%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Revealed%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2015%26volume%3D192%26spage%3D539%26epage%3D544%26doi%3D10.1016%2Fj.jsb.2015.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Littlefield, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mysore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jura, N.</span><span> </span><span class="NLM_article-title">Structural Analysis of the EGFR/HER3 Heterodimer Reveals the Molecular Basis for Activating HER3Mutations</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">ra114</span><span class="refDoi"> DOI: 10.1126/scisignal.2005786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1126%2Fscisignal.2005786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=25468994" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=ra114&author=P.+Littlefieldauthor=L.+J.+Liuauthor=V.+Mysoreauthor=Y.+B.+Shanauthor=D.+E.+Shawauthor=N.+Jura&title=Structural+Analysis+of+the+EGFR%2FHER3+Heterodimer+Reveals+the+Molecular+Basis+for+Activating+HER3Mutations&doi=10.1126%2Fscisignal.2005786"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2005786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2005786%26sid%3Dliteratum%253Aachs%26aulast%3DLittlefield%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DMysore%26aufirst%3DV.%26aulast%3DShan%26aufirst%3DY.%2BB.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DJura%26aufirst%3DN.%26atitle%3DStructural%2520Analysis%2520of%2520the%2520EGFR%252FHER3%2520Heterodimer%2520Reveals%2520the%2520Molecular%2520Basis%2520for%2520Activating%2520HER3Mutations%26jtitle%3DSci.%2520Signaling%26date%3D2014%26volume%3D7%26spage%3Dra114%26doi%3D10.1126%2Fscisignal.2005786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauerlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jank, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5630</span><span class="NLM_x">–</span> <span class="NLM_lpage">5640</span><span class="refDoi"> DOI: 10.1021/jm800373t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800373t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5630-5640&author=P.+Kochauthor=C.+Bauerleinauthor=H.+Jankauthor=S.+Laufer&title=Targeting+the+Ribose+and+Phosphate+Binding+Site+of+p38+Mitogen-Activated+Protein+%28MAP%29+Kinase%3A+Synthesis+and+Biological+Testing+of+2-Alkylsulfanyl-%2C+4%285%29-Aryl-%2C+5%284%29-Heteroaryl-Substituted+Imidazoles&doi=10.1021%2Fjm800373t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles</span></div><div class="casAuthors">Koch, Pierre; Baeuerlein, Christiane; Jank, Hartmut; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5630-5640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three series of substituted 2-alkylsulfanyl-4-(4-fluorophenyl)imidazoles, 5-pyridinyl-, 1-methyl-5-pyridinyl-, and 5-(2-aminopyridin-4-yl)-imidazoles, were prepd. and tested for their ability to inhibit p38 MAP kinase and TNF-α release.  These compds. were tested by applying a nonradioactive p38 MAP kinase assay and by measurement of TNF-α release in human whole blood.  Potent inhibitors (IC50values in the low nanomolar range, as low as 2 nM in the enzyme assay and 37 nM in the human whole blood test) were identified by variation of substituents at the imidazole-C2-thio position as well as at the 2-aminopyridinyl functionality.  In contrast to other known kinase inhibitors, these novel imidazole derivs. with the substituents at the imidazole-C2-thio position may interact with the ribose as well as with the phosphate binding site of the p38 MAP kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodYYCjSY3UNbVg90H21EOLACvtfcHk0lgdQZQp5Wj7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbrK&md5=508c3e699dd65ee83a6592f2e719d17a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm800373t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800373t%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DBauerlein%26aufirst%3DC.%26aulast%3DJank%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520Ribose%2520and%2520Phosphate%2520Binding%2520Site%2520of%2520p38%2520Mitogen-Activated%2520Protein%2520%2528MAP%2529%2520Kinase%253A%2520Synthesis%2520and%2520Biological%2520Testing%2520of%25202-Alkylsulfanyl-%252C%25204%25285%2529-Aryl-%252C%25205%25284%2529-Heteroaryl-Substituted%2520Imidazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5630%26epage%3D5640%26doi%3D10.1021%2Fjm800373t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Schmidt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrowietz, U.</span><span> </span><span class="NLM_article-title">Reactivity of Dimethyl Fumarate and Methylhydrogen Fumarate Towards Glutathione and N-Acetyl-L-Cysteine - Preparation of S-Substituted Thiosuccinic Acid Esters</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.09.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.bmc.2006.09.053" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=333-342&author=T.+J.+Schmidtauthor=M.+Akauthor=U.+Mrowietz&title=Reactivity+of+Dimethyl+Fumarate+and+Methylhydrogen+Fumarate+Towards+Glutathione+and+N-Acetyl-L-Cysteine+-+Preparation+of+S-Substituted+Thiosuccinic+Acid+Esters&doi=10.1016%2Fj.bmc.2006.09.053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.09.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.09.053%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DT.%2BJ.%26aulast%3DAk%26aufirst%3DM.%26aulast%3DMrowietz%26aufirst%3DU.%26atitle%3DReactivity%2520of%2520Dimethyl%2520Fumarate%2520and%2520Methylhydrogen%2520Fumarate%2520Towards%2520Glutathione%2520and%2520N-Acetyl-L-Cysteine%2520-%2520Preparation%2520of%2520S-Substituted%2520Thiosuccinic%2520Acid%2520Esters%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D333%26epage%3D342%26doi%3D10.1016%2Fj.bmc.2006.09.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volak, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tegley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvedson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span> </span><span class="NLM_article-title">Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9171</span><span class="NLM_x">–</span> <span class="NLM_lpage">9178</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGrsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9171-9178&author=V.+J.+Ceeauthor=L.+P.+Volakauthor=Y.+P.+Chenauthor=M.+D.+Bartbergerauthor=C.+Tegleyauthor=T.+Arvedsonauthor=J.+McCarterauthor=A.+S.+Taskerauthor=C.+Fotsch&title=Systematic+Study+of+the+Glutathione+%28GSH%29+Reactivity+of+N-Arylacrylamides%3A+1.+Effects+of+Aryl+Substitution&doi=10.1021%2Facs.jmedchem.5b01018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution</span></div><div class="casAuthors">Cee, Victor J.; Volak, Laurie P.; Chen, Yuping; Bartberger, Michael D.; Tegley, Chris; Arvedson, Tara; McCarter, John; Tasker, Andrew S.; Fotsch, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9171-9178</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Success in the design of targeted covalent inhibitors depends in part on a knowledge of the factors influencing electrophile reactivity.  In an effort to further develop an understanding of structure-reactivity relations among N-arylacrylamides, the authors detd. glutathione (GSH) reaction rates for a family of N-arylacrylamides independently substituted at ortho-, meta-, and para-positions with 11 different groups common to inhibitor design.  Substituent effects on reaction rates show a linear Hammett correlation for ortho-, meta-, and para-substitution.  The authors note a correlation between 1H and 13C NMR chem. shifts of the acrylamide with GSH reaction rates, suggesting that NMR chem. shifts may be a convenient surrogate measure of relative acrylamide reactivity.  D. functional theory calcns. reveal a correlation between computed activation parameters and exptl. detd. reaction rates, validating the use of such methodol. for the screening of synthetic candidates in a prospective fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAoYRfo0lRj7Vg90H21EOLACvtfcHk0lgdQZQp5Wj7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGrsLfN&md5=2f3a816446dd73d5be061ad8d2195e2d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01018%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DVolak%26aufirst%3DL.%2BP.%26aulast%3DChen%26aufirst%3DY.%2BP.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DTegley%26aufirst%3DC.%26aulast%3DArvedson%26aufirst%3DT.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DFotsch%26aufirst%3DC.%26atitle%3DSystematic%2520Study%2520of%2520the%2520Glutathione%2520%2528GSH%2529%2520Reactivity%2520of%2520N-Arylacrylamides%253A%25201.%2520Effects%2520of%2520Aryl%2520Substitution%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9171%26epage%3D9178%26doi%3D10.1021%2Facs.jmedchem.5b01018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Weinstein, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, A.</span><span> </span><span class="NLM_article-title">Oncogene Addiction</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3077</span><span class="NLM_x">–</span> <span class="NLM_lpage">3080</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-3293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F0008-5472.CAN-07-3293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=18451130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3077-3080&author=I.+B.+Weinsteinauthor=A.+Joe&title=Oncogene+Addiction&doi=10.1158%2F0008-5472.CAN-07-3293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene Addiction</span></div><div class="casAuthors">Weinstein, I. Bernard; Joe, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3077-3080</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Cancer cells contain multiple genetic and epigenetic abnormalities.  Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene.  This phenomenon, called "oncogene addiction," provides a rationale for mol. targeted therapy.  The efficacy of this strategy requires novel methods, including integrative genomics and systems biol., to identify the state of oncogene addiction (i.e., the "Achilles heel") in specific cancers.  Combination therapy may also be required to prevent the escape of cancers from a given state of oncogene addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobVcTGxEyDNLVg90H21EOLACvtfcHk0li04NrvVotbhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSmtrk%253D&md5=fc62277a0200431335f79c420ebb02a6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-3293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-3293%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DI.%2BB.%26aulast%3DJoe%26aufirst%3DA.%26atitle%3DOncogene%2520Addiction%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3077%26epage%3D3080%26doi%3D10.1158%2F0008-5472.CAN-07-3293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Chuang, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, T.-H.</span><span> </span><span class="NLM_article-title">MAP4K Family Kinases in Immunity and Inflammation</span> <span class="citation_source-journal">Adv. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span><span class="refDoi"> DOI: 10.1016/bs.ai.2015.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fbs.ai.2015.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=26791862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFCmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2016&pages=277-314&author=H.-C.+Chuangauthor=X.+Wangauthor=T.-H.+Tan&title=MAP4K+Family+Kinases+in+Immunity+and+Inflammation&doi=10.1016%2Fbs.ai.2015.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">MAP4K family kinases in immunity and inflammation</span></div><div class="casAuthors">Chuang, Huai-Chia; Wang, Xiaohong; Tan, Tse-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277-314</span>CODEN:
                <span class="NLM_cas:coden">ADIMAV</span>;
        ISSN:<span class="NLM_cas:issn">0065-2776</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  MAP kinase kinase kinase kinases (MAP4Ks) belong to the mammalian Ste20-like family of serine/threonine kinases.  MAP4Ks including MAP4K1/HPK1, MAP4K2/GCK, MAP4K3/GLK, MAP4K4/HGK, MAP4K5/KHS, and MAP4K6/MINK have been reported to induce JNK activation through activating the MAP3K-MAP2K cascade.  The physiol. roles of MAP4Ks in immunity and inflammation are largely unknown until recent studies using biochem. approaches and knockout mice.  Surprisingly, JNK is not the major target of MAP4Ks in immune cells; MAP4Ks regulate immune responses through novel targets.  HPK1 inhibits T-cell receptor (TCR) signaling and B-cell receptor signaling via inducing phosphorylation/ubiquitination of SLP-76 and BLNK, resp.  GLK activates TCR signaling through phosphorylating/activating PKCθ.  T-cell-mediated immune responses and Th17-mediated exptl. autoimmune diseases are enhanced in HPK1 knockout mice but ameliorated in GLK knockout mice.  Consistently, HPK1 levels are decreased in peripheral blood mononuclear cells and T cells from patients with psoriatic arthritis and systemic lupus erythematosus (SLE), resp.  Moreover, GLK levels are increased in T cells from patients with SLE, rheumatoid arthritis, or adult-onset Still's disease; the percentages of GLK-overexpression T cells are correlated with the disease activity.  In addn., HGK phosphorylates and induces TRAF2 protein degrdn., leading to neg. regulation of IL-6 prodn. in resting T cells.  Loss of HGK in T cells results in spontaneous systemic inflammation and type 2 diabetes in mice.  HGK is also involved in cancer cell migration.  To date, the phenotypes of knockout mice for GCK, KHS, and MINK have not been reported; the roles of these three MAP4Ks in immune cell signaling are discussed in this review.  Taken together, MAP4K family kinases play diverse roles in immune cell signaling, immune responses, and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1p4FYLzTKFLVg90H21EOLACvtfcHk0li04NrvVotbhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFCmsLo%253D&md5=95bcabb6f63312daafffad87adb92b3b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fbs.ai.2015.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.ai.2015.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DChuang%26aufirst%3DH.-C.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DT.-H.%26atitle%3DMAP4K%2520Family%2520Kinases%2520in%2520Immunity%2520and%2520Inflammation%26jtitle%3DAdv.%2520Immunol.%26date%3D2016%26volume%3D129%26spage%3D277%26epage%3D314%26doi%3D10.1016%2Fbs.ai.2015.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+Irreversible+Inhibitors+of+the+Protein+Kinase+Cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0li04NrvVotbhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520Irreversible%2520Inhibitors%2520of%2520the%2520Protein%2520Kinase%2520Cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A Quantitative Analysis of Kinase Inhibitor Selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+Quantitative+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0livxEadUuNAoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520Quantitative%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Koul, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, S.</span><span> </span><span class="NLM_article-title">Role of p38 MAP Kinase Signal Transduction in Solid Tumors</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span><span class="refDoi"> DOI: 10.1177/1947601913507951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1177%2F1947601913507951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=24349632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGktbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=342-359&author=H.+K.+Koulauthor=M.+Palauthor=S.+Koul&title=Role+of+p38+MAP+Kinase+Signal+Transduction+in+Solid+Tumors&doi=10.1177%2F1947601913507951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Role of p38 MAP kinase signal transduction in solid tumors</span></div><div class="casAuthors">Koul, Hari K.; Pal, Mintu; Koul, Sweaty</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">342-359, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinases (MAPKs) mediate a wide variety of cellular behaviors in response to extracellular stimuli.  One of the main subgroups, the p38 MAP kinases, has been implicated in a wide range of complex biol. processes, such as cell proliferation, cell differentiation, cell death, cell migration, and invasion.  Dysregulation of p38 MAPK levels in patients are assocd. with advanced stages and short survival in cancer patients (e.g., prostate, breast, bladder, liver, and lung cancer).  P38 MAPK plays a dual role as a regulator of cell death, and it can either mediate cell survival or cell death depending not only on the type of stimulus but also in a cell type specific manner.  In addn. to modulating cell survival, an essential role of p38 MAPK in modulation of cell migration and invasion offers a distinct opportunity to target this pathway with respect to tumor metastasis.  The specific function of p38 MAPK appears to depend not only on the cell type but also on the stimuli and/or the isoform that is activated.  P38 MAPK signaling pathway is activated in response to diverse stimuli and mediates its function by components downstream of p38.  Extrapolation of the knowledge gained from lab. findings is essential to address the clin. significance of p38 MAPK signaling pathways.  The goal of this review is to provide an overview on recent progress made in defining the functions of p38 MAPK pathways with respect to solid tumor biol. and generate testable hypothesis with respect to the role of p38 MAPK as an attractive target for intervention of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB6A4yxL-gLLVg90H21EOLACvtfcHk0livxEadUuNAoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGktbfP&md5=a7803ce5e47e58b277f614616e526209</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1177%2F1947601913507951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601913507951%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DH.%2BK.%26aulast%3DPal%26aufirst%3DM.%26aulast%3DKoul%26aufirst%3DS.%26atitle%3DRole%2520of%2520p38%2520MAP%2520Kinase%2520Signal%2520Transduction%2520in%2520Solid%2520Tumors%26jtitle%3DGenes%2520Cancer%26date%3D2013%26volume%3D4%26spage%3D342%26epage%3D359%26doi%3D10.1177%2F1947601913507951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Greenberg, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchou-Wong, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rom, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. C.</span><span> </span><span class="NLM_article-title">Selective p38 Activation in Human Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1165/ajrcmb.26.5.4689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1165%2Fajrcmb.26.5.4689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=11970907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFWkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=558-564&author=A.+K.+Greenbergauthor=S.+Basuauthor=J.+Huauthor=T.+A.+Yieauthor=K.+M.+Tchou-Wongauthor=W.+N.+Romauthor=T.+C.+Lee&title=Selective+p38+Activation+in+Human+Non-Small+Cell+Lung+Cancer&doi=10.1165%2Fajrcmb.26.5.4689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Selective p38 activation in human non-small cell lung cancer</span></div><div class="casAuthors">Greenberg, Alissa K.; Basu, Sharmila; Hu, Jing; Yie, Ting-An; Tchou-Wong, Kam Meng; Rom, William N.; Lee, Theodore C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">558-564</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathways transmit signals from the cell membrane to the nucleus.  Activation of MAPK cascades may play a role in malignant transformation.  We hypothesized that enhanced expression of one or more of these pathways would occur in human lung cancers.  Using Western blot anal. of tissue homogenates from resected non-small cell lung cancers and matched non-neoplastic lung tissue, we detd. that only activated p38 was consistently increased in tumor compared with normal tissue.  In vitro kinase assays confirmed that the levels of activated MAPK correlated with the activity of the enzymes, and immunohistochem. anal. confirmed the cellular localization of the activated MAPKs.  We incubated a lung cancer cell line in a hypoxic chamber to simulate the hypoxic environment in solid lung tumors, but found no increase in p38 activation.  Contrary to our expectations, ERK and JNK, the MAPK pathways traditionally assocd. with cell growth and perhaps malignant transformation, were not consistently activated in the human lung tumor samples.  However, p38, a MAPK usually assocd. with stress responses, growth arrest, and apoptosis, was activated in all of the human lung cancer samples, suggesting an addnl. role for this pathway in malignant cell growth or transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIAmfxqEZ1wLVg90H21EOLACvtfcHk0livxEadUuNAoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFWkt7g%253D&md5=f0d7d71351549557a4650e9774dd39e7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1165%2Fajrcmb.26.5.4689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Fajrcmb.26.5.4689%26sid%3Dliteratum%253Aachs%26aulast%3DGreenberg%26aufirst%3DA.%2BK.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DYie%26aufirst%3DT.%2BA.%26aulast%3DTchou-Wong%26aufirst%3DK.%2BM.%26aulast%3DRom%26aufirst%3DW.%2BN.%26aulast%3DLee%26aufirst%3DT.%2BC.%26atitle%3DSelective%2520p38%2520Activation%2520in%2520Human%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2002%26volume%3D26%26spage%3D558%26epage%3D564%26doi%3D10.1165%2Fajrcmb.26.5.4689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Sterling, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span> </span><span class="NLM_article-title">ZINC 15-Ligand Discovery for Everyone</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2324</span><span class="NLM_x">–</span> <span class="NLM_lpage">2337</span><span class="refDoi"> DOI: 10.1021/acs.jcim.5b00559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=2324-2337&author=T.+Sterlingauthor=J.+J.+Irwin&title=ZINC+15-Ligand+Discovery+for+Everyone&doi=10.1021%2Facs.jcim.5b00559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">ZINC 15 - Ligand Discovery for Everyone</span></div><div class="casAuthors">Sterling, Teague; Irwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2324-2337</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many questions about the biol. activity and availability of small mols. remain inaccessible to investigators who could most benefit from their answers.  To narrow the gap between chemoinformatics and biol., we have developed a suite of ligand annotation, purchasability, target, and biol. assocn. tools, incorporated into ZINC and meant for investigators who are not computer specialists.  The new version contains over 120 million purchasable "drug-like" compds. - effectively all org. mols. that are for sale - a quarter of which are available for immediate delivery.  ZINC connects purchasable compds. to high-value ones such as metabolites, drugs, natural products, and annotated compds. from the literature.  Compds. may be accessed by the genes for which they are annotated as well as the major and minor target classes to which those genes belong.  It offers new anal. tools that are easy for nonspecialists yet with few limitations for experts.  ZINC retains its original 3D roots - all mols. are available in biol. relevant, ready-to-dock formats.  ZINC is freely available at http://zinc15.docking.org.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWfkDnal3D3bVg90H21EOLACvtfcHk0lj1lXzu7b78zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurbF&md5=e767c26c1d0aff7432c403c59a5d2b8b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00559%26sid%3Dliteratum%253Aachs%26aulast%3DSterling%26aufirst%3DT.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26atitle%3DZINC%252015-Ligand%2520Discovery%2520for%2520Everyone%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D2324%26epage%3D2337%26doi%3D10.1021%2Facs.jcim.5b00559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Villadsen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephansen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maolanon, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, C. A.</span><span> </span><span class="NLM_article-title">Total Synthesis and Full Histone Deacetylase Inhibitory Profiling of Azumamides A-E as Well as beta(2)-epi-Azumaide E and beta(3)-epi-Azumaide E</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6512</span><span class="NLM_x">–</span> <span class="NLM_lpage">6520</span><span class="refDoi"> DOI: 10.1021/jm4008449</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008449" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6512-6520&author=J.+S.+Villadsenauthor=H.+M.+Stephansenauthor=A.+R.+Maolanonauthor=P.+Harrisauthor=C.+A.+Olsen&title=Total+Synthesis+and+Full+Histone+Deacetylase+Inhibitory+Profiling+of+Azumamides+A-E+as+Well+as+beta%282%29-epi-Azumaide+E+and+beta%283%29-epi-Azumaide+E&doi=10.1021%2Fjm4008449"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm4008449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008449%26sid%3Dliteratum%253Aachs%26aulast%3DVilladsen%26aufirst%3DJ.%2BS.%26aulast%3DStephansen%26aufirst%3DH.%2BM.%26aulast%3DMaolanon%26aufirst%3DA.%2BR.%26aulast%3DHarris%26aufirst%3DP.%26aulast%3DOlsen%26aufirst%3DC.%2BA.%26atitle%3DTotal%2520Synthesis%2520and%2520Full%2520Histone%2520Deacetylase%2520Inhibitory%2520Profiling%2520of%2520Azumamides%2520A-E%2520as%2520Well%2520as%2520beta%25282%2529-epi-Azumaide%2520E%2520and%2520beta%25283%2529-epi-Azumaide%2520E%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6512%26epage%3D6520%26doi%3D10.1021%2Fjm4008449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Berliner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belecki, K.</span><span> </span><span class="NLM_article-title">Simple, Rapid Procedure for the Synthesis of Chloromethyl Methyl Ether and Other Chloro Alkyl Ethers</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">9618</span><span class="NLM_x">–</span> <span class="NLM_lpage">9621</span><span class="refDoi"> DOI: 10.1021/jo051344g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo051344g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2nu7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=9618-9621&author=M.+A.+Berlinerauthor=K.+Belecki&title=Simple%2C+Rapid+Procedure+for+the+Synthesis+of+Chloromethyl+Methyl+Ether+and+Other+Chloro+Alkyl+Ethers&doi=10.1021%2Fjo051344g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Simple, rapid procedure for the synthesis of chloromethyl methyl ether and other chloro alkyl ethers</span></div><div class="casAuthors">Berliner, Martin A.; Belecki, Katherine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9618-9621</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Zinc(II) salts catalyzed the reaction between acetals and acid halides to provide haloalkyl ethers in near-quant. yield.  Reactions from millimole to mole scale are typically complete in 1-4 h with 0.01 mol % catalyst.  The solns. of haloalkyl ethers thus obtained can be utilized directly in reactions in which the presence of the ester byproduct does not interfere.  Excess haloalkyl ether was destroyed on workup, thereby minimizing exposure to this class of carcinogenic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKEcjSYOlDCrVg90H21EOLACvtfcHk0lj1lXzu7b78zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2nu7%252FE&md5=396533045484bec17a4ac2d3afe3177d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjo051344g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo051344g%26sid%3Dliteratum%253Aachs%26aulast%3DBerliner%26aufirst%3DM.%2BA.%26aulast%3DBelecki%26aufirst%3DK.%26atitle%3DSimple%252C%2520Rapid%2520Procedure%2520for%2520the%2520Synthesis%2520of%2520Chloromethyl%2520Methyl%2520Ether%2520and%2520Other%2520Chloro%2520Alkyl%2520Ethers%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D9618%26epage%3D9621%26doi%3D10.1021%2Fjo051344g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Labadie, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stille, J. K.</span><span> </span><span class="NLM_article-title">Mechanisms of the Palladium-Catalyzed Couplings of Acid-Chlorides with Organotin Reagents</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">6129</span><span class="NLM_x">–</span> <span class="NLM_lpage">6137</span><span class="refDoi"> DOI: 10.1021/ja00357a026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00357a026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1983&pages=6129-6137&author=J.+W.+Labadieauthor=J.+K.+Stille&title=Mechanisms+of+the+Palladium-Catalyzed+Couplings+of+Acid-Chlorides+with+Organotin+Reagents&doi=10.1021%2Fja00357a026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fja00357a026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00357a026%26sid%3Dliteratum%253Aachs%26aulast%3DLabadie%26aufirst%3DJ.%2BW.%26aulast%3DStille%26aufirst%3DJ.%2BK.%26atitle%3DMechanisms%2520of%2520the%2520Palladium-Catalyzed%2520Couplings%2520of%2520Acid-Chlorides%2520with%2520Organotin%2520Reagents%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1983%26volume%3D105%26spage%3D6129%26epage%3D6137%26doi%3D10.1021%2Fja00357a026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Peng, J.; Costanzo, M. J.; Greco, M. N.; Green, M. A.; Wilde, V. L.; Zhang, D.</span><span> </span><span class="NLM_article-title">Preparation of Substituted 2-Anilinopyrimidine Derivatives as EGFR Modulators</span>. WO2016094821A2,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Peng&author=M.+J.+Costanzo&author=M.+N.+Greco&author=M.+A.+Green&author=V.+L.+Wilde&author=D.+Zhang&title=Preparation+of+Substituted+2-Anilinopyrimidine+Derivatives+as+EGFR+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520Substituted%25202-Anilinopyrimidine%2520Derivatives%2520as%2520EGFR%2520Modulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Borzilleri, R. M.; Chen, Z.; Huynh, T. N.; Vaccaro, W.; Chen, X.-T.; Kim, K. S.; Cai, Z.-W.</span><span> </span><span class="NLM_article-title">Preparation of Fused Heterocyclic Kinase Inhibitors</span>. US20050288290A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=R.+M.+Borzilleri&author=Z.+Chen&author=T.+N.+Huynh&author=W.+Vaccaro&author=X.-T.+Chen&author=K.+S.+Kim&author=Z.-W.+Cai&title=Preparation+of+Fused+Heterocyclic+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DPreparation%2520of%2520Fused%2520Heterocyclic%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Duong-Ly, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horiuchi, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">772</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span><span class="refDoi"> DOI: 10.1016/j.celrep.2015.12.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.celrep.2015.12.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=26776524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVaqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=772-781&author=K.+C.+Duong-Lyauthor=K.+Devarajanauthor=S.+G.+Liangauthor=K.+Y.+Horiuchiauthor=Y.+R.+Wangauthor=H.+C.+Maauthor=J.+R.+Peterson&title=Kinase+Inhibitor+Profiling+Reveals+Unexpected+Opportunities+to+Inhibit+Disease-Associated+Mutant+Kinases&doi=10.1016%2Fj.celrep.2015.12.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases</span></div><div class="casAuthors">Duong-Ly, Krisna C.; Devarajan, Karthik; Liang, Shuguang; Horiuchi, Kurumi Y.; Wang, Yuren; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">772-781</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors have typically been designed to inhibit wild-type kinases rather than the mutant forms that frequently arise in diseases such as cancer.  Mutations can have serious clin. implications by increasing kinase catalytic activity or conferring therapeutic resistance.  To identify opportunities to repurpose inhibitors against disease-assocd. mutant kinases, we conducted a large-scale functional screen of 183 known kinase inhibitors against 76 recombinant mutant kinases.  The results revealed lead compds. with activity against clin. important mutant kinases, including ALK, LRRK2, RET, and EGFR, as well as unexpected opportunities for repurposing FDA-approved kinase inhibitors as leads for addnl. indications.  Furthermore, using T674I PDGFRα as an example, we show how single-dose screening data can provide predictive structure-activity data to guide subsequent inhibitor optimization.  This study provides a resource for the development of inhibitors against numerous disease-assocd. mutant kinases and illustrates the potential of unbiased profiling as an approach to compd.-centric inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXqJUD9YoWLVg90H21EOLACvtfcHk0lgu_fUULDqVXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVaqt7c%253D&md5=b01e8f6ce2aa441400531399d8cf88fc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.12.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.12.080%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DS.%2BG.%26aulast%3DHoriuchi%26aufirst%3DK.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DMa%26aufirst%3DH.%2BC.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DKinase%2520Inhibitor%2520Profiling%2520Reveals%2520Unexpected%2520Opportunities%2520to%2520Inhibit%2520Disease-Associated%2520Mutant%2520Kinases%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D772%26epage%3D781%26doi%3D10.1016%2Fj.celrep.2015.12.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Anastassiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-1045&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+C.+Maauthor=J.+R.+Peterson&title=Comprehensive+Assay+of+Kinase+Catalytic+Activity+Reveals+Features+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0lgu_fUULDqVXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%2BC.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520Assay%2520of%2520Kinase%2520Catalytic%2520Activity%2520Reveals%2520Features%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1039%26epage%3D1045%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule-Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgu_fUULDqVXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule-Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Goettert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Optimization of a Nonradioactive Immunosorbent Assay for p38 Alpha Mitogen-Activated Protein Kinase Activity</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">406</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.ab.2010.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.ab.2010.07.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2010&pages=233-234&author=M.+Goettertauthor=R.+Graeserauthor=S.+A.+Laufer&title=Optimization+of+a+Nonradioactive+Immunosorbent+Assay+for+p38+Alpha+Mitogen-Activated+Protein+Kinase+Activity&doi=10.1016%2Fj.ab.2010.07.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2010.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2010.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DGraeser%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DOptimization%2520of%2520a%2520Nonradioactive%2520Immunosorbent%2520Assay%2520for%2520p38%2520Alpha%2520Mitogen-Activated%2520Protein%2520Kinase%2520Activity%26jtitle%3DAnal.%2520Biochem.%26date%3D2010%26volume%3D406%26spage%3D233%26epage%3D234%26doi%3D10.1016%2Fj.ab.2010.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 31 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Georg Baumann, Tobias Meckel, Kevin Böhm, Yung-Hsin Shih, Mirco Dickhaut, Torben Reichardt, Johannes Pilakowski, Ulrich Pehl, <span class="NLM_string-name hlFld-ContribAuthor">Boris Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">Illuminating a Dark Kinase: Structure-Guided Design, Synthesis, and Evaluation of a Potent Nek1 Inhibitor and Its Effects on the Embryonic Zebrafish Pronephros. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02118%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIlluminating%252Ba%252BDark%252BKinase%25253A%252BStructure-Guided%252BDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%252Bof%252Ba%252BPotent%252BNek1%252BInhibitor%252Band%252BIts%252BEffects%252Bon%252Bthe%252BEmbryonic%252BZebrafish%252BPronephros%26aulast%3DBaumann%26aufirst%3DGeorg%26date%3D2021%26date%3D2020%26date%3D08122020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David E. Heppner, Marcel Günther, Florian Wittlinger, Stefan A. Laufer, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Eck</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4293-4305. <a href="https://doi.org/10.1021/acs.jmedchem.0c00200" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bfor%252BEGFR%252BMutant%252BInhibition%252Bby%252BTrisubstituted%252BImidazole%252BInhibitors%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D14042020%26date%3D03042020%26volume%3D63%26issue%3D8%26spage%3D4293%26epage%3D4305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Harald Engelhardt, Dietrich Böse, Mark Petronczki, Dirk Scharn, Gerd Bader, Anke Baum, Andreas Bergner, Eugene Chong, Sandra Döbel, Georg Egger, Christian Engelhardt, Peter Ettmayer, Julian E. Fuchs, Thomas Gerstberger, Nina Gonnella, Andreas Grimm, Elisabeth Grondal, Nizar Haddad, Barbara Hopfgartner, Roland Kousek, Mariusz Krawiec, Monika Kriz, Lyne Lamarre, Joyce Leung, Moriz Mayer, Nitinchandra D. Patel, Biljana Peric Simov, Jonathan T. Reeves, Renate Schnitzer, Andreas Schrenk, Bernadette Sharps, Flavio Solca, Heinz Stadtmüller, Zhulin Tan, Tobias Wunberg, Andreas Zoephel, <span class="NLM_string-name hlFld-ContribAuthor">Darryl B. McConnell</span>. </span><span class="cited-content_cbyCitation_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10272-10293. <a href="https://doi.org/10.1021/acs.jmedchem.9b01169" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStart%252BSelective%252Band%252BRigidify%25253A%252BThe%252BDiscovery%252BPath%252Btoward%252Ba%252BNext%252BGeneration%252Bof%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DEngelhardt%26aufirst%3DHarald%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14082019%26date%3D13112019%26date%3D05112019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, <span class="NLM_string-name hlFld-ContribAuthor">Michelle M. Kuttel</span>. </span><span class="cited-content_cbyCitation_article-title">A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (41)
                                     , 4246-4259. <a href="https://doi.org/10.1021/acs.biochem.9b00710" title="DOI URL">https://doi.org/10.1021/acs.biochem.9b00710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.9b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.9b00710%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DA%252BMechanistic%252BStudy%252Bof%252Ba%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252Bagainst%252Bthe%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D23092019%26date%3D07102019%26volume%3D58%26issue%3D41%26spage%3D4246%26epage%3D4259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sean T. Toenjes, Valeria Garcia, Sean M. Maddox, Gregory A. Dawson, Maria A. Ortiz, F. Javier Piedrafita, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey L. Gustafson</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (9)
                                     , 1930-1939. <a href="https://doi.org/10.1021/acschembio.9b00407" title="DOI URL">https://doi.org/10.1021/acschembio.9b00407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00407%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DLeveraging%252BAtropisomerism%252Bto%252BObtain%252Ba%252BSelective%252BInhibitor%252Bof%252BRET%252BKinase%252Bwith%252BSecondary%252BActivities%252Btoward%252BEGFR%252BMutants%26aulast%3DToenjes%26aufirst%3DSean%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22052019%26date%3D19082019%26date%3D29082019%26date%3D19082019%26volume%3D14%26issue%3D9%26spage%3D1930%26epage%3D1939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Michael J. Zacuto</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Acrylamides via the Doebner–Knoevenagel Condensation. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (10)
                                     , 6465-6474. <a href="https://doi.org/10.1021/acs.joc.9b00450" title="DOI URL">https://doi.org/10.1021/acs.joc.9b00450</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b00450%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BAcrylamides%252Bvia%252Bthe%252BDoebner%2525E2%252580%252593Knoevenagel%252BCondensation%26aulast%3DZacuto%26aufirst%3DMichael%2BJ.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14022019%26date%3D29042019%26date%3D18042019%26volume%3D84%26issue%3D10%26spage%3D6465%26epage%3D6474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zheng Zhao, Lei Xie, <span class="NLM_string-name hlFld-ContribAuthor">Philip E. Bourne</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (1)
                                     , 453-462. <a href="https://doi.org/10.1021/acs.jcim.8b00458" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00458</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00458%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DStructural%252BInsights%252Binto%252BCharacterizing%252BBinding%252BSites%252Bin%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BKinase%252BMutants%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D10072018%26date%3D11012019%26date%3D24122018%26volume%3D59%26issue%3D1%26spage%3D453%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mohamed
S. A. Elsayed, Jeffery J. Nielsen, Sungtae Park, Jeongho Park, Qingyang Liu, Chang H. Kim, Yves Pommier, Keli Agama, Philip S. Low, <span class="NLM_string-name hlFld-ContribAuthor">Mark Cushman</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[c]pyrrolo[2,3-h][1,6]naphthyridin-5-one (BPN) Series. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10440-10462. <a href="https://doi.org/10.1021/acs.jmedchem.8b00510" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00510</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00510%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DApplication%252Bof%252BSequential%252BPalladium%252BCatalysis%252Bfor%252Bthe%252BDiscovery%252Bof%252BJanus%252BKinase%252BInhibitors%252Bin%252Bthe%252BBenzo%25255Bc%25255Dpyrrolo%25255B2%25252C3-h%25255D%25255B1%25252C6%25255Dnaphthyridin-5-one%252B%252528BPN%252529%252BSeries%26aulast%3DElsayed%26aufirst%3DMohamed%2BS.%2BA.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D31032018%26date%3D21112018%26volume%3D61%26issue%3D23%26spage%3D10440%26epage%3D10462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Tao Zhang, Su-Jie Zhu, Qiuju Xun, Lingjiang Tong, Xianglong Hu, Yan Li, Shingpan Chan, Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai-Hong Yun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (11)
                                     , 1123-1127. <a href="https://doi.org/10.1021/acsmedchemlett.8b00373" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BJND3229%252Bas%252Ba%252BNew%252BEGFRC797S%252BMutant%252BInhibitor%252Bwith%252BIn%252BVivo%252BMonodrug%252BEfficacy%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15082018%26date%3D08102018%26date%3D10102018%26date%3D08102018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lingfeng Chen, Weitao Fu, Lulu Zheng, Zhiguo Liu, <span class="NLM_string-name hlFld-ContribAuthor">Guang Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 4290-4300. <a href="https://doi.org/10.1021/acs.jmedchem.7b01310" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bof%252BSmall-Molecule%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BC797S%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D02092017%26date%3D27112017%26date%3D14112017%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Xiong</span>, <span class="hlFld-ContribAuthor ">Xiao  Wei</span>, <span class="hlFld-ContribAuthor ">Zi-Ming  Liu</span>, and <span class="hlFld-ContribAuthor ">Ming-Wu  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of Polysubstituted Imidazoles via Sequential Staudinger/aza-Wittig/Ag(I)-Catalyzed Cyclization/Isomerization. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (24)
                                     , 13735-13739. <a href="https://doi.org/10.1021/acs.joc.7b02606" title="DOI URL">https://doi.org/10.1021/acs.joc.7b02606</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b02606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b02606%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BPolysubstituted%252BImidazoles%252Bvia%252BSequential%252BStaudinger%25252Faza-Wittig%25252FAg%252528I%252529-Catalyzed%252BCyclization%25252FIsomerization%26aulast%3DXiong%26aufirst%3DJun%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D12102017%26date%3D28112017%26date%3D15122017%26date%3D17112017%26volume%3D82%26issue%3D24%26spage%3D13735%26epage%3D13739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Heppner</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>. </span><span class="cited-content_cbyCitation_article-title">A structural perspective on targeting the
              RTK
              /Ras/
              MAP
              kinase pathway in cancer. </span><span class="cited-content_cbyCitation_journal-name">Protein Science</span><span> <strong>2021,</strong> <em>30 </em>
                                    (8)
                                     , 1535-1553. <a href="https://doi.org/10.1002/pro.4125" title="DOI URL">https://doi.org/10.1002/pro.4125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pro.4125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpro.4125%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Science%26atitle%3DA%252Bstructural%252Bperspective%252Bon%252Btargeting%252Bthe%252BRTK%252B%25252FRas%25252F%252BMAP%252Bkinase%252Bpathway%252Bin%252Bcancer%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D8%26spage%3D1535%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iqrar  Ahmad</span>, <span class="hlFld-ContribAuthor ">Matin  Shaikh</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>, <span class="hlFld-ContribAuthor ">Arabinda  Ghosh</span>, <span class="hlFld-ContribAuthor ">Harun  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>3 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2020.1844801" title="DOI URL">https://doi.org/10.1080/07391102.2020.1844801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1844801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1844801%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3Dp38%2525CE%2525B1%252BMAP%252Bkinase%252Binhibitors%252Bto%252Bovercome%252BEGFR%252Btertiary%252BC797S%252Bpoint%252Bmutation%252Bassociated%252Bwith%252Bosimertinib%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%25253A%252Bemergence%252Bof%252Bfourth-generation%252BEGFR%252Binhibitor%26aulast%3DAhmad%26aufirst%3DIqrar%26date%3D2020%26date%3D2020%26volume%3D3%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sourav  Kalra</span>, <span class="hlFld-ContribAuthor ">Gaurav  Joshi</span>, <span class="hlFld-ContribAuthor ">Manvendra  Kumar</span>, <span class="hlFld-ContribAuthor ">Sahil  Arora</span>, <span class="hlFld-ContribAuthor ">Harsimrat  Kaur</span>, <span class="hlFld-ContribAuthor ">Sandeep  Singh</span>, <span class="hlFld-ContribAuthor ">Anjana  Munshi</span>, <span class="hlFld-ContribAuthor ">Raj  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism
              via
              epidermal growth factor receptor (EGFR) inhibition. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (8)
                                     , 923-939. <a href="https://doi.org/10.1039/D0MD00146E" title="DOI URL">https://doi.org/10.1039/D0MD00146E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00146E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00146E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DAnticancer%252Bpotential%252Bof%252Bsome%252Bimidazole%252Band%252Bfused%252Bimidazole%252Bderivatives%25253A%252Bexploring%252Bthe%252Bmechanism%252Bvia%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibition%26aulast%3DKalra%26aufirst%3DSourav%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D8%26spage%3D923%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xianglong  Hu</span>, <span class="hlFld-ContribAuthor ">Qiuju  Xun</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Su-Jie  Zhu</span>, <span class="hlFld-ContribAuthor ">Qian  Li</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Mengzhen  Lai</span>, <span class="hlFld-ContribAuthor ">Tao  Huang</span>, <span class="hlFld-ContribAuthor ">Cai-Hong  Yun</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (5)
                                     , 1281-1287. <a href="https://doi.org/10.1016/j.cclet.2019.09.044" title="DOI URL">https://doi.org/10.1016/j.cclet.2019.09.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2019.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2019.09.044%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3D2-Oxo-3%25252C4-dihydropyrimido%25255B4%25252C5-d%25255D%252Bpyrimidines%252Bas%252Bnew%252Breversible%252Binhibitors%252Bof%252BEGFR%252BC797S%252B%252528Cys797%252Bto%252BSer797%252529%252Bmutant%26aulast%3DHu%26aufirst%3DXianglong%26date%3D2020%26volume%3D31%26issue%3D5%26spage%3D1281%26epage%3D1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Shu  Fan</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan-Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Jun-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">A-Qun  Zheng</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111888. <a href="https://doi.org/10.1016/j.ejmech.2019.111888" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111888</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111888%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B9-heterocyclyl%252Bsubstituted%252B9H-purines%252Bas%252BL858R%25252FT790M%25252FC797S%252Bmutant%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DLei%26aufirst%3DHao%26date%3D2020%26volume%3D186%26spage%3D111888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shanshan  Liu</span>, <span class="hlFld-ContribAuthor ">Heng  Yang</span>, <span class="hlFld-ContribAuthor ">Lin-Yu  Jiao</span>, <span class="hlFld-ContribAuthor ">Jian-Hua  Zhang</span>, <span class="hlFld-ContribAuthor ">Chen  Zhao</span>, <span class="hlFld-ContribAuthor ">Yangmin  Ma</span>, <span class="hlFld-ContribAuthor ">Xiufang  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective deoxygenative chalcogenation of 7-azindole
              N
              -oxides promoted by I
              2
              /PEG-200. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (47)
                                     , 10073-10087. <a href="https://doi.org/10.1039/C9OB02044F" title="DOI URL">https://doi.org/10.1039/C9OB02044F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB02044F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB02044F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRegioselective%252Bdeoxygenative%252Bchalcogenation%252Bof%252B7-azindole%252BN%252B-oxides%252Bpromoted%252Bby%252BI%252B2%252B%25252FPEG-200%26aulast%3DLiu%26aufirst%3DShanshan%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D47%26spage%3D10073%26epage%3D10087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Philip  Klövekorn</span>, <span class="hlFld-ContribAuthor ">Hannah L.  Tumbrink</span>, <span class="hlFld-ContribAuthor ">Janina  Niggenaber</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Müller</span>, <span class="hlFld-ContribAuthor ">Luke  Hodson</span>, <span class="hlFld-ContribAuthor ">Maren  Flaßhoff</span>, <span class="hlFld-ContribAuthor ">Julia  Hardick</span>, <span class="hlFld-ContribAuthor ">Tobias  Grabe</span>, <span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">Carsten  Schultz-Fademrecht</span>, <span class="hlFld-ContribAuthor ">Matthias  Baumann</span>, <span class="hlFld-ContribAuthor ">Julia  Ketzer</span>, <span class="hlFld-ContribAuthor ">Thomas  Mühlenberg</span>, <span class="hlFld-ContribAuthor ">Wolf  Hiller</span>, <span class="hlFld-ContribAuthor ">Georgia  Günther</span>, <span class="hlFld-ContribAuthor ">Anke  Unger</span>, <span class="hlFld-ContribAuthor ">Heiko  Müller</span>, <span class="hlFld-ContribAuthor ">Alena  Heimsoeth</span>, <span class="hlFld-ContribAuthor ">Christopher  Golz</span>, <span class="hlFld-ContribAuthor ">Bernhard  Blank-Landeshammer</span>, <span class="hlFld-ContribAuthor ">Laxmikanth  Kollipara</span>, <span class="hlFld-ContribAuthor ">René P.  Zahedi</span>, <span class="hlFld-ContribAuthor ">Carsten  Strohmann</span>, <span class="hlFld-ContribAuthor ">Jan G.  Hengstler</span>, <span class="hlFld-ContribAuthor ">Willem A. L.  van Otterlo</span>, <span class="hlFld-ContribAuthor ">Sebastian  Bauer</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (46)
                                     , 10789-10801. <a href="https://doi.org/10.1039/C9SC03445E" title="DOI URL">https://doi.org/10.1039/C9SC03445E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC03445E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC03445E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DInhibition%252Bof%252Bosimertinib-resistant%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252BEGFR-T790M%25252FC797S%26aulast%3DLategahn%26aufirst%3DJonas%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D46%26spage%3D10789%26epage%3D10801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Efthymios-Spyridon  Gavriil</span>, <span class="hlFld-ContribAuthor ">Aris  Doukatas</span>, <span class="hlFld-ContribAuthor ">Theodoros  Karampelas</span>, <span class="hlFld-ContribAuthor ">Vassilios  Myrianthopoulos</span>, <span class="hlFld-ContribAuthor ">Spyridon  Dimitrakis</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Mikros</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Marakos</span>, <span class="hlFld-ContribAuthor ">Constantin  Tamvakopoulos</span>, <span class="hlFld-ContribAuthor ">Nicole  Pouli</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>176 </em>, 393-409. <a href="https://doi.org/10.1016/j.ejmech.2019.05.029" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.029%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bsubstituted%252Bpurine%252Bisosters%252Bas%252BEGFR%252Bkinase%252Binhibitors%25252C%252Bwith%252Bpromising%252Bpharmacokinetic%252Bprofile%252Band%252Bin%2525C2%2525A0vivo%252Befficacy%26aulast%3DGavriil%26aufirst%3DEfthymios-Spyridon%26date%3D2019%26volume%3D176%26spage%3D393%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel  Štarha</span>, <span class="hlFld-ContribAuthor ">Zdeněk  Trávníček</span>. </span><span class="cited-content_cbyCitation_article-title">Azaindoles: Suitable ligands of cytotoxic transition metal complexes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2019,</strong> <em>197 </em>, 110695. <a href="https://doi.org/10.1016/j.jinorgbio.2019.110695" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2019.110695</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2019.110695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2019.110695%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DAzaindoles%25253A%252BSuitable%252Bligands%252Bof%252Bcytotoxic%252Btransition%252Bmetal%252Bcomplexes%26aulast%3D%25C5%25A0tarha%26aufirst%3DPavel%26date%3D2019%26volume%3D197%26spage%3D110695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farideh Badichi  Akher</span>, <span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Mahmoud E. S.  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">Noteworthy effect of slight variation in aliphatic chain length of trisubstituted imidazole inhibitors against epidermal growth factor receptor L858R/T790M/C797S mutant in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2019,</strong> <em>93 </em>
                                    (5)
                                     , 798-810. <a href="https://doi.org/10.1111/cbdd.13467" title="DOI URL">https://doi.org/10.1111/cbdd.13467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13467%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DNoteworthy%252Beffect%252Bof%252Bslight%252Bvariation%252Bin%252Baliphatic%252Bchain%252Blength%252Bof%252Btrisubstituted%252Bimidazole%252Binhibitors%252Bagainst%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252BL858R%25252FT790M%25252FC797S%252Bmutant%252Bin%252Bcancer%252Btherapy%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26volume%3D93%26issue%3D5%26spage%3D798%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farideh Badichi  Akher</span>, <span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Mahmoud E. S.  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent vs. Non‐Covalent Inhibition: Tackling Drug Resistance in EGFR – A Thorough Dynamic Perspective. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2019,</strong> <em>16 </em>
                                    (3)
                                     , e1800518. <a href="https://doi.org/10.1002/cbdv.201800518" title="DOI URL">https://doi.org/10.1002/cbdv.201800518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201800518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201800518%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DCovalent%252Bvs.%252BNon%2525E2%252580%252590Covalent%252BInhibition%25253A%252BTackling%252BDrug%252BResistance%252Bin%252BEGFR%252B%2525E2%252580%252593%252BA%252BThorough%252BDynamic%252BPerspective%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26volume%3D16%26issue%3D3%26spage%3De1800518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcel  Günther</span>, <span class="hlFld-ContribAuthor ">Julian  Laux</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure‑activity‑relationship of 3,4‑Diaryl‑1H‑pyrrolo[2,3‑b]pyridines as irreversible Inhibitors of mutant EGFR‑L858R/T790M. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2019,</strong> <em>128 </em>, 91-96. <a href="https://doi.org/10.1016/j.ejps.2018.11.021" title="DOI URL">https://doi.org/10.1016/j.ejps.2018.11.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2018.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2018.11.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DSynthesis%252Band%252Bstructure%2525E2%252580%252591activity%2525E2%252580%252591relationship%252Bof%252B3%25252C4%2525E2%252580%252591Diaryl%2525E2%252580%2525911H%2525E2%252580%252591pyrrolo%25255B2%25252C3%2525E2%252580%252591b%25255Dpyridines%252Bas%252Birreversible%252BInhibitors%252Bof%252Bmutant%252BEGFR%2525E2%252580%252591L858R%25252FT790M%26aulast%3DG%25C3%25BCnther%26aufirst%3DMarcel%26date%3D2019%26volume%3D128%26spage%3D91%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Xue-Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (12)
                                     , 3619-3633. <a href="https://doi.org/10.1016/j.bmc.2018.05.039" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.05.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.05.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.05.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Birreversible%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%252Bcontaining%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bscaffold%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D26%26issue%3D12%26spage%3D3619%26epage%3D3633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>. </span><span class="cited-content_cbyCitation_article-title">Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (16)
                                     , 4456-4470. <a href="https://doi.org/10.1002/ange.201707875" title="DOI URL">https://doi.org/10.1002/ange.201707875</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201707875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201707875%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DDas%252BCysteinom%252Bder%252BProteinkinasen%252Bals%252BZielstruktur%252Bin%252Bder%252BArzneistoffentwicklung%26aulast%3DChaikuad%26aufirst%3DApirat%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D16%26spage%3D4456%26epage%3D4470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>. </span><span class="cited-content_cbyCitation_article-title">The Cysteinome of Protein Kinases as a Target in Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (16)
                                     , 4372-4385. <a href="https://doi.org/10.1002/anie.201707875" title="DOI URL">https://doi.org/10.1002/anie.201707875</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201707875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201707875%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DThe%252BCysteinome%252Bof%252BProtein%252BKinases%252Bas%252Ba%252BTarget%252Bin%252BDrug%252BDevelopment%26aulast%3DChaikuad%26aufirst%3DApirat%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D16%26spage%3D4372%26epage%3D4385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Duan</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 221-237. <a href="https://doi.org/10.1016/j.ejmech.2018.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4%25252C6-trisubstitued%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnew%252BEGFR-TKIs%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tsutomu  Fukuda</span>, <span class="hlFld-ContribAuthor ">Teppei  Umeki</span>, <span class="hlFld-ContribAuthor ">Keiji  Tokushima</span>, <span class="hlFld-ContribAuthor ">Gao  Xiang</span>, <span class="hlFld-ContribAuthor ">Yuki  Yoshida</span>, <span class="hlFld-ContribAuthor ">Fumito  Ishibashi</span>, <span class="hlFld-ContribAuthor ">Yusuke  Oku</span>, <span class="hlFld-ContribAuthor ">Naoyuki  Nishiya</span>, <span class="hlFld-ContribAuthor ">Yoshimasa  Uehara</span>, <span class="hlFld-ContribAuthor ">Masatomo  Iwao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (24)
                                     , 6563-6580. <a href="https://doi.org/10.1016/j.bmc.2017.10.030" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.10.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.10.030%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bevaluation%252Bof%252BA-ring-modified%252Blamellarin%252BN%252Banalogues%252Bas%252Bnoncovalent%252Binhibitors%252Bof%252Bthe%252BEGFR%252BT790M%25252FL858R%252Bmutant%26aulast%3DFukuda%26aufirst%3DTsutomu%26date%3D2017%26volume%3D25%26issue%3D24%26spage%3D6563%26epage%3D6580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuqin  Hu</span>, <span class="hlFld-ContribAuthor ">Disha  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Tong</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Shiliang  Li</span>, <span class="hlFld-ContribAuthor ">You  Yang</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2017,</strong> <em>5 </em><a href="https://doi.org/10.3389/fchem.2017.00101" title="DOI URL">https://doi.org/10.3389/fchem.2017.00101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2017.00101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2017.00101%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%252Bof%252BRibose-Modified%252BAnilinopyrimidine%252BDerivatives%252Bas%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DHu%26aufirst%3DXiuqin%26date%3D2017%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0001.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Molecular docking of lead structure <b>11g</b> in the EGFR T790M kinase domain X-ray structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Hydrogen bonds are shown in orange dots. The angle between the imidazole and the fluorophenyl residue is visualized as blue dots. The Met790 gatekeeper is shown as spheres to visualize steric demands. Hydrophobic region I: area that is occupied by fluorophenyl residue, shown with purple coloration. (B) Addressed regions in our SAR study. <b>HR I</b>: hydrophobic region I, gatekeeper. <b>PBS</b>: phosphate binding site, much space, polar amino acids, Cys797 accessible. <b>RP</b>: ribose pocket, Cys797 accessible. <b>HR II</b>: hydrophobic region II, Cys797 accessible.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Reversible EGFR Inhibitors of <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> (<b>11a</b>–<b>f</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) <i>n</i>-BuLi, Sn(Bu)<sub>3</sub>Cl, THF, −78 °C to rt (compound <b>9d</b>: (1) NIS, MeCN, rt, (2) (CH<sub>3</sub>)<sub>2</sub>CHMgCl·LiCl, Sn(Bu)<sub>3</sub>Cl, THF, 0 °C to rt); (b) Pd(OAc)<sub>2</sub>:X-Phos (3:1), dioxane, reflux; (c) HCl (conc), MeOH, reflux (<b>11e</b>: (1) DCM, TFA, rt; (2) MeOH, K<sub>2</sub>CO<sub>3(aq)</sub>, rt).</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Amide Coupling of the Benzylamines <b>18a</b>,<b>b</b> to the Inhibitors <b>19a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Acrylic acid (<b>19a</b>,<b>c</b>)/(<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride (<b>19b</b>), TBTU, DIPEA, THF, rt.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of the Building Blocks for the EGFR Inhibitors <b>27a</b>,<b>b</b> and <b>33</b> of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NH<sub>4</sub>OAc, MeOH, rt; (b) NaH, MOM-Cl, THF, 0 °C to rt; (c) <i>n</i>-BuLi, Sn(Bu)<sub>3</sub>Cl, THF −78 °C to rt; (d) DIPA, <i>n</i>-BuLi, I<sub>2</sub>, THF, −78 °C to rt; (e) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, MeCN, 1 M K<sub>2</sub>CO<sub>3(aq)</sub>, 60 °C; (f) (1) <i>m</i>CPBA, EA, 0 °C to rt, (2) mesyl chloride, DMF, 70 °C; (g) <i>n</i>-BuLi, B(OMe)<sub>3</sub>, Et<sub>2</sub>O, −40 °C to rt.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of the EGFR Inhibitors with a Michael Acceptor at the Phenyl Ring Attached to the 7-Azaindole (<b>27a</b>,<b>b</b> and <b>33</b>) of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Pd(OAc)<sub>2</sub>:X-Phos (3:1), dioxane, reflux; (b) HCl (conc), MeOH, reflux; (c) (1) 3-chloropropanoyl chloride, THF, −15 °C, (2) NaOH, H<sub>2</sub>O, 60 °C; (d) propionyl chloride, THF, rt; (e) acrylic acid, TBTU, DIPEA, THF, 0 °C to rt.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route of 7-Azaindole Hinge Binder Motifs to Study the Best Attachment Point for a Michael Acceptor (<b>37</b>, <b>41</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NaH, SEM-Cl, DMF, 0 °C to rt; (b) <i>n</i>-BuLi, B(OMe)<sub>3</sub>, Et<sub>2</sub>O, −40 °C to rt; (c) (1) 3-bromo benzylamine, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, H<sub>2</sub>O, 80 °C, (2) acryloyl chloride, DIPEA, THF, 0 °C; (d) (1) TFA, DCM, rt, (2) MeOH, NaHCO<sub>3(aq)</sub>, rt; (e) NIS, MeCN, 0–50 °C; (f) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, 1 M Na<sub>2</sub>CO<sub>3(aq)</sub>, MeCN, 60 °C; (g) (1) TFA, DCM, rt, (2) EtOH, NaHCO<sub>3(aq)</sub>, rt.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route of EGFR Inhibitors with Michael Acceptor at the Phenyl Ring Attached to the 3-Position of 7-Azaindole (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>R<sup>1</sup>–R<sup>3</sup> analogous to <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. (a) NH<sub>4</sub>OAc, MeOH, rt (<b>C</b><sub><b>3</b></sub><b>HBr</b><sub><b>2</b></sub><b>F</b><sub><b>3</b></sub><b>O</b>: (1) NH<sub>4</sub>OAc, H<sub>2</sub>O, 100 °C; (2) NH<sub>4</sub>OAc, MeOH, rt); (b) NaH, SEM-Cl, DMF, 0 °C to rt; (c) <i>n</i>-BuLi, Sn(Bu)<sub>3</sub>Cl, THF, −78 °C to rt (<b>9g</b>: (1) NIS, MeCN, rt; (2) (CH<sub>3</sub>)<sub>2</sub>CHMgCl·LiCl, Sn(Bu)<sub>3</sub>Cl, THF 0 °C to rt); (d) Pd(OAc)<sub>2</sub>:X-Phos 3:1, dioxane, reflux; (e) NBS, THF, rt (<b>10f</b>: NIS, MeCN 0–50 °C); (f) (1) 3-nitrophenyl boronic acid, K<sub>2</sub>CO<sub>3</sub> or K<sub>3</sub>PO<sub>4</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF or dioxane, H<sub>2</sub>O, 80 or 100 °C, (2) H<sub>2</sub>, Pd/C, EA, 1, 3, or 6 bar, rt or 75 °C; (f) acryloyl chloride or propionyl chloride, DIPEA, THF, 0 °C; (g) (1) TFA, DCM, rt, (2) K<sub>2</sub>CO<sub>3(aq)</sub> or NaHCO<sub>3(aq)</sub>, MeOH or EtOH, rt.</p></p></figure><figure data-id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Molecular docking of <b>11h</b> (light-gray sticks) in a crystal structure of ADP bound to EGFR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW">4RIW</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> ADP (black lines), covalent interactions (gray dots), and magnesium ion (cyan sphere) are adapted from the crystal structure. Polar interactions of <b>11h</b> with hinge region and Asp831 (red dots) are postulated via Glide docking software.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Covalent docking of <b>19a</b> (A) and <b>27a</b> (B) in EGFR T790M kinase active site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Predicted hydrogen bonds are indicated as red dots.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/medium/jm-2017-001787_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Covalent docking of <b>45a</b> in EGFR T790M kinase active site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Predicted hydrogen bonds are indicated as red dots. (B) 2D schematic view of docked 3D structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00178&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 53 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vivanco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Larriba, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertran-Alamillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span> </span><span class="NLM_article-title">Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">958</span><span class="NLM_x">–</span> <span class="NLM_lpage">967</span><span class="refDoi"> DOI: 10.1056/NEJMoa0904554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1056%2FNEJMoa0904554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=19692684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=958-967&author=R.+Rosellauthor=T.+Moranauthor=C.+Queraltauthor=R.+Portaauthor=F.+Cardenalauthor=C.+Campsauthor=M.+Majemauthor=G.+Lopez-Vivancoauthor=D.+Islaauthor=M.+Provencioauthor=A.+Insaauthor=B.+Massutiauthor=J.+L.+Gonzalez-Larribaauthor=L.+Paz-Aresauthor=I.+Boverauthor=R.+Garcia-Campeloauthor=M.+A.+Morenoauthor=S.+Catotauthor=C.+Rolfoauthor=N.+Reguartauthor=R.+Palmeroauthor=J.+M.+Sanchezauthor=R.+Bastusauthor=C.+Mayoauthor=J.+Bertran-Alamilloauthor=M.+A.+Molinaauthor=J.+J.+Sanchezauthor=M.+Taron&title=Screening+for+Epidermal+Growth+Factor+Receptor+Mutations+in+Lung+Cancer&doi=10.1056%2FNEJMoa0904554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Screening for epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Rosell, Rafael; Moran, Teresa; Queralt, Cristina; Porta, Rut; Cardenal, Felipe; Camps, Carlos; Majem, Margarita; Lopez-Vivanco, Guillermo; Isla, Dolores; Provencio, Mariano; Insa, Amelia; Massuti, Bartomeu; Gonzalez-Larriba, Jose Luis; Paz-Ares, Luis; Bover, Isabel; Garcia-Campelo, Rosario; Moreno, Miguel Angel; Catot, Silvia; Rolfo, Christian; Reguart, Noemi; Palmero, Ramon; Sanchez, Jose Miguel; Bastus, Roman; Mayo, Clara; Bertran-Alamillo, Jordi; Molina, Miguel Angel; Sanchez, Jose Javier; Taron, Miquel; Cuello, M.; Pallares, C.; Lianes, P.; Remon, J.; Ibeas, R.; Martinez del Prado, P.; Angeles Sala, M.; Santander-Lobera, C.; Velez de Mendizabal, E.; Vinolas, N.; Terrasa, J.; Valdivia, J.; Diz, P.; Jimenez-Berlana, U.; Velasco-Ortiz de Taranco, A.; Ales Martinez, E.; Sanchez-Escribano, R.; Carrato, A.; Guillen-Ponce, C.; Mesia, C.; Antonio Macias, J.; Lopez-Brea, M.; Oramas, J.; Barneto, I.; Garrido, P.; Mayol, M. J.; Lopez, A.; Artal, A.; Saenz, A.; Hernando, S.; Cobo, M.; Blanco, R.; Bernabe, R.; Guillem, V.; Angel Munoz, M.; Maestu, I.; Salvatierra, A.; De Las Penas, R.; Alfaro, J.; Alberola, V.; Juan, O.; Martin, C.; Puertas, J.; Felip, E.; Gonzalez-Gonzalez, J. F.; Iglesias-Docampo, L.; Dorta, F. J.; Martinez-Aguillo, M.; Salgado, E.; Mesia, R.; Lastra-Aras, E.; Garcia-Munoz, J. P.; Lastra, R.; Alvarez, I.; Roig, J.; Oruezabal, J.; Poveda, A.; Lavernia, J.; Gutierrez, D.; Filipovich, E.; Aguiar, D.; Rodriguez, D.; Buxo, J.; Cardona, A. F.; Bes, P.; Paredes, A.; Tortorella, A. M.; Moreno, J. A.; Martinez-Garcia, J.; Alonso, J. L.; Lopez-Martin, A.; Echarri-Gonzalez, M. J.; Van Kooten, M.; Guerrero, A.; Domine, M.; Diaz, I.; Heras, L.; Garcia, R.; Anton, I.; Jarchum, G.; Bartolucci, R. E.; Lomas, M.; Rubiales, A.; Duque, J. L.; Escriva de Romani, S.; Barbeta, E.; Reina, J. J.; Castro, J.; Belda, C.; Vidal, J. M.; Trigo, J. M.; Vadell, C.; Zarba, J. J.; Esunza, P.; Garau, I.; Lopez-Pousa, A.; De la Gandara, I.; Widakowich, J.; Morales, S.; Martinez, M.; Luis, R.; de la Colina, M.; Calzas, J.; Garcia-Castro, I.; Ruiz, C.; Lopez-Criado, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">958-967</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer.  We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the assocn. between the mutations and the outcome of erlotinib treatment.  From Apr. 2005 through Nov. 2008, lung cancers from 2105 patients in 129 institutions in Spain were screened for EGFR mutations.  The anal. was performed in a central lab.  Patients with tumors carrying EGFR mutations were eligible for erlotinib treatment.  EGFR mutations were found in 350 of 2105 patients (16.6%).  Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%) (P < 0.001 for all comparisons).  The mutations were deletions in exon 19 (62.2%) and L858R (37.8%).  Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 mo and 27 mo, resp.  The adjusted hazard ratios for the duration of progression-free survival were 2.94 for men (P < 0.001); 1.92 for the presence of the L858R mutation, as compared with a deletion in exon 19 (P = 0.02); and 1.68 for the presence of the L858R mutation in paired serum DNA, as compared with the absence of the mutation (P = 0.02).  The most common adverse events were mild rashes and diarrhea; grade 3 cutaneous toxic effects were recorded in 16 patients (7.4%) and grade 3 diarrhea in 8 patients (3.7%).  Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvZWnSnU_ScbVg90H21EOLACvtfcHk0lgp6jGbbWlwyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M&md5=288ea35bd5201579d8c89ad6d7c4306a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904554%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCardenal%26aufirst%3DF.%26aulast%3DCamps%26aufirst%3DC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DGonzalez-Larriba%26aufirst%3DJ.%2BL.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DCatot%26aufirst%3DS.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DBastus%26aufirst%3DR.%26aulast%3DMayo%26aufirst%3DC.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DTaron%26aufirst%3DM.%26atitle%3DScreening%2520for%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Mutations%2520in%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D958%26epage%3D967%26doi%3D10.1056%2FNEJMoa0904554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor Mutations in Lung Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+Growth+Factor+Receptor+Mutations+in+Lung+Cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lgDWu0tpHP5MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520Mutations%2520in%2520Lung%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Lung Adenocarcinoma: Guiding EGFR-Targeted Therapy and Beyond</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">S16</span><span class="NLM_x">–</span> <span class="NLM_lpage">S22</span><span class="refDoi"> DOI: 10.1038/modpathol.3801018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fmodpathol.3801018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=S16-S22&author=M.+Ladanyiauthor=W.+Pao&title=Lung+Adenocarcinoma%3A+Guiding+EGFR-Targeted+Therapy+and+Beyond&doi=10.1038%2Fmodpathol.3801018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.3801018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.3801018%26sid%3Dliteratum%253Aachs%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DLung%2520Adenocarcinoma%253A%2520Guiding%2520EGFR-Targeted%2520Therapy%2520and%2520Beyond%26jtitle%3DMod.%2520Pathol.%26date%3D2008%26volume%3D21%26spage%3DS16%26epage%3DS22%26doi%3D10.1038%2Fmodpathol.3801018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Q.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+Lung+Cancer-Derived+EGFR+Mutants+and+Inhibitor+Complexes%3A+Mechanism+of+Activation+and+Insights+into+Differential+Inhibitor+Sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lgDWu0tpHP5MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520Lung%2520Cancer-Derived%2520EGFR%2520Mutants%2520and%2520Inhibitor%2520Complexes%253A%2520Mechanism%2520of%2520Activation%2520and%2520Insights%2520into%2520Differential%2520Inhibitor%2520Sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Carey, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+Analysis+of+Epidermal+Growth+Factor+Receptor+Somatic+Mutant+Proteins+Shows+Increased+Sensitivity+to+the+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor%2C+Erlotinib&doi=10.1158%2F0008-5472.CAN-06-0453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0lgDWu0tpHP5MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520Analysis%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Somatic%2520Mutant%2520Proteins%2520Shows%2520Increased%2520Sensitivity%2520to%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520Erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171%26doi%3D10.1158%2F0008-5472.CAN-06-0453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span> </span><span class="NLM_article-title">Activating and Resistance Mutations of EGFR in Non-Small-Cell Lung Cancer: Role in Clinical Response to EGFR Tyrosine Kinase Inhibitors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">S24</span><span class="NLM_x">–</span> <span class="NLM_lpage">S31</span><span class="refDoi"> DOI: 10.1038/onc.2009.198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fonc.2009.198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=19680293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=S24-S31&author=A.+F.+Gazdar&title=Activating+and+Resistance+Mutations+of+EGFR+in+Non-Small-Cell+Lung+Cancer%3A+Role+in+Clinical+Response+to+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1038%2Fonc.2009.198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors</span></div><div class="casAuthors">Gazdar, A. F.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S24-S31</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-5' triphosphate-binding site.  Somatic activating mutations of the EGFR gene, increased gene copy no. and certain clin. and pathol. features have been assocd. with dramatic tumor responses and favorable clin. outcomes with these agents in patients with non-small-cell lung cancer (NSCLC).  The specific types of activating mutations that confer sensitivity to EGFR TKIs are present in the tyrosine kinase (TK) domain of the EGFR gene.  Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed classical' mutations.  The NSCLC tumors insensitive to EGFR TKIs include those driven by the KRAS and MET oncogenes.  Most patients who initially respond to gefitinib and erlotinib eventually become resistant and experience progressive disease.  The point mutation T790M accounts for about one half of these cases of acquired resistance.  Various second-generation EGFR TKIs are currently being evaluated and may have the potential to overcome T790M-mediated resistance by virtue of their irreversible inhibition of the receptor TK domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruiv2mv5eIb7Vg90H21EOLACvtfcHk0lgXbiscd2bL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCrsLY%253D&md5=28d24b3739ac038b29dd0ec327808857</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.198%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26atitle%3DActivating%2520and%2520Resistance%2520Mutations%2520of%2520EGFR%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%253A%2520Role%2520in%2520Clinical%2520Response%2520to%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DOncogene%26date%3D2009%26volume%3D28%26spage%3DS24%26epage%3DS31%26doi%3D10.1038%2Fonc.2009.198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, Biologically Based Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span><span class="refDoi"> DOI: 10.1038/nrc2947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+Biologically+Based+Treatment+of+EGFR-Mutant+Non-Small-Cell+Lung+Cancer&doi=10.1038%2Fnrc2947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0lgXbiscd2bL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520Biologically%2520Based%2520Treatment%2520of%2520EGFR-Mutant%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774%26doi%3D10.1038%2Fnrc2947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is Associated with a Second Mutation in the EGFR Kinase Domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+Resistance+of+Lung+Adenocarcinomas+to+Gefitinib+or+Erlotinib+is+Associated+with+a+Second+Mutation+in+the+EGFR+Kinase+Domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2ebzM6ISVlf7v7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520Resistance%2520of%2520Lung%2520Adenocarcinomas%2520to%2520Gefitinib%2520or%2520Erlotinib%2520is%2520Associated%2520with%2520a%2520Second%2520Mutation%2520in%2520the%2520EGFR%2520Kinase%2520Domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Takezawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirazzoli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR(T790M) Mutation</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">933</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F2159-8290.CD-12-0108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=922-933&author=K.+Takezawaauthor=V.+Pirazzoliauthor=M.+E.+Arcilaauthor=C.+A.+Nebhanauthor=X.+L.+Songauthor=E.+de+Stanchinaauthor=K.+Ohashiauthor=Y.+Y.+Janjigianauthor=P.+J.+Spitzlerauthor=M.+A.+Melnickauthor=G.+J.+Rielyauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=K.+Politiauthor=W.+Pao&title=HER2+Amplification%3A+A+Potential+Mechanism+of+Acquired+Resistance+to+EGFR+Inhibition+in+EGFR-Mutant+Lung+Cancers+That+Lack+the+Second-Site+EGFR%28T790M%29+Mutation&doi=10.1158%2F2159-8290.CD-12-0108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0108%26sid%3Dliteratum%253Aachs%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DPirazzoli%26aufirst%3DV.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSong%26aufirst%3DX.%2BL.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DMelnick%26aufirst%3DM.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DHER2%2520Amplification%253A%2520A%2520Potential%2520Mechanism%2520of%2520Acquired%2520Resistance%2520to%2520EGFR%2520Inhibition%2520in%2520EGFR-Mutant%2520Lung%2520Cancers%2520That%2520Lack%2520the%2520Second-Site%2520EGFR%2528T790M%2529%2520Mutation%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D922%26epage%3D933%26doi%3D10.1158%2F2159-8290.CD-12-0108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1126/science.1141478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+C.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+J.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+Amplification+Leads+to+Gefitinib+Resistance+in+Lung+Cancer+by+Activating+ERBB3+Signaling&doi=10.1126%2Fscience.1141478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0lgyBajCvai9rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%2BC.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%2BJ.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520Amplification%2520Leads%2520to%2520Gefitinib%2520Resistance%2520in%2520Lung%2520Cancer%2520by%2520Activating%2520ERBB3%2520Signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1141478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shien, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Cuesta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vnencak-Jones, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Lung Cancers with Acquired Resistance to EGFR Inhibitors Occasionally Harbor BRAF Gene Mutations but Lack Mutations in KRAS, NRAS, or MEK1</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">E2127</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1073/pnas.1203530109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1073%2Fpnas.1203530109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=E2127-133&author=K.+Ohashiauthor=L.+V.+Sequistauthor=M.+E.+Arcilaauthor=T.+Moranauthor=J.+Chmieleckiauthor=Y.+L.+Linauthor=Y.+Panauthor=L.+Wangauthor=E.+de+Stanchinaauthor=K.+Shienauthor=K.+Aoeauthor=S.+Toyookaauthor=K.+Kiuraauthor=L.+Fernandez-Cuestaauthor=P.+Fidiasauthor=J.+C.+Yangauthor=V.+A.+Millerauthor=G.+J.+Rielyauthor=M.+G.+Krisauthor=J.+A.+Engelmanauthor=C.+L.+Vnencak-Jonesauthor=D.+Dias-Santagataauthor=M.+Ladanyiauthor=W.+Pao&title=Lung+Cancers+with+Acquired+Resistance+to+EGFR+Inhibitors+Occasionally+Harbor+BRAF+Gene+Mutations+but+Lack+Mutations+in+KRAS%2C+NRAS%2C+or+MEK1&doi=10.1073%2Fpnas.1203530109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1203530109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1203530109%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DShien%26aufirst%3DK.%26aulast%3DAoe%26aufirst%3DK.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DFernandez-Cuesta%26aufirst%3DL.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DVnencak-Jones%26aufirst%3DC.%2BL.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DLung%2520Cancers%2520with%2520Acquired%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520Occasionally%2520Harbor%2520BRAF%2520Gene%2520Mutations%2520but%2520Lack%2520Mutations%2520in%2520KRAS%252C%2520NRAS%252C%2520or%2520MEK1%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3DE2127%26epage%3D133%26doi%3D10.1073%2Fpnas.1203530109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Shien, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thu, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takigawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span> </span><span class="NLM_article-title">Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">3051</span><span class="NLM_x">–</span> <span class="NLM_lpage">3061</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-4136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F0008-5472.CAN-12-4136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=3051-3061&author=K.+Shienauthor=S.+Toyookaauthor=H.+Yamamotoauthor=J.+Sohauthor=M.+Jidaauthor=K.+L.+Thuauthor=S.+Hashidaauthor=Y.+Makiauthor=E.+Ichiharaauthor=H.+Asanoauthor=K.+Tsukudaauthor=N.+Takigawaauthor=K.+Kiuraauthor=A.+F.+Gazdarauthor=W.+L.+Lamauthor=S.+Miyoshi&title=Acquired+Resistance+to+EGFR+Inhibitors+Is+Associated+with+a+Manifestation+of+Stem+Cell-like+Properties+in+Cancer+Cells&doi=10.1158%2F0008-5472.CAN-12-4136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-4136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-4136%26sid%3Dliteratum%253Aachs%26aulast%3DShien%26aufirst%3DK.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DJida%26aufirst%3DM.%26aulast%3DThu%26aufirst%3DK.%2BL.%26aulast%3DHashida%26aufirst%3DS.%26aulast%3DMaki%26aufirst%3DY.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DAsano%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DK.%26aulast%3DTakigawa%26aufirst%3DN.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DLam%26aufirst%3DW.%2BL.%26aulast%3DMiyoshi%26aufirst%3DS.%26atitle%3DAcquired%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520Is%2520Associated%2520with%2520a%2520Manifestation%2520of%2520Stem%2520Cell-like%2520Properties%2520in%2520Cancer%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D3051%26epage%3D3061%26doi%3D10.1158%2F0008-5472.CAN-12-4136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Blakely, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">872</span><span class="NLM_x">–</span> <span class="NLM_lpage">875</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F2159-8290.CD-12-0387" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=872-875&author=C.+M.+Blakelyauthor=T.+G.+Bivona&title=Resiliency+of+Lung+Cancers+to+EGFR+Inhibitor+Treatment+Unveiled%2C+Offering+Opportunities+to+Divide+and+Conquer+EGFR+Inhibitor+Resistance&doi=10.1158%2F2159-8290.CD-12-0387"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0387%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DResiliency%2520of%2520Lung%2520Cancers%2520to%2520EGFR%2520Inhibitor%2520Treatment%2520Unveiled%252C%2520Offering%2520Opportunities%2520to%2520Divide%2520and%2520Conquer%2520EGFR%2520Inhibitor%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D872%26epage%3D875%26doi%3D10.1158%2F2159-8290.CD-12-0387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+Tumor+Specimens+at+the+Time+of+Acquired+Resistance+to+EGFR-TKI+Therapy+in+155+Patients+with+EGFR-Mutant+Lung+Cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lgAuqKyzHUQZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520Tumor%2520Specimens%2520at%2520the%2520Time%2520of%2520Acquired%2520Resistance%2520to%2520EGFR-TKI%2520Therapy%2520in%2520155%2520Patients%2520with%2520EGFR-Mutant%2520Lung%2520Cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Chen, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, Y. Q.</span><span> </span><span class="NLM_article-title">Clinical Perspective of Afatinib in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">161</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2013.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.lungcan.2013.02.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=155-161&author=X.+F.+Chenauthor=Q.+Zhuauthor=L.+J.+Zhuauthor=D.+Peiauthor=Y.+Q.+Liuauthor=Y.+M.+Yinauthor=M.+Schulerauthor=Y.+Q.+Shu&title=Clinical+Perspective+of+Afatinib+in+Non-Small+Cell+Lung+Cancer&doi=10.1016%2Fj.lungcan.2013.02.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2013.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2013.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BF.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DL.%2BJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%2BQ.%26aulast%3DYin%26aufirst%3DY.%2BM.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DShu%26aufirst%3DY.%2BQ.%26atitle%3DClinical%2520Perspective%2520of%2520Afatinib%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DLung%2520Cancer%26date%3D2013%26volume%3D81%26spage%3D155%26epage%3D161%26doi%3D10.1016%2Fj.lungcan.2013.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Boyer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of PF299804 Versus Erlotinib (E): A global, Randomized Phase II Trial in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) after Failure of Chemotherapy (CT)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">18s</span><span class="NLM_x">) </span> <span class="NLM_fpage">LBA7523</span><span class="refDoi"> DOI: 10.1200/jco.2010.28.18_suppl.lba7523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1200%2Fjco.2010.28.18_suppl.lba7523" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=LBA7523&issue=18s&author=M.+J.+Boyerauthor=F.+H.+Blackhallauthor=K.+Parkauthor=C.+H.+Barriosauthor=M.+J.+Krzakowskiauthor=I.+Taylorauthor=J.+Q.+Liangauthor=L.+J.+Denisauthor=J.+P.+O%E2%80%99Connellauthor=S.+S.+Ramalingam&title=Efficacy+and+Safety+of+PF299804+Versus+Erlotinib+%28E%29%3A+A+global%2C+Randomized+Phase+II+Trial+in+Patients+%28pts%29+with+Advanced+Non-Small+Cell+Lung+Cancer+%28NSCLC%29+after+Failure+of+Chemotherapy+%28CT%29&doi=10.1200%2Fjco.2010.28.18_suppl.lba7523"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1200%2Fjco.2010.28.18_suppl.lba7523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2010.28.18_suppl.lba7523%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DM.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%2BH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DKrzakowski%26aufirst%3DM.%2BJ.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DJ.%2BQ.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%2BP.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520PF299804%2520Versus%2520Erlotinib%2520%2528E%2529%253A%2520A%2520global%252C%2520Randomized%2520Phase%2520II%2520Trial%2520in%2520Patients%2520%2528pts%2529%2520with%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%2520after%2520Failure%2520of%2520Chemotherapy%2520%2528CT%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D18s%26spage%3DLBA7523%26doi%3D10.1200%2Fjco.2010.28.18_suppl.lba7523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors Against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+J.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+N.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+Against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lh-1msiHABxIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%2BN.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520Against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8249</span><span class="NLM_x">–</span> <span class="NLM_lpage">8267</span><span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+Potent+and+Selective+EGFR+Inhibitor+%28AZD9291%29+of+Both+Sensitizing+and+T790M+Resistance+Mutations+That+Spares+the+Wild+Type+Form+of+the+Receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lh-1msiHABxIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520EGFR%2520Inhibitor%2520%2528AZD9291%2529%2520of%2520Both%2520Sensitizing%2520and%2520T790M%2520Resistance%2520Mutations%2520That%2520Spares%2520the%2520Wild%2520Type%2520Form%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+Mutant-Selective+Covalent+Inhibitor+of+EGFR+that+Overcomes+T790M-Mediated+Resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0ljvQjmsYOvkSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt.%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Mutant-Selective%2520Covalent%2520Inhibitor%2520of%2520EGFR%2520that%2520Overcomes%2520T790M-Mediated%2520Resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caunt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span> </span><span class="NLM_article-title">First-In-Human Evaluation of CO-1686, an Irreversible, Highly Selective Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15s</span><span class="NLM_x">) </span> <span class="NLM_fpage">8010</span><span class="refDoi"> DOI: 10.1200/jco.2014.32.15_suppl.8010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1200%2Fjco.2014.32.15_suppl.8010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8010&issue=15s&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=S.+M.+Gadgeelauthor=H.+A.+Wakeleeauthor=D.+R.+Camidgeauthor=A.+Vargaauthor=B.+J.+Solomonauthor=V.+Papadimitrakopoulouauthor=S.+S.+Jaw-Tsaiauthor=L.+Cauntauthor=P.+Kaurauthor=L.+Rolfeauthor=A.+R.+Allenauthor=J.+W.+Goldman&title=First-In-Human+Evaluation+of+CO-1686%2C+an+Irreversible%2C+Highly+Selective+Tyrosine+Kinase+Inhibitor+of+Mutations+of+EGFR+%28Activating+and+T790M%29&doi=10.1200%2Fjco.2014.32.15_suppl.8010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.8010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.8010%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DJaw-Tsai%26aufirst%3DS.%2BS.%26aulast%3DCaunt%26aufirst%3DL.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26atitle%3DFirst-In-Human%2520Evaluation%2520of%2520CO-1686%252C%2520an%2520Irreversible%252C%2520Highly%2520Selective%2520Tyrosine%2520Kinase%2520Inhibitor%2520of%2520Mutations%2520of%2520EGFR%2520%2528Activating%2520and%2520T790M%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15s%26spage%3D8010%26doi%3D10.1200%2Fjco.2014.32.15_suppl.8010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Clinical Activity of the Mutant-Selective EGFR Inhibitor AZD9291 in Patients (pts) with EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15s</span><span class="NLM_x">) </span> <span class="NLM_fpage">8009</span><span class="refDoi"> DOI: 10.1200/jco.2014.32.15_suppl.8009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1200%2Fjco.2014.32.15_suppl.8009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8009&issue=15s&author=P.+A.+J%C3%A4nneauthor=S.+S.+Ramalingamauthor=J.+C.+H.+Yangauthor=M.+J.+Ahnauthor=D.+W.+Kimauthor=S.+W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=E.+Felipauthor=C.+Watkinsauthor=M.+Cantariniauthor=S.+Ghiorghiuauthor=M.+Ranson&title=Clinical+Activity+of+the+Mutant-Selective+EGFR+Inhibitor+AZD9291+in+Patients+%28pts%29+with+EGFR+Inhibitor-Resistant+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&doi=10.1200%2Fjco.2014.32.15_suppl.8009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.8009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.8009%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DClinical%2520Activity%2520of%2520the%2520Mutant-Selective%2520EGFR%2520Inhibitor%2520AZD9291%2520in%2520Patients%2520%2528pts%2529%2520with%2520EGFR%2520Inhibitor-Resistant%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15s%26spage%3D8009%26doi%3D10.1200%2Fjco.2014.32.15_suppl.8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Piotrowska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlovich, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalsy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digumarthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzikansky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvey, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiCecca, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span> </span><span class="NLM_article-title">Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">722</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F2159-8290.CD-15-0399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=25934077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=713-722&author=Z.+Piotrowskaauthor=M.+J.+Niederstauthor=C.+A.+Karlovichauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=M.+Mino-Kenudsonauthor=L.+Fultonauthor=A.+N.+Hataauthor=E.+L.+Lockermanauthor=A.+Kalsyauthor=S.+Digumarthyauthor=A.+Muzikanskyauthor=M.+Raponiauthor=A.+R.+Garciaauthor=H.+E.+Mulveyauthor=M.+K.+Parksauthor=R.+H.+DiCeccaauthor=D.+Dias-Santagataauthor=A.+J.+Iafrateauthor=A.+T.+Shawauthor=A.+R.+Allenauthor=J.+A.+Engelmanauthor=L.+V.+Sequist&title=Heterogeneity+Underlies+the+Emergence+of+EGFRT790+Wild-Type+Clones+Following+Treatment+of+T790M-Positive+Cancers+with+a+Third-Generation+EGFR+Inhibitor&doi=10.1158%2F2159-8290.CD-15-0399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span></div><div class="casAuthors">Piotrowska, Zofia; Niederst, Matthew J.; Karlovich, Chris A.; Wakelee, Heather A.; Neal, Joel W.; Mino-Kenudson, Mari; Fulton, Linnea; Hata, Aaron N.; Lockerman, Elizabeth L.; Kalsy, Anuj; Digumarthy, Subba; Muzikansky, Alona; Raponi, Mitch; Garcia, Angel R.; Mulvey, Hillary E.; Parks, Melissa K.; DiCecca, Richard H.; Dias-Santagata, Dora; Iafrate, A. John; Shaw, Alice T.; Allen, Andrew R.; Engelman, Jeffrey A.; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance.  We biopsied patients at rociletinib progression to explore resistance mechanisms.  Among 12 patients with T790M-pos. cancers at rociletinib initiation, six had T790-wild-type rociletinib-resistant biopsies.  Two T790-wild-type cancers underwent small cell lung cancer transformation; three T790M-pos. cancers acquired EGFR amplification.  We documented T790-wild-type and T790M-pos. clones coexisting within a single pre-rociletinib biopsy.  The pretreatment fraction of T790M-pos. cells affected response to rociletinib.  Longitudinal circulating tumor DNA (ctDNA) anal. revealed an increase in plasma EGFR-activating mutation, and T790M heralded rociletinib resistance in some patients, whereas in others the activating mutation increased but T790M remained suppressed.  Together, these findings demonstrate the role of tumor heterogeneity when therapies targeting a singular resistance mechanism are used.  To further improve outcomes, combination regimens that also target T790-wild-type clones are required.  Significance: This report documents that half of T790M-pos. EGFR-mutant lung cancers treated with rociletinib are T790-wild-type upon progression, suggesting that T790-wild-type clones can emerge as the dominant source of resistance.  We show that tumor heterogeneity has important clin. implications and that plasma ctDNA analyses can sometimes predict emerging resistance mechanisms.  Cancer Discov; 5(7); 713-22. ©2015 AACR.  See related commentary by Ichihara and Lovly, p. 694.  This article is highlighted in the In This Issue feature, p.  681.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4z_KYM4-R7Vg90H21EOLACvtfcHk0ljPhMtHNEX0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF&md5=6512fff2abf24f5bef615a70b0f89c56</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0399%26sid%3Dliteratum%253Aachs%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKalsy%26aufirst%3DA.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DParks%26aufirst%3DM.%2BK.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DHeterogeneity%2520Underlies%2520the%2520Emergence%2520of%2520EGFRT790%2520Wild-Type%2520Clones%2520Following%2520Treatment%2520of%2520T790M-Positive%2520Cancers%2520with%2520a%2520Third-Generation%2520EGFR%2520Inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D713%26epage%3D722%26doi%3D10.1158%2F2159-8290.CD-15-0399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Eberlein, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovets, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meador, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahdesmaki, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratcliffe, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, E. L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dry, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thress, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span> </span><span class="NLM_article-title">Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">2489</span><span class="NLM_x">–</span> <span class="NLM_lpage">2500</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F0008-5472.CAN-14-3167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=25870145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFSjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2489-2500&author=C.+A.+Eberleinauthor=D.+Stetsonauthor=A.+A.+Markovetsauthor=K.+J.+Al-Kadhimiauthor=Z.+Laiauthor=P.+R.+Fisherauthor=C.+B.+Meadorauthor=P.+Spitzlerauthor=E.+Ichiharaauthor=S.+J.+Rossauthor=M.+J.+Ahdesmakiauthor=A.+Ahmedauthor=L.+E.+Ratcliffeauthor=E.+L.+C.+O%E2%80%99Brienauthor=C.+H.+Barnesauthor=H.+Brownauthor=P.+D.+Smithauthor=J.+R.+Dryauthor=G.+Beranauthor=K.+S.+Thressauthor=B.+Doughertyauthor=W.+Paoauthor=D.+A.+E.+Cross&title=Acquired+Resistance+to+the+Mutant-Selective+EGFR+Inhibitor+AZD9291+Is+Associated+with+Increased+Dependence+on+RAS+Signaling+in+Preclinical+Models&doi=10.1158%2F0008-5472.CAN-14-3167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models</span></div><div class="casAuthors">Eberlein, Catherine A.; Stetson, Daniel; Markovets, Aleksandra A.; Al-Kadhimi, Katherine J.; Lai, Zhongwu; Fisher, Paul R.; Meador, Catherine B.; Spitzler, Paula; Ichihara, Eiki; Ross, Sarah J.; Ahdesmaki, Miika J.; Ahmed, Ambar; Ratcliffe, Laura E.; O'Brien, Elizabeth L. Christey; Barnes, Claire H.; Brown, Henry; Smith, Paul D.; Dry, Jonathan R.; Beran, Garry; Thress, Kenneth S.; Dougherty, Brian; Pao, William; Cross, Darren A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2489-2500</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These results offer early insight into how acquired resistance arises to a new mutation-selective inhibitor of EGFR that is in fast-track clin. development, illustrating the inescapable cat-and-mouse chase in the evolution of cancer cell-targeting drugs in the management of cancer patients.  Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers.  Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies.  We describe the detection of heterogeneous mechanisms of resistance within populations of EGFR-mutant cells (PC9 and/or NCI-H1975) with acquired resistance to current and newly developed EGFR tyrosine kinase inhibitors, including AZD9291.  We report the detection of NRAS mutations, including a novel E63K mutation, and a gain of copy no. of WT NRAS or WT KRAS in cell populations resistant to gefitinib, afatinib, WZ4002, or AZD9291.  Compared with parental cells, a no. of resistant cell populations were more sensitive to inhibition by the MEK inhibitor selumetinib (AZD6244; ARRY-142886) when treated in combination with the originating EGFR inhibitor.  In vitro, a combination of AZD9291 with selumetinib prevented emergence of resistance in PC9 cells and delayed resistance in NCI-H1975 cells.  In vivo, concomitant dosing of AZD9291 with selumetinib caused regression of AZD9291-resistant tumors in an EGFRm/T790M transgenic model.  Our data support the use of a combination of AZD9291 with a MEK inhibitor to delay or prevent resistance to AZD9291 in EGFRm and/or EGFRm/T790M tumors.  Furthermore, these findings suggest that NRAS modifications in tumor samples from patients who have progressed on current or EGFR inhibitors in development may support subsequent treatment with a combination of EGFR and MEK inhibition.  Cancer Res; 75(12); 2489-500. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZwyXo13dZBbVg90H21EOLACvtfcHk0ljPhMtHNEX0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFSjurw%253D&md5=63691ddbbf38e2079b39b5d8f43ddef4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3167%26sid%3Dliteratum%253Aachs%26aulast%3DEberlein%26aufirst%3DC.%2BA.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%2BA.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%2BJ.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DFisher%26aufirst%3DP.%2BR.%26aulast%3DMeador%26aufirst%3DC.%2BB.%26aulast%3DSpitzler%26aufirst%3DP.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DRoss%26aufirst%3DS.%2BJ.%26aulast%3DAhdesmaki%26aufirst%3DM.%2BJ.%26aulast%3DAhmed%26aufirst%3DA.%26aulast%3DRatcliffe%26aufirst%3DL.%2BE.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DE.%2BL.%2BC.%26aulast%3DBarnes%26aufirst%3DC.%2BH.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DDry%26aufirst%3DJ.%2BR.%26aulast%3DBeran%26aufirst%3DG.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26atitle%3DAcquired%2520Resistance%2520to%2520the%2520Mutant-Selective%2520EGFR%2520Inhibitor%2520AZD9291%2520Is%2520Associated%2520with%2520Increased%2520Dependence%2520on%2520RAS%2520Signaling%2520in%2520Preclinical%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D2489%26epage%3D2500%26doi%3D10.1158%2F0008-5472.CAN-14-3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Thress, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovets, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivancos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span> </span><span class="NLM_article-title">Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+Mutation+Mediates+Resistance+to+AZD9291+in+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0ljQ1Ce2HP8DKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mutation%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Günther, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juchum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Lung Cancer: EGFR Inhibitors With Low Nanomolar Activity Against a Therapy-Resistant L858R/T790M/C797S Mutant</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10890</span><span class="NLM_x">–</span> <span class="NLM_lpage">10894</span><span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&author=M.+G%C3%BCntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+Cancer%3A+EGFR+Inhibitors+With+Low+Nanomolar+Activity+Against+a+Therapy-Resistant+L858R%2FT790M%2FC797S+Mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Guenther, Marcel; Juchum, Michael; Kelter, Gerhard; Fiebig, Heiner; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-10894</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clin. relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that addnl. mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compds. show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1QH6nrxYrVg90H21EOLACvtfcHk0ljQ1Ce2HP8DKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK&md5=c3909faa7f781c2a3679f75bd3b6c5ac</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520Cancer%253A%2520EGFR%2520Inhibitors%2520With%2520Low%2520Nanomolar%2520Activity%2520Against%2520a%2520Therapy-Resistant%2520L858R%252FT790M%252FC797S%2520Mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Selig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goettert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schattel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schollmeyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8429</span><span class="NLM_x">–</span> <span class="NLM_lpage">8439</span><span class="refDoi"> DOI: 10.1021/jm300852w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300852w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8429-8439&author=R.+Seligauthor=M.+Goettertauthor=V.+Schattelauthor=D.+Schollmeyerauthor=W.+Albrechtauthor=S.+Laufer&title=A+Frozen+Analogue+Approach+to+Aminopyridinylimidazoles+Leading+to+Novel+and+Promising+p38+MAP+Kinase+Inhibitors&doi=10.1021%2Fjm300852w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm300852w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300852w%26sid%3Dliteratum%253Aachs%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DA%2520Frozen%2520Analogue%2520Approach%2520to%2520Aminopyridinylimidazoles%2520Leading%2520to%2520Novel%2520and%2520Promising%2520p38%2520MAP%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8429%26epage%3D8439%26doi%3D10.1021%2Fjm300852w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Dimova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubbutat, M. H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schächtele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Assessing the Target Differentiation Potential of Imidazole-Based Protein Kinase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">11067</span><span class="NLM_x">–</span> <span class="NLM_lpage">11071</span><span class="refDoi"> DOI: 10.1021/jm3014508</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3014508" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOls73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=11067-11071&author=D.+Dimovaauthor=P.+Iyerauthor=M.+Vogtauthor=F.+Totzkeauthor=M.+H.+G.+Kubbutatauthor=C.+Sch%C3%A4chteleauthor=S.+Lauferauthor=J.+Bajorath&title=Assessing+the+Target+Differentiation+Potential+of+Imidazole-Based+Protein+Kinase+Inhibitors&doi=10.1021%2Fjm3014508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the Target Differentiation Potential of Imidazole-Based Protein Kinase Inhibitors</span></div><div class="casAuthors">Dimova, Dilyana; Iyer, Preeti; Vogt, Martin; Totzke, Frank; Kubbutat, Michael H. G.; Schaechtele, Christoph; Laufer, Stefan; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11067-11071</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A library of 484 imidazole-based candidate inhibitors was tested against 24 protein kinases.  The resulting activity data have been systematically analyzed to search for compds. that effectively differentiate between kinases.  Six imidazole derivs. with high kinase differentiation potential were identified.  Nearest neighbor anal. revealed the presence of close analogs with varying differentiation potential.  Small structural modifications of active compds. were found to shift their inhibitory profiles toward kinases with different functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW1f6gXOAlXrVg90H21EOLACvtfcHk0ljQ1Ce2HP8DKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOls73E&md5=2e0745b30fb1085641ee59024e89b4e5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm3014508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3014508%26sid%3Dliteratum%253Aachs%26aulast%3DDimova%26aufirst%3DD.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DVogt%26aufirst%3DM.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%2BG.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DAssessing%2520the%2520Target%2520Differentiation%2520Potential%2520of%2520Imidazole-Based%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D11067%26epage%3D11071%26doi%3D10.1021%2Fjm3014508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Muth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Günther, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Döring, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drückes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köppler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trappe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothbauer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Tetra-Substituted Pyridinylimidazoles As Dual Inhibitors of p38 alpha Mitogen-Activated Protein Kinase and c-Jun N-Terminal Kinase 3 for Potential Treatment of Neurodegenerative Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span><span class="refDoi"> DOI: 10.1021/jm501557a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501557a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=443-456&author=F.+Muthauthor=M.+G%C3%BCntherauthor=S.+M.+Bauerauthor=E.+D%C3%B6ringauthor=S.+Fischerauthor=J.+Maierauthor=P.+Dr%C3%BCckesauthor=J.+K%C3%B6pplerauthor=J.+Trappeauthor=U.+Rothbauerauthor=P.+Kochauthor=S.+A.+Laufer&title=Tetra-Substituted+Pyridinylimidazoles+As+Dual+Inhibitors+of+p38+alpha+Mitogen-Activated+Protein+Kinase+and+c-Jun+N-Terminal+Kinase+3+for+Potential+Treatment+of+Neurodegenerative+Diseases&doi=10.1021%2Fjm501557a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm501557a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501557a%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DF.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DJ.%26aulast%3DDr%25C3%25BCckes%26aufirst%3DP.%26aulast%3DK%25C3%25B6ppler%26aufirst%3DJ.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DRothbauer%26aufirst%3DU.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DTetra-Substituted%2520Pyridinylimidazoles%2520As%2520Dual%2520Inhibitors%2520of%2520p38%2520alpha%2520Mitogen-Activated%2520Protein%2520Kinase%2520and%2520c-Jun%2520N-Terminal%2520Kinase%25203%2520for%2520Potential%2520Treatment%2520of%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D443%26epage%3D456%26doi%3D10.1021%2Fjm501557a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Yoshikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukimoto-Niino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terazawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirouzu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, S.</span><span> </span><span class="NLM_article-title">Structural Basis for the Altered Drug Sensitivities of Non-small Cell Lung Cancer-Associated Mutants of Human Epidermal Growth Factor Receptor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1038/onc.2012.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fonc.2012.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=22349823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFKl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=27-38&author=S.+Yoshikawaauthor=M.+Kukimoto-Niinoauthor=L.+Parkerauthor=N.+Handaauthor=T.+Teradaauthor=T.+Fujimotoauthor=Y.+Terazawaauthor=M.+Wakiyamaauthor=M.+Satoauthor=S.+Sanoauthor=T.+Kobayashiauthor=T.+Tanakaauthor=L.+Chenauthor=Z.+J.+Liuauthor=B.+C.+Wangauthor=M.+Shirouzuauthor=S.+Kawaauthor=K.+Sembaauthor=T.+Yamamotoauthor=S.+Yokoyama&title=Structural+Basis+for+the+Altered+Drug+Sensitivities+of+Non-small+Cell+Lung+Cancer-Associated+Mutants+of+Human+Epidermal+Growth+Factor+Receptor&doi=10.1038%2Fonc.2012.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor</span></div><div class="casAuthors">Yoshikawa, S.; Kukimoto-Niino, M.; Parker, L.; Handa, N.; Terada, T.; Fujimoto, T.; Terazawa, Y.; Wakiyama, M.; Sato, M.; Sano, S.; Kobayashi, T.; Tanaka, T.; Chen, L.; Liu, Z.-J.; Wang, B.-C.; Shirouzu, M.; Kawa, S.; Semba, K.; Yamamoto, T.; Yokoyama, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-38</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain.  The non-small cell lung cancer (NSCLC)-assocd. EGFR mutants, L858R and G719S, are constitutively active and oncogenic.  They display sensitivity to TK inhibitors, including gefitinib and erlotinib.  In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants.  In this study, our biochem. analyses revealed that the introduction of the T790M mutation confers gefitinib resistance on the G719S mutant.  The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity.  The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant.  Structural analyses of the G719S/T790M double mutant, as well as the wild type and the G719S and L858R mutants, revealed that the T790M mutation stabilizes the hydrophobic spine of the active EGFR-TK conformation.  The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands.  In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop.  Notably, the introduction of the F723A mutation greatly enhanced the gefitinib sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity.  Taken together, our results provide a structural basis for the altered drug sensitivities caused by distinct NSCLC-assocd. EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr7hEqvdS5i7Vg90H21EOLACvtfcHk0lgSU3VgU4uuWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFKl&md5=f9b29aac7bcb52cc0605f157f7f14809</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.21%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DS.%26aulast%3DKukimoto-Niino%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DL.%26aulast%3DHanda%26aufirst%3DN.%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DTerazawa%26aufirst%3DY.%26aulast%3DWakiyama%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSano%26aufirst%3DS.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26aulast%3DWang%26aufirst%3DB.%2BC.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DKawa%26aufirst%3DS.%26aulast%3DSemba%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Altered%2520Drug%2520Sensitivities%2520of%2520Non-small%2520Cell%2520Lung%2520Cancer-Associated%2520Mutants%2520of%2520Human%2520Epidermal%2520Growth%2520Factor%2520Receptor%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D27%26epage%3D38%26doi%3D10.1038%2Fonc.2012.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Cha, M. Y.; Kim, M. R.; Kang, S. J.; Kim, S. Y.; Jung, Y. H.; Lee, K. O.; Song, J. Y.; Kim, Y. H.; Kim, E. Y.; Kim, M. S.</span><span> </span><span class="NLM_article-title">Preparation of Pyrimidine Derivative for Inhibiting the Growth of Cancer Cells</span>. WO2011099764A2,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Y.+Cha&author=M.+R.+Kim&author=S.+J.+Kang&author=S.+Y.+Kim&author=Y.+H.+Jung&author=K.+O.+Lee&author=J.+Y.+Song&author=Y.+H.+Kim&author=E.+Y.+Kim&author=M.+S.+Kim&title=Preparation+of+Pyrimidine+Derivative+for+Inhibiting+the+Growth+of+Cancer+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520Derivative%2520for%2520Inhibiting%2520the%2520Growth%2520of%2520Cancer%2520Cells%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Barawkar, D.; Bende, T.; Zahler, R.; Bandyopadhyay, A.; Sarangthem, R. S.; Doshi, J.; Waman, Y.; Jadhav, R.; Singh, U. P.</span><span> </span><span class="NLM_article-title">Preparation of Substituted Fused Tricyclic Compounds as JAK Kinase Inhibitors, Compositions and Medicinal Applications Thereof</span>. WO2012127506A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Barawkar&author=T.+Bende&author=R.+Zahler&author=A.+Bandyopadhyay&author=R.+S.+Sarangthem&author=J.+Doshi&author=Y.+Waman&author=R.+Jadhav&author=U.+P.+Singh&title=Preparation+of+Substituted+Fused+Tricyclic+Compounds+as+JAK+Kinase+Inhibitors%2C+Compositions+and+Medicinal+Applications+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarawkar%26aufirst%3DD.%26atitle%3DPreparation%2520of%2520Substituted%2520Fused%2520Tricyclic%2520Compounds%2520as%2520JAK%2520Kinase%2520Inhibitors%252C%2520Compositions%2520and%2520Medicinal%2520Applications%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Kwiatkowski, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelluma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soundararajan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manak, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deveraux, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kops, G. J. P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Small-Molecule Kinase Inhibitors Provide Insight into Mps1 Cell Cycle Function</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span><span class="refDoi"> DOI: 10.1038/nchembio.345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnchembio.345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=20383151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFaktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=359-368&author=N.+Kwiatkowskiauthor=N.+Jellumaauthor=P.+Filippakopoulosauthor=M.+Soundararajanauthor=M.+S.+Manakauthor=M.+Kwonauthor=H.+G.+Choiauthor=T.+Simauthor=Q.+L.+Deverauxauthor=S.+Rottmannauthor=D.+Pellmanauthor=J.+V.+Shahauthor=G.+J.+P.+L.+Kopsauthor=S.+Knappauthor=N.+S.+Gray&title=Small-Molecule+Kinase+Inhibitors+Provide+Insight+into+Mps1+Cell+Cycle+Function&doi=10.1038%2Fnchembio.345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function</span></div><div class="casAuthors">Kwiatkowski, Nicholas; Jelluma, Nannette; Filippakopoulos, Panagis; Soundararajan, Meera; Manak, Michael S.; Kwon, Mijung; Choi, Hwan Geun; Sim, Taebo; Deveraux, Quinn L.; Rottmann, Sabine; Pellman, David; Shah, Jagesh V.; Kops, Geert J. P. L.; Knapp, Stefan; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">359-368</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mps1, a dual-specificity kinase, is required for the proper functioning of the spindle assembly checkpoint and for the maintenance of chromosomal stability.  As Mps1 function has been implicated in numerous phases of the cell cycle, the development of a potent, selective small-mol. inhibitor of Mps1 should facilitate dissection of Mps1-related biol.  We describe the cellular effects and Mps1 cocrystal structures of new, selective small-mol. inhibitors of Mps1.  Consistent with RNAi studies, chem. inhibition of Mps1 leads to defects in Mad1 and Mad2 establishment at unattached kinetochores, decreased Aurora B kinase activity, premature mitotic exit and gross aneuploidy, without any evidence of centrosome duplication defects.  However, in U2OS cells having extra centrosomes (an abnormality found in some cancers), Mps1 inhibition increases the frequency of multipolar mitoses.  Lastly, Mps1 inhibitor treatment resulted in a decrease in cancer cell viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUsnJhF04gwrVg90H21EOLACvtfcHk0ljT0RfCJzuswA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFaktb0%253D&md5=965e5e5e4f85e21c5ec27b0ea9417914</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.345%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DJelluma%26aufirst%3DN.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DSoundararajan%26aufirst%3DM.%26aulast%3DManak%26aufirst%3DM.%2BS.%26aulast%3DKwon%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DDeveraux%26aufirst%3DQ.%2BL.%26aulast%3DRottmann%26aufirst%3DS.%26aulast%3DPellman%26aufirst%3DD.%26aulast%3DShah%26aufirst%3DJ.%2BV.%26aulast%3DKops%26aufirst%3DG.%2BJ.%2BP.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DSmall-Molecule%2520Kinase%2520Inhibitors%2520Provide%2520Insight%2520into%2520Mps1%2520Cell%2520Cycle%2520Function%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D359%26epage%3D368%26doi%3D10.1038%2Fnchembio.345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Yosaatmadja, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeage, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squire, C. J.</span><span> </span><span class="NLM_article-title">Binding Mode of the Breakthrough Inhibitor AZD9291 to Epidermal Growth Factor Receptor Revealed</span> <span class="citation_source-journal">J. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span><span class="refDoi"> DOI: 10.1016/j.jsb.2015.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.jsb.2015.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=26522274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2015&pages=539-544&author=Y.+Yosaatmadjaauthor=S.+Silvaauthor=J.+M.+Dicksonauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=J.+U.+Flanaganauthor=M.+J.+McKeageauthor=C.+J.+Squire&title=Binding+Mode+of+the+Breakthrough+Inhibitor+AZD9291+to+Epidermal+Growth+Factor+Receptor+Revealed&doi=10.1016%2Fj.jsb.2015.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed</span></div><div class="casAuthors">Yosaatmadja, Yuliana; Silva, Shevan; Dickson, James M.; Patterson, Adam V.; Smaill, Jeff B.; Flanagan, Jack U.; McKeage, Mark J.; Squire, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">539-544</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The discovery of genetic drivers of lung cancer in patient sub-groups has led to their use as predictive biomarkers and as targets for selective drug therapy.  Some of the most important lung cancer drivers are mutations in the EGFR gene, for example, the exon 19 deletions and the L858R variant that confer sensitivity to the front line drugs erlotinib and gefitinib; the acquired T790M variants confer drug resistance and a poor prognosis.  A challenge then in targeting EGFR is to produce drugs that inhibit both sensitizing variants and resistance variants, leaving wild type protein in healthy cells unaffected.  One such agent is AstraZeneca's "breakthrough" AZD9291 mol. that shows a 200-fold selectivity for T790M/L858R over wild type EGFR.  Our X-ray crystal structure reveals the binding mode of AZD9291 to the kinase domain of wild type EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZ-1Gcecv3LVg90H21EOLACvtfcHk0ljT0RfCJzuswA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksLbN&md5=330ba9239615813dbe0009e29d2e0983</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2015.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2015.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DSilva%26aufirst%3DS.%26aulast%3DDickson%26aufirst%3DJ.%2BM.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DMcKeage%26aufirst%3DM.%2BJ.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DBinding%2520Mode%2520of%2520the%2520Breakthrough%2520Inhibitor%2520AZD9291%2520to%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Revealed%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2015%26volume%3D192%26spage%3D539%26epage%3D544%26doi%3D10.1016%2Fj.jsb.2015.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Littlefield, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mysore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jura, N.</span><span> </span><span class="NLM_article-title">Structural Analysis of the EGFR/HER3 Heterodimer Reveals the Molecular Basis for Activating HER3Mutations</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">ra114</span><span class="refDoi"> DOI: 10.1126/scisignal.2005786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1126%2Fscisignal.2005786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=25468994" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=ra114&author=P.+Littlefieldauthor=L.+J.+Liuauthor=V.+Mysoreauthor=Y.+B.+Shanauthor=D.+E.+Shawauthor=N.+Jura&title=Structural+Analysis+of+the+EGFR%2FHER3+Heterodimer+Reveals+the+Molecular+Basis+for+Activating+HER3Mutations&doi=10.1126%2Fscisignal.2005786"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2005786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2005786%26sid%3Dliteratum%253Aachs%26aulast%3DLittlefield%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DMysore%26aufirst%3DV.%26aulast%3DShan%26aufirst%3DY.%2BB.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DJura%26aufirst%3DN.%26atitle%3DStructural%2520Analysis%2520of%2520the%2520EGFR%252FHER3%2520Heterodimer%2520Reveals%2520the%2520Molecular%2520Basis%2520for%2520Activating%2520HER3Mutations%26jtitle%3DSci.%2520Signaling%26date%3D2014%26volume%3D7%26spage%3Dra114%26doi%3D10.1126%2Fscisignal.2005786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauerlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jank, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5630</span><span class="NLM_x">–</span> <span class="NLM_lpage">5640</span><span class="refDoi"> DOI: 10.1021/jm800373t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800373t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5630-5640&author=P.+Kochauthor=C.+Bauerleinauthor=H.+Jankauthor=S.+Laufer&title=Targeting+the+Ribose+and+Phosphate+Binding+Site+of+p38+Mitogen-Activated+Protein+%28MAP%29+Kinase%3A+Synthesis+and+Biological+Testing+of+2-Alkylsulfanyl-%2C+4%285%29-Aryl-%2C+5%284%29-Heteroaryl-Substituted+Imidazoles&doi=10.1021%2Fjm800373t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles</span></div><div class="casAuthors">Koch, Pierre; Baeuerlein, Christiane; Jank, Hartmut; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5630-5640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three series of substituted 2-alkylsulfanyl-4-(4-fluorophenyl)imidazoles, 5-pyridinyl-, 1-methyl-5-pyridinyl-, and 5-(2-aminopyridin-4-yl)-imidazoles, were prepd. and tested for their ability to inhibit p38 MAP kinase and TNF-α release.  These compds. were tested by applying a nonradioactive p38 MAP kinase assay and by measurement of TNF-α release in human whole blood.  Potent inhibitors (IC50values in the low nanomolar range, as low as 2 nM in the enzyme assay and 37 nM in the human whole blood test) were identified by variation of substituents at the imidazole-C2-thio position as well as at the 2-aminopyridinyl functionality.  In contrast to other known kinase inhibitors, these novel imidazole derivs. with the substituents at the imidazole-C2-thio position may interact with the ribose as well as with the phosphate binding site of the p38 MAP kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodYYCjSY3UNbVg90H21EOLACvtfcHk0lhZXyqKrIArcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbrK&md5=508c3e699dd65ee83a6592f2e719d17a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm800373t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800373t%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DBauerlein%26aufirst%3DC.%26aulast%3DJank%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520Ribose%2520and%2520Phosphate%2520Binding%2520Site%2520of%2520p38%2520Mitogen-Activated%2520Protein%2520%2528MAP%2529%2520Kinase%253A%2520Synthesis%2520and%2520Biological%2520Testing%2520of%25202-Alkylsulfanyl-%252C%25204%25285%2529-Aryl-%252C%25205%25284%2529-Heteroaryl-Substituted%2520Imidazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5630%26epage%3D5640%26doi%3D10.1021%2Fjm800373t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Schmidt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrowietz, U.</span><span> </span><span class="NLM_article-title">Reactivity of Dimethyl Fumarate and Methylhydrogen Fumarate Towards Glutathione and N-Acetyl-L-Cysteine - Preparation of S-Substituted Thiosuccinic Acid Esters</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.09.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.bmc.2006.09.053" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=333-342&author=T.+J.+Schmidtauthor=M.+Akauthor=U.+Mrowietz&title=Reactivity+of+Dimethyl+Fumarate+and+Methylhydrogen+Fumarate+Towards+Glutathione+and+N-Acetyl-L-Cysteine+-+Preparation+of+S-Substituted+Thiosuccinic+Acid+Esters&doi=10.1016%2Fj.bmc.2006.09.053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.09.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.09.053%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DT.%2BJ.%26aulast%3DAk%26aufirst%3DM.%26aulast%3DMrowietz%26aufirst%3DU.%26atitle%3DReactivity%2520of%2520Dimethyl%2520Fumarate%2520and%2520Methylhydrogen%2520Fumarate%2520Towards%2520Glutathione%2520and%2520N-Acetyl-L-Cysteine%2520-%2520Preparation%2520of%2520S-Substituted%2520Thiosuccinic%2520Acid%2520Esters%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D333%26epage%3D342%26doi%3D10.1016%2Fj.bmc.2006.09.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volak, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tegley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvedson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span> </span><span class="NLM_article-title">Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9171</span><span class="NLM_x">–</span> <span class="NLM_lpage">9178</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGrsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9171-9178&author=V.+J.+Ceeauthor=L.+P.+Volakauthor=Y.+P.+Chenauthor=M.+D.+Bartbergerauthor=C.+Tegleyauthor=T.+Arvedsonauthor=J.+McCarterauthor=A.+S.+Taskerauthor=C.+Fotsch&title=Systematic+Study+of+the+Glutathione+%28GSH%29+Reactivity+of+N-Arylacrylamides%3A+1.+Effects+of+Aryl+Substitution&doi=10.1021%2Facs.jmedchem.5b01018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution</span></div><div class="casAuthors">Cee, Victor J.; Volak, Laurie P.; Chen, Yuping; Bartberger, Michael D.; Tegley, Chris; Arvedson, Tara; McCarter, John; Tasker, Andrew S.; Fotsch, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9171-9178</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Success in the design of targeted covalent inhibitors depends in part on a knowledge of the factors influencing electrophile reactivity.  In an effort to further develop an understanding of structure-reactivity relations among N-arylacrylamides, the authors detd. glutathione (GSH) reaction rates for a family of N-arylacrylamides independently substituted at ortho-, meta-, and para-positions with 11 different groups common to inhibitor design.  Substituent effects on reaction rates show a linear Hammett correlation for ortho-, meta-, and para-substitution.  The authors note a correlation between 1H and 13C NMR chem. shifts of the acrylamide with GSH reaction rates, suggesting that NMR chem. shifts may be a convenient surrogate measure of relative acrylamide reactivity.  D. functional theory calcns. reveal a correlation between computed activation parameters and exptl. detd. reaction rates, validating the use of such methodol. for the screening of synthetic candidates in a prospective fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAoYRfo0lRj7Vg90H21EOLACvtfcHk0lhZXyqKrIArcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGrsLfN&md5=2f3a816446dd73d5be061ad8d2195e2d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01018%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DVolak%26aufirst%3DL.%2BP.%26aulast%3DChen%26aufirst%3DY.%2BP.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DTegley%26aufirst%3DC.%26aulast%3DArvedson%26aufirst%3DT.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DFotsch%26aufirst%3DC.%26atitle%3DSystematic%2520Study%2520of%2520the%2520Glutathione%2520%2528GSH%2529%2520Reactivity%2520of%2520N-Arylacrylamides%253A%25201.%2520Effects%2520of%2520Aryl%2520Substitution%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9171%26epage%3D9178%26doi%3D10.1021%2Facs.jmedchem.5b01018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Weinstein, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, A.</span><span> </span><span class="NLM_article-title">Oncogene Addiction</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3077</span><span class="NLM_x">–</span> <span class="NLM_lpage">3080</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-3293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1158%2F0008-5472.CAN-07-3293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=18451130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3077-3080&author=I.+B.+Weinsteinauthor=A.+Joe&title=Oncogene+Addiction&doi=10.1158%2F0008-5472.CAN-07-3293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene Addiction</span></div><div class="casAuthors">Weinstein, I. Bernard; Joe, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3077-3080</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Cancer cells contain multiple genetic and epigenetic abnormalities.  Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene.  This phenomenon, called "oncogene addiction," provides a rationale for mol. targeted therapy.  The efficacy of this strategy requires novel methods, including integrative genomics and systems biol., to identify the state of oncogene addiction (i.e., the "Achilles heel") in specific cancers.  Combination therapy may also be required to prevent the escape of cancers from a given state of oncogene addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobVcTGxEyDNLVg90H21EOLACvtfcHk0li89lu7rv3VMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSmtrk%253D&md5=fc62277a0200431335f79c420ebb02a6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-3293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-3293%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DI.%2BB.%26aulast%3DJoe%26aufirst%3DA.%26atitle%3DOncogene%2520Addiction%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3077%26epage%3D3080%26doi%3D10.1158%2F0008-5472.CAN-07-3293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Chuang, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, T.-H.</span><span> </span><span class="NLM_article-title">MAP4K Family Kinases in Immunity and Inflammation</span> <span class="citation_source-journal">Adv. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span><span class="refDoi"> DOI: 10.1016/bs.ai.2015.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fbs.ai.2015.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=26791862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFCmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2016&pages=277-314&author=H.-C.+Chuangauthor=X.+Wangauthor=T.-H.+Tan&title=MAP4K+Family+Kinases+in+Immunity+and+Inflammation&doi=10.1016%2Fbs.ai.2015.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">MAP4K family kinases in immunity and inflammation</span></div><div class="casAuthors">Chuang, Huai-Chia; Wang, Xiaohong; Tan, Tse-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277-314</span>CODEN:
                <span class="NLM_cas:coden">ADIMAV</span>;
        ISSN:<span class="NLM_cas:issn">0065-2776</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  MAP kinase kinase kinase kinases (MAP4Ks) belong to the mammalian Ste20-like family of serine/threonine kinases.  MAP4Ks including MAP4K1/HPK1, MAP4K2/GCK, MAP4K3/GLK, MAP4K4/HGK, MAP4K5/KHS, and MAP4K6/MINK have been reported to induce JNK activation through activating the MAP3K-MAP2K cascade.  The physiol. roles of MAP4Ks in immunity and inflammation are largely unknown until recent studies using biochem. approaches and knockout mice.  Surprisingly, JNK is not the major target of MAP4Ks in immune cells; MAP4Ks regulate immune responses through novel targets.  HPK1 inhibits T-cell receptor (TCR) signaling and B-cell receptor signaling via inducing phosphorylation/ubiquitination of SLP-76 and BLNK, resp.  GLK activates TCR signaling through phosphorylating/activating PKCθ.  T-cell-mediated immune responses and Th17-mediated exptl. autoimmune diseases are enhanced in HPK1 knockout mice but ameliorated in GLK knockout mice.  Consistently, HPK1 levels are decreased in peripheral blood mononuclear cells and T cells from patients with psoriatic arthritis and systemic lupus erythematosus (SLE), resp.  Moreover, GLK levels are increased in T cells from patients with SLE, rheumatoid arthritis, or adult-onset Still's disease; the percentages of GLK-overexpression T cells are correlated with the disease activity.  In addn., HGK phosphorylates and induces TRAF2 protein degrdn., leading to neg. regulation of IL-6 prodn. in resting T cells.  Loss of HGK in T cells results in spontaneous systemic inflammation and type 2 diabetes in mice.  HGK is also involved in cancer cell migration.  To date, the phenotypes of knockout mice for GCK, KHS, and MINK have not been reported; the roles of these three MAP4Ks in immune cell signaling are discussed in this review.  Taken together, MAP4K family kinases play diverse roles in immune cell signaling, immune responses, and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1p4FYLzTKFLVg90H21EOLACvtfcHk0li89lu7rv3VMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFCmsLo%253D&md5=95bcabb6f63312daafffad87adb92b3b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fbs.ai.2015.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.ai.2015.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DChuang%26aufirst%3DH.-C.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DT.-H.%26atitle%3DMAP4K%2520Family%2520Kinases%2520in%2520Immunity%2520and%2520Inflammation%26jtitle%3DAdv.%2520Immunol.%26date%3D2016%26volume%3D129%26spage%3D277%26epage%3D314%26doi%3D10.1016%2Fbs.ai.2015.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+Irreversible+Inhibitors+of+the+Protein+Kinase+Cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0li89lu7rv3VMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520Irreversible%2520Inhibitors%2520of%2520the%2520Protein%2520Kinase%2520Cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A Quantitative Analysis of Kinase Inhibitor Selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+Quantitative+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0liXvSGDIn-iBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520Quantitative%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Koul, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, S.</span><span> </span><span class="NLM_article-title">Role of p38 MAP Kinase Signal Transduction in Solid Tumors</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span><span class="refDoi"> DOI: 10.1177/1947601913507951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1177%2F1947601913507951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=24349632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGktbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=342-359&author=H.+K.+Koulauthor=M.+Palauthor=S.+Koul&title=Role+of+p38+MAP+Kinase+Signal+Transduction+in+Solid+Tumors&doi=10.1177%2F1947601913507951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Role of p38 MAP kinase signal transduction in solid tumors</span></div><div class="casAuthors">Koul, Hari K.; Pal, Mintu; Koul, Sweaty</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">342-359, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinases (MAPKs) mediate a wide variety of cellular behaviors in response to extracellular stimuli.  One of the main subgroups, the p38 MAP kinases, has been implicated in a wide range of complex biol. processes, such as cell proliferation, cell differentiation, cell death, cell migration, and invasion.  Dysregulation of p38 MAPK levels in patients are assocd. with advanced stages and short survival in cancer patients (e.g., prostate, breast, bladder, liver, and lung cancer).  P38 MAPK plays a dual role as a regulator of cell death, and it can either mediate cell survival or cell death depending not only on the type of stimulus but also in a cell type specific manner.  In addn. to modulating cell survival, an essential role of p38 MAPK in modulation of cell migration and invasion offers a distinct opportunity to target this pathway with respect to tumor metastasis.  The specific function of p38 MAPK appears to depend not only on the cell type but also on the stimuli and/or the isoform that is activated.  P38 MAPK signaling pathway is activated in response to diverse stimuli and mediates its function by components downstream of p38.  Extrapolation of the knowledge gained from lab. findings is essential to address the clin. significance of p38 MAPK signaling pathways.  The goal of this review is to provide an overview on recent progress made in defining the functions of p38 MAPK pathways with respect to solid tumor biol. and generate testable hypothesis with respect to the role of p38 MAPK as an attractive target for intervention of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB6A4yxL-gLLVg90H21EOLACvtfcHk0liXvSGDIn-iBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGktbfP&md5=a7803ce5e47e58b277f614616e526209</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1177%2F1947601913507951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601913507951%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DH.%2BK.%26aulast%3DPal%26aufirst%3DM.%26aulast%3DKoul%26aufirst%3DS.%26atitle%3DRole%2520of%2520p38%2520MAP%2520Kinase%2520Signal%2520Transduction%2520in%2520Solid%2520Tumors%26jtitle%3DGenes%2520Cancer%26date%3D2013%26volume%3D4%26spage%3D342%26epage%3D359%26doi%3D10.1177%2F1947601913507951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Greenberg, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchou-Wong, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rom, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. C.</span><span> </span><span class="NLM_article-title">Selective p38 Activation in Human Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1165/ajrcmb.26.5.4689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1165%2Fajrcmb.26.5.4689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=11970907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFWkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=558-564&author=A.+K.+Greenbergauthor=S.+Basuauthor=J.+Huauthor=T.+A.+Yieauthor=K.+M.+Tchou-Wongauthor=W.+N.+Romauthor=T.+C.+Lee&title=Selective+p38+Activation+in+Human+Non-Small+Cell+Lung+Cancer&doi=10.1165%2Fajrcmb.26.5.4689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Selective p38 activation in human non-small cell lung cancer</span></div><div class="casAuthors">Greenberg, Alissa K.; Basu, Sharmila; Hu, Jing; Yie, Ting-An; Tchou-Wong, Kam Meng; Rom, William N.; Lee, Theodore C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">558-564</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathways transmit signals from the cell membrane to the nucleus.  Activation of MAPK cascades may play a role in malignant transformation.  We hypothesized that enhanced expression of one or more of these pathways would occur in human lung cancers.  Using Western blot anal. of tissue homogenates from resected non-small cell lung cancers and matched non-neoplastic lung tissue, we detd. that only activated p38 was consistently increased in tumor compared with normal tissue.  In vitro kinase assays confirmed that the levels of activated MAPK correlated with the activity of the enzymes, and immunohistochem. anal. confirmed the cellular localization of the activated MAPKs.  We incubated a lung cancer cell line in a hypoxic chamber to simulate the hypoxic environment in solid lung tumors, but found no increase in p38 activation.  Contrary to our expectations, ERK and JNK, the MAPK pathways traditionally assocd. with cell growth and perhaps malignant transformation, were not consistently activated in the human lung tumor samples.  However, p38, a MAPK usually assocd. with stress responses, growth arrest, and apoptosis, was activated in all of the human lung cancer samples, suggesting an addnl. role for this pathway in malignant cell growth or transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIAmfxqEZ1wLVg90H21EOLACvtfcHk0liXvSGDIn-iBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFWkt7g%253D&md5=f0d7d71351549557a4650e9774dd39e7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1165%2Fajrcmb.26.5.4689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Fajrcmb.26.5.4689%26sid%3Dliteratum%253Aachs%26aulast%3DGreenberg%26aufirst%3DA.%2BK.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DYie%26aufirst%3DT.%2BA.%26aulast%3DTchou-Wong%26aufirst%3DK.%2BM.%26aulast%3DRom%26aufirst%3DW.%2BN.%26aulast%3DLee%26aufirst%3DT.%2BC.%26atitle%3DSelective%2520p38%2520Activation%2520in%2520Human%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2002%26volume%3D26%26spage%3D558%26epage%3D564%26doi%3D10.1165%2Fajrcmb.26.5.4689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Sterling, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span> </span><span class="NLM_article-title">ZINC 15-Ligand Discovery for Everyone</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2324</span><span class="NLM_x">–</span> <span class="NLM_lpage">2337</span><span class="refDoi"> DOI: 10.1021/acs.jcim.5b00559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=2324-2337&author=T.+Sterlingauthor=J.+J.+Irwin&title=ZINC+15-Ligand+Discovery+for+Everyone&doi=10.1021%2Facs.jcim.5b00559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">ZINC 15 - Ligand Discovery for Everyone</span></div><div class="casAuthors">Sterling, Teague; Irwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2324-2337</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many questions about the biol. activity and availability of small mols. remain inaccessible to investigators who could most benefit from their answers.  To narrow the gap between chemoinformatics and biol., we have developed a suite of ligand annotation, purchasability, target, and biol. assocn. tools, incorporated into ZINC and meant for investigators who are not computer specialists.  The new version contains over 120 million purchasable "drug-like" compds. - effectively all org. mols. that are for sale - a quarter of which are available for immediate delivery.  ZINC connects purchasable compds. to high-value ones such as metabolites, drugs, natural products, and annotated compds. from the literature.  Compds. may be accessed by the genes for which they are annotated as well as the major and minor target classes to which those genes belong.  It offers new anal. tools that are easy for nonspecialists yet with few limitations for experts.  ZINC retains its original 3D roots - all mols. are available in biol. relevant, ready-to-dock formats.  ZINC is freely available at http://zinc15.docking.org.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWfkDnal3D3bVg90H21EOLACvtfcHk0liQZxvjX6SHvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurbF&md5=e767c26c1d0aff7432c403c59a5d2b8b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00559%26sid%3Dliteratum%253Aachs%26aulast%3DSterling%26aufirst%3DT.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26atitle%3DZINC%252015-Ligand%2520Discovery%2520for%2520Everyone%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D2324%26epage%3D2337%26doi%3D10.1021%2Facs.jcim.5b00559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Villadsen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephansen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maolanon, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, C. A.</span><span> </span><span class="NLM_article-title">Total Synthesis and Full Histone Deacetylase Inhibitory Profiling of Azumamides A-E as Well as beta(2)-epi-Azumaide E and beta(3)-epi-Azumaide E</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6512</span><span class="NLM_x">–</span> <span class="NLM_lpage">6520</span><span class="refDoi"> DOI: 10.1021/jm4008449</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008449" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6512-6520&author=J.+S.+Villadsenauthor=H.+M.+Stephansenauthor=A.+R.+Maolanonauthor=P.+Harrisauthor=C.+A.+Olsen&title=Total+Synthesis+and+Full+Histone+Deacetylase+Inhibitory+Profiling+of+Azumamides+A-E+as+Well+as+beta%282%29-epi-Azumaide+E+and+beta%283%29-epi-Azumaide+E&doi=10.1021%2Fjm4008449"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm4008449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008449%26sid%3Dliteratum%253Aachs%26aulast%3DVilladsen%26aufirst%3DJ.%2BS.%26aulast%3DStephansen%26aufirst%3DH.%2BM.%26aulast%3DMaolanon%26aufirst%3DA.%2BR.%26aulast%3DHarris%26aufirst%3DP.%26aulast%3DOlsen%26aufirst%3DC.%2BA.%26atitle%3DTotal%2520Synthesis%2520and%2520Full%2520Histone%2520Deacetylase%2520Inhibitory%2520Profiling%2520of%2520Azumamides%2520A-E%2520as%2520Well%2520as%2520beta%25282%2529-epi-Azumaide%2520E%2520and%2520beta%25283%2529-epi-Azumaide%2520E%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6512%26epage%3D6520%26doi%3D10.1021%2Fjm4008449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Berliner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belecki, K.</span><span> </span><span class="NLM_article-title">Simple, Rapid Procedure for the Synthesis of Chloromethyl Methyl Ether and Other Chloro Alkyl Ethers</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">9618</span><span class="NLM_x">–</span> <span class="NLM_lpage">9621</span><span class="refDoi"> DOI: 10.1021/jo051344g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo051344g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2nu7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=9618-9621&author=M.+A.+Berlinerauthor=K.+Belecki&title=Simple%2C+Rapid+Procedure+for+the+Synthesis+of+Chloromethyl+Methyl+Ether+and+Other+Chloro+Alkyl+Ethers&doi=10.1021%2Fjo051344g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Simple, rapid procedure for the synthesis of chloromethyl methyl ether and other chloro alkyl ethers</span></div><div class="casAuthors">Berliner, Martin A.; Belecki, Katherine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9618-9621</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Zinc(II) salts catalyzed the reaction between acetals and acid halides to provide haloalkyl ethers in near-quant. yield.  Reactions from millimole to mole scale are typically complete in 1-4 h with 0.01 mol % catalyst.  The solns. of haloalkyl ethers thus obtained can be utilized directly in reactions in which the presence of the ester byproduct does not interfere.  Excess haloalkyl ether was destroyed on workup, thereby minimizing exposure to this class of carcinogenic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKEcjSYOlDCrVg90H21EOLACvtfcHk0liQZxvjX6SHvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2nu7%252FE&md5=396533045484bec17a4ac2d3afe3177d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjo051344g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo051344g%26sid%3Dliteratum%253Aachs%26aulast%3DBerliner%26aufirst%3DM.%2BA.%26aulast%3DBelecki%26aufirst%3DK.%26atitle%3DSimple%252C%2520Rapid%2520Procedure%2520for%2520the%2520Synthesis%2520of%2520Chloromethyl%2520Methyl%2520Ether%2520and%2520Other%2520Chloro%2520Alkyl%2520Ethers%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D9618%26epage%3D9621%26doi%3D10.1021%2Fjo051344g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Labadie, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stille, J. K.</span><span> </span><span class="NLM_article-title">Mechanisms of the Palladium-Catalyzed Couplings of Acid-Chlorides with Organotin Reagents</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">6129</span><span class="NLM_x">–</span> <span class="NLM_lpage">6137</span><span class="refDoi"> DOI: 10.1021/ja00357a026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00357a026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1983&pages=6129-6137&author=J.+W.+Labadieauthor=J.+K.+Stille&title=Mechanisms+of+the+Palladium-Catalyzed+Couplings+of+Acid-Chlorides+with+Organotin+Reagents&doi=10.1021%2Fja00357a026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fja00357a026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00357a026%26sid%3Dliteratum%253Aachs%26aulast%3DLabadie%26aufirst%3DJ.%2BW.%26aulast%3DStille%26aufirst%3DJ.%2BK.%26atitle%3DMechanisms%2520of%2520the%2520Palladium-Catalyzed%2520Couplings%2520of%2520Acid-Chlorides%2520with%2520Organotin%2520Reagents%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1983%26volume%3D105%26spage%3D6129%26epage%3D6137%26doi%3D10.1021%2Fja00357a026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Peng, J.; Costanzo, M. J.; Greco, M. N.; Green, M. A.; Wilde, V. L.; Zhang, D.</span><span> </span><span class="NLM_article-title">Preparation of Substituted 2-Anilinopyrimidine Derivatives as EGFR Modulators</span>. WO2016094821A2,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Peng&author=M.+J.+Costanzo&author=M.+N.+Greco&author=M.+A.+Green&author=V.+L.+Wilde&author=D.+Zhang&title=Preparation+of+Substituted+2-Anilinopyrimidine+Derivatives+as+EGFR+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520Substituted%25202-Anilinopyrimidine%2520Derivatives%2520as%2520EGFR%2520Modulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Borzilleri, R. M.; Chen, Z.; Huynh, T. N.; Vaccaro, W.; Chen, X.-T.; Kim, K. S.; Cai, Z.-W.</span><span> </span><span class="NLM_article-title">Preparation of Fused Heterocyclic Kinase Inhibitors</span>. US20050288290A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=R.+M.+Borzilleri&author=Z.+Chen&author=T.+N.+Huynh&author=W.+Vaccaro&author=X.-T.+Chen&author=K.+S.+Kim&author=Z.-W.+Cai&title=Preparation+of+Fused+Heterocyclic+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DPreparation%2520of%2520Fused%2520Heterocyclic%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Duong-Ly, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horiuchi, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">772</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span><span class="refDoi"> DOI: 10.1016/j.celrep.2015.12.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.celrep.2015.12.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=26776524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVaqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=772-781&author=K.+C.+Duong-Lyauthor=K.+Devarajanauthor=S.+G.+Liangauthor=K.+Y.+Horiuchiauthor=Y.+R.+Wangauthor=H.+C.+Maauthor=J.+R.+Peterson&title=Kinase+Inhibitor+Profiling+Reveals+Unexpected+Opportunities+to+Inhibit+Disease-Associated+Mutant+Kinases&doi=10.1016%2Fj.celrep.2015.12.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases</span></div><div class="casAuthors">Duong-Ly, Krisna C.; Devarajan, Karthik; Liang, Shuguang; Horiuchi, Kurumi Y.; Wang, Yuren; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">772-781</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors have typically been designed to inhibit wild-type kinases rather than the mutant forms that frequently arise in diseases such as cancer.  Mutations can have serious clin. implications by increasing kinase catalytic activity or conferring therapeutic resistance.  To identify opportunities to repurpose inhibitors against disease-assocd. mutant kinases, we conducted a large-scale functional screen of 183 known kinase inhibitors against 76 recombinant mutant kinases.  The results revealed lead compds. with activity against clin. important mutant kinases, including ALK, LRRK2, RET, and EGFR, as well as unexpected opportunities for repurposing FDA-approved kinase inhibitors as leads for addnl. indications.  Furthermore, using T674I PDGFRα as an example, we show how single-dose screening data can provide predictive structure-activity data to guide subsequent inhibitor optimization.  This study provides a resource for the development of inhibitors against numerous disease-assocd. mutant kinases and illustrates the potential of unbiased profiling as an approach to compd.-centric inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXqJUD9YoWLVg90H21EOLACvtfcHk0lhH60G2ay6qEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVaqt7c%253D&md5=b01e8f6ce2aa441400531399d8cf88fc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.12.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.12.080%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DS.%2BG.%26aulast%3DHoriuchi%26aufirst%3DK.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DMa%26aufirst%3DH.%2BC.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DKinase%2520Inhibitor%2520Profiling%2520Reveals%2520Unexpected%2520Opportunities%2520to%2520Inhibit%2520Disease-Associated%2520Mutant%2520Kinases%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D772%26epage%3D781%26doi%3D10.1016%2Fj.celrep.2015.12.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Anastassiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-1045&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+C.+Maauthor=J.+R.+Peterson&title=Comprehensive+Assay+of+Kinase+Catalytic+Activity+Reveals+Features+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0lhH60G2ay6qEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%2BC.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520Assay%2520of%2520Kinase%2520Catalytic%2520Activity%2520Reveals%2520Features%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1039%26epage%3D1045%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule-Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0ljddF98no66Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule-Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Goettert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Optimization of a Nonradioactive Immunosorbent Assay for p38 Alpha Mitogen-Activated Protein Kinase Activity</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">406</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.ab.2010.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;key=10.1016%2Fj.ab.2010.07.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2010&pages=233-234&author=M.+Goettertauthor=R.+Graeserauthor=S.+A.+Laufer&title=Optimization+of+a+Nonradioactive+Immunosorbent+Assay+for+p38+Alpha+Mitogen-Activated+Protein+Kinase+Activity&doi=10.1016%2Fj.ab.2010.07.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2010.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2010.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DGraeser%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DOptimization%2520of%2520a%2520Nonradioactive%2520Immunosorbent%2520Assay%2520for%2520p38%2520Alpha%2520Mitogen-Activated%2520Protein%2520Kinase%2520Activity%26jtitle%3DAnal.%2520Biochem.%26date%3D2010%26volume%3D406%26spage%3D233%26epage%3D234%26doi%3D10.1016%2Fj.ab.2010.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU','PDB','2JIU'); return false;">PDB: 2JIU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW','PDB','4RIW'); return false;">PDB: 4RIW</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i71"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00178">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_55655"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00178">10.1021/acs.jmedchem.7b00178</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional chemistry (schemes and description); general procedures of ESI-HRMS and HPLC; all general methods; experimental section of materials and intermediates; metabolic stability determination in vitro; in vitro reactivity study with glutathione; solubility; cellular data; <i>K</i><sub>d</sub> values of different study arms, raw data, and graphs; kinome selectivity screen (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf">PDF</a>)</p></li><li><p class="inline">3D coordinates for docking plus ligand of <b>11h</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RIW">4RIW</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_002.pdb">PDB</a>)</p></li><li><p class="inline">3D coordinates for covalent docking of <b>27a</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>)  (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_003.pdb">PDB</a>)</p></li><li><p class="inline">3D coordinates for covalent docking of <b>19a</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_004.pdb">PDB</a>)</p></li><li><p class="inline">3D coordinates for covalent docking of <b>45a</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_005.pdb">PDB</a>)</p></li><li><p class="inline">3D coordinates for molecular docking of <b>11g</b> in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_006.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_001.pdf">jm7b00178_si_001.pdf (1.26 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_002.pdb">jm7b00178_si_002.pdb (587.61 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_003.pdb">jm7b00178_si_003.pdb (393.6 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_004.pdb">jm7b00178_si_004.pdb (393.9 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_005.pdb">jm7b00178_si_005.pdb (393.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_006.csv">jm7b00178_si_006.csv (2.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00178/suppl_file/jm7b00178_si_007.pdb">jm7b00178_si_007.pdb (401.31 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-11%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00178%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00178" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a605b2ae023f8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
